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Abstract
The Caliciviridae comprises a family of related viruses infecting a wide variety 
of vertebrates including humans. Human pathogens belong to the genera 
Norovirus and Sapovirus and induce enteric infections. Of these, the noroviruses 
are by far the most important and account for the bulk of infectious 
gastroenteritis in adults. Although Norovirus gastroenteritis is self-limiting, the 
economic burden of infection is considerable and uncontrolled manifestations 
can result in severe dehydration and possibly death. Noroviruses form an 
antigenically diverse group of agents and cross-reactive immunity is poor, serial 
infections occur even with the homologous vims in susceptible individuals. 
These features present a considerable challenge for vaccine development but 
approaches have been based around the use of empty virus-like particles 
produced by self-assembly of the virus capsid protein. Such structures have been 
delivered by conventional means to control animal infections, but the formation 
of a stable particle that can withstand passage thiough the gut has raised the 
possibility of enteric immunisation via edible vaccines and this approach has 
shown promise in some systems. This project addresses these issues by 
attempting to engineer stable particles of Hawaii virus capsid protein that 
induces more broadly cross-reactive antibody by deleting those 
immunodominant regions that evoke type-specific responses. These constructs 
were expressed using the Baculovirus system and the results obtained support 
the concept that bridging the gap with poly-glycine chains where the 
hypervariable region had been removed was permitting some form of structural 
assembly including ring form and virus-like particles. In an attempt to improve 
the protein yield we changed the expression system to yeast which showed a 
better expression level of the engineered proteins that we could purify. To 
evaluate such particles as potential carriers of antigenic domains from unrelated 
viruses, part of the hemagglutinin domain of influenza ‘A’ virus was carefully
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selected to replace the poly-glycine chain and this construct was also expressed 
in yeast. All expressed protein constructs were administered in dried whole yeast 
cells orally to mice in an attempt to evoke a local immune response, while the 
purified proteins were used as controls for intravenous immunisation of mice to 
confirm the induction of systemic immune response. In this analysis, we have 
been able to determine immune reactivity towards the engineered Hawaii virus 
capsid protein which may indicate potential for greater response if 
administration could be prolonged. Analysis of reactivity towards influenza 
hemagglutinin segment included in the engineered Hawaii-Hemagglutinin 
chimeric protein is clearly of interest and will be considered in future work.
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Chapter 1 ; General Introduction
1.1 Gastroenteritis
Gastroenteritis is a commonly encountered human disease. In the 
developed countries it is considered the second most common cause of acute 
illness following viral upper respiratory tract infection (Kapikian et al. 1976). 
Manifestations of acute gastroenteritis are usually mild, and mainly in the form 
of diarrhoea. However, dehydration fi'om profuse diarrhoea and finally death 
due to neglected rehydration may occur in an estimated 3.5 to 5 million cases of 
all-cause diarrhoea annually with the majority in developing countries (Snyder 
and Merson 1982).
In the USA it is estimated that everybody experiences at least one episode 
of gastroenteritis per year with a higher incidence amongst those at age extremes 
(Estes et al. 2000; Green et al. 2002a). In the UK the rate of gastroenteritis in 
the community was 19.4 per 100 persons-years and the estimated average cost 
of a case is £79 or £250 for case presented to a GP, all costs at year 2000 prices 
(FSA 2000). It is estimated that about 700 million episodes of acute 
gastroenteritis cases occur globally every year affecting only children who are 
less than five years of age (Snyder and Merson 1982). Difficulties in diagnosis 
have meant that in only some 50% of cases of presumed infectious origin can 
the causative organism be identified. Recent estimates in the UK, Netherlands 
and the USA have suggested that the bulk of this diagnostic void is actually 
made up by Norovirus infections (Mead et al. 1999; FSA 2000; de Wit et al.
2001). These recent new estimates include community acquired cases: studies in 
England suggest that for every case actually identified as Norovirus-induced, 
1562 cases are likely umeported in the community and hence noroviruses are 
responsible for about 16% of 9.4 million gastroenteritis cases reported annually 
(Wheeler et al. 1999; Carter 2005). These new data make noroviruses the 
single largest viral etiologic agent of gastroenteritis (Jenkins et al. 2007).
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Despite this significance, caliciviruses were identified relatively late in 
the study of human viral diaiThoea. The first human virus identified was the 
Rotavirus (Bishop et al. 1973) followed by the enteric adenoviruses (Flewett et 
al. 1973), and astroviruses (Madeley and Cosgrove 1975). Human caliciviruses 
were added to the list in 1976 (Madeley and Cosgrove 1976). This project 
concerns only the caliciviruses and thus it is appropriate to consider these in 
more detail.
1.2 Caliciviruses
1.2.1 History
Human caliciviruses were discovered by electron microscopy of stools 
from children with diaiThoea (Madeley and Cosgrove 1976). Their distinctive 
appearance immediately suggested a link with animal viruses of similar 
morphology which had derived their name from the cup-like depressions that 
cover the particle surface. Two types of human caliciviruses were quickly 
apparent: the first showed a clear calicivirus-like structure and are now known 
as the sapo viruses (SaVs). The second group had a less distinct structure but 
clearly had underlying morphological similarities. These are now known as the 
noroviruses (NoVs). These particles are illustrated in (figure 1), as seen under 
the electron microscope (a, and b) and structures determined by cryo-electron 
microscopy (cryo-EM) (c, and d). It is clear that both particles are constructed in 
a similar manner.
Caliciviruses were previously classified within the Picornaviridae as they 
are similar in size, lack an envelope and contain single stranded positive sense 
RNA. However, in 1978 it was found that caliciviruses have only a single major 
structural protein compared to the four seen in most picornaviruses (Cooper et 
al. 1978). Further the caliciviruses also induced a separate sub-genomic RNA 
inside the infected cell (Ehresmann and Schaffer 1977; Neill and Mengeling
14
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1988). These properties distinguished them fundamentally from the 
picornaviruses and hence they were transferred to a separate family called 
Caliciviridae (Schaffer et al. 1980a). The Caliciviridae family is currently 
divided into four established genera by clustal analysis; NoV, SaV, Lagovims, 
and Vesivirus (Green et al. 2000), while two new genera are proposed to the 
International Committee on Taxonomy of Viruses (ICTV); ‘Becovirus’ and 
‘Recovirus’ by Oliver et al. (2006) and Farkas et al. (2008) respectively. Each 
genus is separated in several genogroups (table 1). However, caliciviruses 
remain in the super-group of Picornavims-like RNA viruses and show sequence 
conservation in three major enzymes: nucleoside triphosphatase, proteinase and 
RNA-dependent RNA polymerase (RdRp) (Koonin and Dolja 1993). More 
recently a second, smaller capsid protein has been identified and the two 
components of the capsid are now designated VPl (Prasad et al. 1994) and VP2 
(Glass et al. 2000; Oehmig et al. 2003) for major and minor proteins 
respectively.
1.2.2 Genome structure
The calicivirus genome is a polyadenylated, positive sense RNA strand, 
7.5 - 8 kb in length (Carter et al. 1992). The genome organisation shows a clear 
separation of structural and non-structural genes; the capsid proteins are encoded 
at the 3’end and the non-structural proteins at the 5’ end (Jiang et al. 1993). 
However, the junction between these two elements is variable; in No Vs and 
vesiviruses these regions are present as different open reading frames (ORFs), 
whilst in SaVs and lagoviruses they are fused in the same frame (figure 2) 
(Carter et al. 1992). The major capsid protein (VPl) gene is followed in all 
genera by a separate gene for the minor capsid protein (VP2) which is always 
specified in a different reading frame. The non-structural region encodes a single 
poly-protein precursor totalling about 200kDa (Neill 1992). Several non- 
structural proteins result from viral proteinase processing of this 1800 amino
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acid translation product. The roles of all of these proteins are not yet clear, but 
they are present in the order: N-terminal protein (45kDa); nucleoside 
triphosphatase (NTPase) (401cDa); “3A-like” protein (22kDa); viral genome- 
linked protein (VPg) (16kDa); proteinase (Pro) (20kDa); RNA-dependent RNA 
polymerase (Pol) (57kDa) (Blakeney et al. 2003). The VPg is covalentely 
linked to the 5’ end of the genome (Burroughs and Brown 1978; Schaffer et 
al. 1980b).
The VPl is directly expressed in its mature form in all genera except 
vesiviruses in which it is encoded as a precursor protein and then processed by 
the viral protease to yield a mature capsid protein of about 601cDa (Carter et al. 
1992).
Calicivirus replication depends on the production of an intermediate 
negative sense RNA strand to be used as the template for the synthesis of 
positive sense full length genome and subgenomic mRNA which serves as a 
template for production of the capsid protein (Meyers et al. 1991; Green et al. 
2002b).
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Figure (1) Calicivirus morphology
Figure (1) (a) and (b): Negative stain transmission electron microscopy of SaV 
and NV respectively, with the latter showing amorphous surface and irregular 
outline. Bar = 50nm (F.P. Williams, U.S. EPA). (c) and (d): Three-dimensional 
structures of recombinant Norwalk virus capsid and primate calicivirus 
determined at 22Â resolution using cryo-EM and computer image processing 
(Prasad et al. 1994a).
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Figure (2) Genomic organisation of Caliciviridae genera
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5314 7329
Figure (2) Diagram of the genomic organisation of different genera of the 
Caliciviridae family. In NoV and Vesivirus, the ORF (1) (shown in blue) 
encodes non-structural poly-protein while, in SaV and Lagovirus it also encodes 
the major capsid protein (VPl) which exists in the same frame. However, the 
VPl of NoV and Vesivirus is encoded in a different frame (ORF2) (shown in 
orange). The minor structural protein (VP2) is encoded in a separate frame 
(ORF3) (shown in green) at the 3' end of the genome of the four genera 
(redrawn from Green et al. 2000).
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1.3 Noroviruses
1.3.1 History
NoVs (previously known as small round structured viruses or Norwalk- 
like viruses) now form a separate genus entitled Norovirus (NoV) in the family 
Caliciviridae and include both human and animal viruses. The prototype strain 
of human No Vs is the Norwalk virus (NV) which takes its name from a 1968 
outbreak of gastroenteritis at a school in Norwalk, Ohio, USA that affected both 
children and adults. Although NoV infections can occur at any time, they are 
more common in winter and had earned this condition the name “Winter 
vomiting disease” (Adler and Zickl 1969).
Based on sequence phylogeny of the capsid and RdRp genes, NoVs are 
divided into five genogroups (Gs) which are then subdivided into genotypes (or 
genetic clusters) and then strains (or genetic variants) (Zheng et al. 2006). The 
con*elation (if any) between this classification approach and any antigenic 
variation between the viruses is not completely established (Green 2007). All 
strains infecting humans are included in GI, GII, and GIV, whereas bovine 
strains are found in GUI and murine strains in GV (Karst et al. 2003). Porcine 
NoV strains have been found to be included also in GII, but in a different 
genetic cluster than human strains (table 1). A close relation was observed 
between GI and GUI and also, between GII and GIV (Deng et al. 2003; Smiley 
et al. 2003) (figure 3).
Analysis of VPl reveals up to 60% similarity between human strains 
within the same genogroup, and 80% for those within the same genetic cluster 
(Green et al. 2001). The number of characterized animal NoVs is relatively 
small in comparison with the number of human strains and this separation may 
not hold up as more strains are analysed (Oliver et al. 2003a).
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Table (1) Classification of Caliciviridae family
Genus Prototype stain Strains
Norovirus 
‘Norwalk-like virus’ Norwalk virus
GI; Human NoVs
- Norwalk virus.
- Southampton virus.
- Desert Shield virus.
- Chiba virus.
GII:
*Huinan NoVs
- Hawaii virus.
- Grimsby virus.
- Mexico virus.
- Snow Moimtain agent.
- Lordsdale virus.
*Porcaine NoVs 
GUI: Bovine NoVs 
GIV:
*Huinaii NoVs
*Lion NoV (Martella et al. 2007) 
*Canine NoV (Martella et al. 2008) 
GV: Murine NoVs (Karst et al. 2003)
Sapovirus
‘Saporo-like virus’ Sapporo virus
Human strains
- Manchester virus.
- Plymouth virus.
Vesivirus Vesicular exanthema of swine virus
-European brown hare syndrome virus. 
- Feline calicivirus.
Lagovirus Rabbit haemonhagic disease virus (RHDY)
San Miguel sea lion virus. 
Primate calicivirus.
Becovirus ‘proposed genus’ 
(Bovine enteric calicivirus)
Newbury agent 
NB ‘Nebraska’
Recovirus ‘proposed genus’ 
(Rliesus enteric calicivirus)
Tulane virus
Table (1) Based on genome organisation and sequence phylogeny the Caliciviridae family is 
divided into four established separate genera termed ‘NoV’, and ‘SaV’ causing gastroenteritis 
mainly in humans, ‘Lagovirus’ and ‘Vesivirus’ affecting mainly animals (Hardy et al. 1997). 
The table also shows two newly proposed genera ‘Becovirus’ and ‘Recovirus’ affecting cattle 
and monkies respectively (Farkas et al. 2008).
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Figure (3) Norovirus genogroups
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Figure (3) Phylogenetic tree constructed on the full-length amino acid sequence 
of the capsid protein. The tree was constructed by using a selection of NoV 
strains representative of the GI to GV. Bo, bovine; po, porcine; mu, murine; hu, 
human; ca canine (Martella et al. 2008).
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1.3.2 Epidemiology
The epidemiologic significance of NoVs was greatly underestimated until 
reliable diagnostic techniques were developed using NV recombinant virus-like 
particles (rVLPs) and RT-PCR (Deneen et al. 2000). In spite of the incomplete 
reporting of all NoV infections in the past, it is believed that NoV outbreaks are 
increasing (CDC 2007).
According to Kaplan et al. (1982), NoV can be inferred as a cause of an 
outbreak if  several criteria are met including: vomiting affecting more than half 
of the suspected group, incubation period of 24-48 hours, continued illness for 
12-60 hours, and stool cultures negative for bacterial pathogens. These criteria 
have recently become valid as a specific discrimination mle in NoV outbreaks 
(Turcios et al. 2006a). When compared to the results of the currently used RT- 
PCR their sensitivity and specificity were found to be 68% and 99% respectively 
(Turcios et al. 2006b).
The high transmissibility of NV is due to its high environmental stability: 
it can resist relatively high concentrations of chlorine (Duizer et al, 2004), 
freezing and temperature up 60°C (reviewed in Patel et al. 2009). This allows 
the virus to survive in ice and brief cooking. Also, viral resistance to drying is 
up to 28 days (Doultree et al. 1999). Environmental transmission is usually via 
water and this is associated with dilution of the input virus. This effect is also 
opposed by the relatively low infectious dose which is estimated at <10 viral 
particles (Tennis et al. 2008).
NoV strains appear to be dynamic and are constantly evolving though 
frequent point mutation. It is believed that this induces an antigenic drift similar 
to that observed in influenza outbreaks in which a circulating strain continues 
for 2-3 years till the development of sufficient immune response when a new
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variant appears (Lopman et al. 2008). Recombinations between strains leading 
to the swapping of structural and non-structural genes have also been indentified 
(Jiang et al, 1999). Simultaneous circulation of multiple strains is to be 
expected; however, only one strain is usually responsible for each outbreak 
which can be easily confirmed by PCR (Blanton et al. 2006).
Several examples of the appearance of a new strain (genetic variant) that 
then sweeps thi'ough the community have been documented (Fankhauser et al. 
2002). Genetic variants of GII-4 genotype became the most commonly detected 
in reported outbreaks in many countries all over the world since NoV 
surveillance has been started in mid-1990s. The first detected variant of GII-4 
‘Lordsdale’ was in the UK in 1993. In Europe the predominant variant was 
shifted to a newly appeared GII-4b in 2000 which was considered the most 
severe of the recorded outbreaks with susceptability of all the population and 
continued to cause outbreaks during winter, spring, and summer until 2004 
when the Hunter GII-4 was detected and again replaced in 2006 by a new 
variant GII-4/2006b which has been reported in about 45 outbreaks on European 
cruise ships since spring 2006 (Lopman et al. 2004a; Phan et al. 2006; Okada 
et al. 2006; Bull et al. 2006). Reuter et al. (2008) have analysed an earlier study 
in Hungary (2000 to 2007) conducted by the State Public Health Service 
(Reuter et al. 2005) and shown that more than 75% of NoV outbreaks were 
associated with genotype GII-4, with the detection of four genetically different 
strains which appeared consecutively one every two years starting in 2000. Each 
of the genetic variants continued to be the etiologic agent over two consecutive 
outbreaks.
In the USA, the GII-4 (Bristol virus) strain has caused a wide range of 
outbreaks in different healthcare and gathering facilities and was thought to be
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more virulent than other No Vs and has become the predominant strain since 
winter 2002 (Lopman et al. 2004a).
Genetic variants of GII-4 genotype were also responsible for pandemics 
in 1995-1996 (US95/96 norovirus strain), 2002 (Farmington Hills strain), 2004 
(Hunter strain), and 2006 (2006a/Minerva and 2006b/Laurens strains) (Said et 
al. 2008). The reason for predominance of the GII-4 especially in closed setting 
outbreaks (Green et al. 2002a) has not been clearly understood, however, it 
seems to be their environmental stability and low population immunity that 
favour their easy transmission (Said et al. 2008).
It is estimated that in the USA there are 23 million cases each year with 
310 deaths in vulnerable groups (Mead et al. 1999). 96% of all reported viral 
gastroenteritis outbreaks and 40% of foodbome outbreaks and about 50% of all­
cause outbreaks all over the world (Table 2) (reviewed by Patel et al. 2009) are 
attributed to No Vs (Gulati et al. 2001). In the UK, about one third of 
gastroenteritis outbreaks in England and Wales are NoV-induced although only 
6% were believed to be foodbome, and the remainder is caused by person to 
person transmission (O’Brien et al. 2000). However, in the USA it was found 
that 40% of foodbome illnesses are thought to be due to NoV infections, which 
were estimated to be responsible for 20000 hospitalizations and 120 deaths 
eveiy year (Mead et al. 1999). Prevalence appears to be increasing across the 
world with greater occurrence of symptomatic illness in children in the USA and 
Europe (Gray et al. 1993). A recent study on hospitalized patients reported 12% 
of severe gastroenteritis affecting children less than five years of age were due 
to NoVs world wide (Monica et al. 2007; Patel et al. 2008).
NoV infection can spread either by the faecal-oral route (including 
foodbome and water-borne transmission) or by person to person direct contact
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(Bresee et a!. 2002; Widdowson et al. 2004). Contact with contaminated 
surfaces, and vomit aerosols are possible means to account for the rapid spread 
of the virus in closed settings. A study demonstrated the ability of a volunteer 
whose hand was contaminated with 30pl of faecal fluid containing NoV to 
distribute the vims between seven different surfaces sequentially (Barker et al. 
2004).
Handling of food which is not followed by further cooking makes the 
ready-to-eat foods (salads, and sandwiches) of high risk for NoV transmission 
(Widdowson et al. 2005b). Foods with liquid constituents such as salad 
dressings and cake icing are more critical in accounting for NoV outbreaks due 
to the easy mixing of small viral inocula with large volume of liquid which will 
be consumed by many persons in the same setting (Parashar et al. 2001). 
Foodbome transmission has been found to be associated with both fiesh and 
frozen produce (fruits, and vegetables) (Ponka et al. 1999) which may be 
contaminated with the virus during growing and harvesting or by food handlers 
during food preparation. NoV was found to be the most common cause of 
outbreaks connected to fresh produce during 1990-2005 with 25% resulting 
from contaminated lettuce and salad greens as shown in the reports of foodbome 
gastroenteritis outbreaks (DeWaal and Bhuiya 2007).
Shellfish represent a major source of infection as they concentrate No Vs 
while filtering sea water to get their nutrients (Morse et al. 1986), and thus 
increasing the viral concentration in their tissues than in the surrounding water 
by 100-1000 fold (reviewed by Carter 2005). Usually these are then consumed 
with little or no cooking so that there are few opportunities for inactivation of 
any viruses within their tissues. Depuration is carried out after harvesting by 
placing shellfish in clean water, allowing them to purge their gut of particulate 
matter. This is effective in also reducing faecal coliform contamination, but is
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not reliable for decreasing NoV load (Morse et al. 1986). The first report of 
shellfish-borne gastroenteritis was in the UK in 1976 in which the bivalve 
molluscan shellfish (oysters, mussels) were the main cause in 33 patients out of 
about 800 individuals (Appleton and Pereira 1977). Later a large shellfish- 
borne NoV epidemic affected more than 2000 individuals in Australia in 1978 
(Murphy et al. 1979).
No Vs have been detected in sewage effluents (Lodder et al. 1999) 
(Schvoerer et al. 2000). In developed countries sewage disposal is probably the 
main way of transmitting faecaly shed viruses and this is helped by the virus’ 
ability to withstand water treatment processes (Fewtrell et al. 1992). Several 
outbreaks resulting hom such transmission were documented (Lawson et al. 
1991; Kukkula et al. 1997; Kukkula et al. 1999; Brown et al. 2001; Boccia et 
al. 2002; Peipins et al. 2002). NoV shedding may continue for up to three 
weeks (Roekx et al. 2002) in the faeces of convalescent individuals and extend 
to over a year, e.g. in pediatric oncology patients (Simon et al. 2006). 
Asymptomatic infections may also occur. These prolonged shedding periods and 
asymptomatic infections are assumed to contribute to transmission (Roekx et al. 
2002).
Polluted running water can spread the virus and represents a major route 
for distribution of the infection throughout populations (Laverick et al. 2004).
Early studies considered only outbreak events which usually centred 
around a common exposure (e.g. restaurant or foodstuff) or closed environments 
such as schools, camps, hotels, hospitals, cruise ships (Lopman et al. 2002), 
institutions, and families within which virus spread is facilitated (Subekti et al.
2002). However, No Vs are now understood as the major cause of infectious 
intestinal disease in community infections as well. This role was under­
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estimated due to inefficient reporting which continued until the late 1990s when 
RT-PCR assays were introduced and began to hint at substantial contribution of 
NoVs to sporadic gastroenteritis affecting all age groups world-wide in different 
settings. Broadly-reactive RT-PCR assays subsequently contributed in the 
identification of NoVs as the second most significant cause of world wide 
endemic diarrhoea in children after rotavirus (Patel et al. 2009).
Traveller’s diarrhoea associated with international mobility is due mainly 
to bacterial agents which have been confirmed in 60-85% of cases. However, 
resistance of some cases to antibiotic therapy suggested the presence of 
additional non bacterial causes (Dupont et al. 2001). In a study conducted on 
international USA students who had developed diarrhoea after visiting Mexico, 
NV was found to be the major cause and hence a low estimation of the viral role 
in such cases in the previous studies was suggested (Ko et al. 2005). This result 
was not matched with previous studies which attributed most of diarrhoea cases 
to bacterial enteric pathogens (Steffen et al. 1999; von Sonnenburg et al. 2000; 
Steffen et al. 2003).
Recently, some characterised bovine NoVs have been found to be closely 
related to some human strains (Smiley et al. 2003) and the possibility of 
zoonotic infections has been considered. Indeed antibodies to bovine strains of 
NoV have been found in humans (Widdowson et al. 2005a). However, it is not 
possible at present to distinguish between cross-reacting human and bovine 
strains and true zoonotic transmission. This cross species infection could 
increase the difficulty of preventing disease in humans by vaccination due to 
persistence of source in animals (Oliver et al. 2003b).
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Table (2) Prevalence of noroviruses among all-cause gastroenteritis
outbreaks
Authors and year Country Study
duration
(months)
Assay Number of 
outbreaks
% Positive 
for NoV
(Buesa et al. 2002) Spain 24 RT-PCR 30 47
(Hedlund et al. 2000) Sweden 48 EM 676 59
(Ike et al. 2006) Germany 48 RT-PCR 544 45
(Lopmam et al. 2003) UK 96 EM 5241 36
(Reuter et al. 2005) Hungary 36 RT-PCR,
EM
581 43
(Van Diiynhoven et al. 2005) Netherlands 12 RT-PCR 281 55
Table (2) Shows review done by (Patel et al. 2009) of studies which examined 
NoV prevalence in all-cause gastroenteritis outbreaks.
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1.3.3 Clinical & pathological changes
NoV gastroenteritis can affect any age group (Roekx et al. 2002), 
resulting in a self-limiting illness lasting for 12-60 hours after an incubation 
period of 12-48 hours (Adler and Zickl 1969). Symptoms have a higher 
incidence in adults and include watery diarrhoea, vomiting, nausea, abdominal 
cramps, and 37-45% of patients report constitutional symptoms including fever 
headache, chills and malaise (Dolin et al, 1972; Wyatt et al. 1974; Gotz et al. 
2001). Illness may extend for up to six days especially when affecting 
hospitalized patients or children below eleven years of age (Lopman et al. 
2004b).
Although infection can be encountered at any time of the year it is more 
common in winter giving rise to a previously known ’winter vomiting disease’ 
or ‘hyperemesis hemis’ previously described by Zahorsky in 1929 in which 
patients suffer from vomiting of acute onset but self-limiting nature. Spring and 
summer peaks of NoV outbreaks in children below 5 years of age (with some 
hospitalized diarrhoeal cases) have been recently reported (Lopman et al. 2003; 
Boga et al. 2004).
Complications such as severe dehydration can occur in infants, the elderly 
and immunocompromised patients such as transplant recipients receiving 
immunosuppressive therapy (Kaufman et al. 2003). If not well controlled, 
severe dehydration can be fatal as reported during outbreaks in nursing homes 
(Dedman et al. 1998; Chadwick et al. 2000). Long-term sequelae of NoV 
infection have not been reported (Patel et al. 2009), an association with a short 
term period (three months) of irritable bowel syndrome has been suggested 
(Marshall et al. 2007). There is a suggestion that NoV might correlate with 
some severe complications including acute renal failure or rejection.
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arrhythmias, and chronic diarrhoea especially in immunocompromised or 
cardiac patients (Mattner et al. 2006; Tu et al. 2008b).
Healthy adults under stressful situations may experience unusual 
manifestations. An outbreak of NoV gastroenteritis occurred in field soldiers in 
Afghanistan, with symptoms, such as confusion, neck stiffness, light sensitivity, 
and disseminated intravascular coagulation. This severe presentation was 
attributed to dehydration resulting from environmental conditions, and work 
stress (Hutson et al. 2004).
On the other hand, asymptomatic infection with NoV was observed in 
1990s. Asymptomatic individuals develop NoV specific antibodies without 
themselves showing any manifestations of the disease (Graham et al. 1994), 
and the development of recombinant assays demonstrated early seroconversion 
in children. At that time it was believed that NoV infection was confined to 
young adults (Jiang and Pickering 2002).
Histopathological changes of gastroenteritis resulting from human 
calicivirus (NoV and SaV) infection have been studied using proximal small 
intestinal biopsies from infected volunteers. Tissue changes appeared in the 
form of inflamed mucosa, shortening of villi and hypertrophic crypts with 
intracellular vacuoles (figure 4) (Schreibe et al. 1973; Dolin et al. 1975). These 
studies also showed that the duodenum and jejunum are the sites of viral 
replication in humans. Other experiments using NV rVLPs showed that both 
pyloric epithelial cells and duodenal enterocytes acted as preferred NV binding 
sites (Marionneau et al. 2002).
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Figure (4) Intestinal hisopathological changes in Norwalk Virus infection
Villi
Crypts Increased vascularity
Figure (4) Small intestinal biopsies taken before and after oral ingestion of NV. 
(A) Normal mucosa before ingestion, long villi and normal cellularity of the 
lamina propria. (B) Two days after ingestion, shortened villi, hypertrophied 
crypts and increased cellularity of the lamina propria. (C) Six days after 
ingestion, persistence of same features as in (B) (Schreibe et al. 1973).
31
General Introduction
1.3.4 Norovirus Genome structure
The nucleotide sequence of the NV genome was the first of this group of 
viruses to be explored. Jiang and colleagues (1993) used a library of cDNAs 
obtained from NV purified from stool samples of human volunteers. It was 
found that the NV genome comprised a total of 7642 nucleotides excluding the 
3’ poly-A tail with a G/C content of 48%. As in other members of the 
Caliciviridae, the genome is covalently linked at its 5’ end to a 12-15 kDa 
protein called VPg (viral protein genome-linked) which is also present in sub 
genomic RNAs (reviewed in Sadovry et al. 2001).
Initiation of protein synthesis in RNA viruses mostly depends on the 
presence of a cap structure at the 5’ end of their genomes and sub genomic 
RNAs. This cap consists of 7-methylguanine (7mG) and is recognised by certain 
initiation factors to promote ribosome attachment and assembly (reviewed by 
Hershey and Merrick 2000). This cap is absent in several RNA vims families 
such as Picornaviridae, Astroviridae and Caliciviridae. Consequently, these 
viruses must use some alternative or variant mechanisms to initiate protein 
synthesis. For example, picornaviruses use an internal ribosomal entry site 
(1RES) contained within the 5’ non-coding region that precedes the initiating 
AUG codon (Jang et al. 1990). However, a similar structure is lacking in 
caliciviruses which have a relatively short 5’ non-coding region. In the case of 
these viruses the VPg perfoiins a distinctly different function to that of the 
Picornaviridae and has been shown to function as a cap analogue. Removal of 
the VPg from calicivirus RNA prevents translation, whereas the same process 
has no effect on picornavirus RNA translation and in fact actually precedes 
translation in the cell (Herbert et al. 1997).
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1,3.5 Norovirus capsid structure
Viruses are characterized by their intrinsic ability to self-assemble using 
their protein subunits to form symmetric shells enclosing their genomes (Crick 
and Watson 1956). As evidenced, all spherical viruses have icosahedral capsids 
(King and Finch 1960). Caspar and Klug suggested the principle of quasi­
equivalence in 1962 applied to most viral capsids containing more than 60 
subunits. This pointed out that subdivision of the triangular facets of an 
icosahedron into smaller equilateral triangles created areas of six-fold as well as 
five-fold symmetry. Groups of six triangles were essentially planar whilst 
groups of five introduced a curvature into the structure leading eventually to a 
closed three-dimensional structure. A closed icosahedral shell is composed of 
hexamers and pentamers and is formed by inserting pentamers at the twelve 
five-fold symmetric axes in the hexamer (Johnson and Speir 1997). However, 
many viruses (including as we now know the Caliciviruses) consist of a single 
type of structural protein. The same protein could not occupy both environments 
in an identical conformation and thus proteins must be able to adopt differing 
structures at each of these two symmetry axes (Caspar and Klug 1962). They 
further pointed out that this subdivision was only possible in a number of ways 
defined by the triangulation number (T) of the particle. A regular icosahedron 
has twenty triangular faces. In order to construct a triangle three subunits are 
required and hence a regular icosahedron may be built from 60 subunits, 
however, more complex structures will require more than 60 subunits for 
construction. Protein units forming the viral capsid can be clustered as 20T 
trimers, or 30T dimers or 60T monomers.
These principles have been born out by the determination of virus capsid 
structui'e using high resolution by X-ray crystallography; this started with 
tomato bushy stunt virus (Harrison et al. 1978), and was then followed by
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many others, including Norwalk virus VLPs (Reddy et al. 2001) and cryo-EM 
studies (Green et al. 1993; Prasad et al. 1999).
When the NV rVLPs are examined by cryo-EM at a resolution of about 
22Â, they appear as a T=3 icosahedral capsid built from 90 dimers of the 
structural protein. This is folded to construct alternating protrusions that make 
contact between adjacent members of a dimer pair to form arches rising above 
the virion surface. Since the protrusions are located at the two-fold axes of 
symmetry the arches themselves are closely packed and form rings enclosing the 
axes of three- and five-fold symmetry. These rings of arches form the cup-like 
structures previously noted by EM. The outer radius of the particle (i.e. to the 
top of the arches) is 190Â, while the inner radius (i.e. to the centre of the 
“depression” is between 100Â and 145Â (Prasad et al. 1994). The structures 
have since been refined by X-ray crystallography to a resolution of 3.4Â 
allowing the conformation of the virus receptor binding site to be accurately 
mapped and now permit a fine dissection of the mechanism of antigenic 
variation amongst these viruses (Prasad et al. 1999).
VPl consists of two main domains, S and P, which are linked together by 
a flexible hinge region (figure 5A). The S domain forms the capsid shell (cup 
base), while the P domain accounts for the prominent protrusions emerging from 
the shell to form the arch-like projections. The P domain is further subdivided 
into PI and P2 subdomains. Furthermore, the amino acids comprising P2 are 
effectively present as an insertion into the PI sequence and divide the PI 
domain into two parts termed Pl-1 and P I-2 (Nilsson et al. 2003). The S 
domain has some similarity to capsid proteins of other viruses and is formed by 
the N-terminal 225 residues of VPl. This is folded to form eight antiparallel p- 
strands between residues 50 and 225 which are termed B-I, and arranged into 
two sheets denoted BIDG and CHEF. This fold, termed a beta barrel or jelly-roll
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fold (Abadzapatero et al. 1980) is typical of many RNA virus capsids, and is 
frequently associated with two a-helical regions ‘aA’ which links strands C and 
D, and ‘aB’ between strands E and F. There is a conserved Pro-Pro-Gly 
sequence among NoV strains found in the connecting loop between strands E 
and F which may have a role in maintaining stable inter-subunit contacts (figure 
5B).
In contrast to the S domain, the P domain is a unique structure that differs 
from other viruses and may even vaiy between different NoV strains. P is 
formed from residues 226 to the COOH terminus of VPl; Pl-1 is represented by 
residues 226 to 278 folded into three short stretches of B-sheet, while the P I-2 
part is represented by residues 406 to 520 with six B-strands and an a-helix 
towards the COOH terminus, a total of 114 residues (Kjeldgaard et al. 1993). 
The P2 subdomain is formed from the intervening residues between 279 and 
405. Residues 285 to 380 forni a six p-sheet fold (figure 6) with some similarity 
to the RNA binding domain (residues 215 to 307 of the elongation factor-Tu 
which is involved in transportation of aminoacyl-tRNAs to ribosomes) (Holm 
and Sander 1993). This raised the possibility that the P2 subdomain has a role 
in viral RNA translation processes.
The similar capsid protein subunits of NV occupy three quasi-equivalent 
positions which are conventionally denoted A, B and C. The dimeric protrusions 
are formed by the P domains of the A and B subunits forming the dimer across 
the quasi two-fold axes, and P domains of the C subunits across the icosahedral 
two-fold axes. These dimers are maintained in position by the interacting side 
chains of the forming monomers (figure 7) (Rossmann and Johnson 1989).
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Figure (5) Structure of recombiuaut Norwalk virus VPl
MA/W •i f
•270aitX»7SLnLII».SSX.BISa&Plil>X8»ZeXfPfi«V08V0rgiORC
60TLD0mL9GMPV8L«MVAKIRQ*a#e*VimiTmM)GIP#WrZCPAMGr»Dl,@CCD#HI#Mtgre«#mQ*QYDVDTTPDTrWMI.CBIQ
 P # '- « ' . . . " . ► /yvwwwv rfso
AllCXOSaaYVaVI,OTIX8PPSHP8GSQV0Z.HKZPHyCS8ZZBRTIIt.XPSVYPPGrCXVZ.V7rNSK)tP8Pgjl.ïn,PC3;.X.PQXTZ«BXA8XQA
PSVCXJUÜI.LKYVDPOtORBXOKPK&yPOart.TCVPaCASSCPQQlPlSaVrVPVStlVE&PyOX.KPVOTXSSARORt.Ot.M• 5 3 0
«Sfif
Figure (5) (A): Ribbon representation of recombinant NV capsid protein. The 
green part represents the N-terminal (residues 10-49) towards the virus interior, 
the yellow part represent the S domain (residues 50-225), the red part represents 
the PI subdomain (residues 226-278 & 406-520) and the blue part represents the 
P2 subdomain (residues 279-405). (B): Sequence and structure analysis of the 
recombinant NV capsid protein. The N-terminal region (residues 10 to 49) is 
shown in green; the S domain (residues 50 to 225), in yellow; the PI subdomain 
(residues 226 to 278, and residues 406 to 520), in red; and the P2 subdomain 
(residues 279 to 405), in blue. Regions involved in the dimer contacts are shaded 
pink, disordered regions are shown in black. The p strands in the 8-stranded p 
sandwich fold are indicated by letters B to I, and those in the P2 subdomain are 
suffixed by Ef. Every 10th residue is indicated by a dot on top. The conserved 
Pro-Pro-Gly sequence among different NoV strains, found in the connecting 
loop between strands E and F is boxed (Prasad et al. 1999).
36
General Introduction
Figure (6) Structure aud sequeuce of recombiuaut NV P2 subdomaiu
Figure (6) Ribbon representation (Upper) of the P2 subdomain in recombinant NV along with 
its respective topology diagrams (Lower). The (3-strands are labeled from A to F (Chen et al. 
2006).
Figure (7) luteractious betweeu VPl subuuits
Figure (7) Interactions between the S domains in the icosahedral shell of the recombinant NV 
capsid. The S domains of the three quasiequivalent subunits, A, B, and C, which constitute the 
asymmetric unit of the T = 3 lattice, are colored in blue, red, and yellow, respectively. The 
asymmetric unit is indicated by a triangle along with the locations of the five- and three-fold 
axes. Application of the icosahedral symmetry elements generates all 60 asymmetric units of 
the lattice, five- and two-fold related asymmetric units, namely B (subscripted by 5) and C 
(subscripted by 2) subunits, respectively, are also shown. The A and B subunits of the five­
fold related asymmetric units interact across the quasi two-fold axis (mid-point of the line 
joining icosahedral three- and five-fold axes) to form the A/B dimer. Similarly, the two C 
subunits related by the icosahedral two-fold axis form the C/C dimer. For clarity the P 
domains are not shown (Prasad et al. 1999).
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In the early studies the NV rVLPs consisted of VPl only; VP2 was not at 
that time known to be a capsid component and VLP production made no attempt 
to include it (White et al. 1997; Bertolotti-Ciarlet et al. 2002). Although VP2 
was clearly not essential for particle formation, more recently expression of VPl 
has been found to be reduced three-fold if expression constructs lacked VP2. 
This suggested a cis-acting role for the VP2 in the up-regulation of VPl 
expression. Furthermore, VP2 helps to promote and stabilize capsid formation 
increasing protease resistance in a manner similar to the adenovirus small 
protein (IX) (Furcinitti et al. 1989). It has been suggested that VP2 is contained 
inside the capsid where it stabilises the VPl structure and might also affect RNA 
packaging as it is veiy basic in nature (Bertolotti-Ciarlet et al. 2003). The VP2 
was detected in two different forms with Western blot studies of NV virions and 
VLPs, either 23kDa (Glass et al. 2000) or a 35kDa version which was shown to 
be phosphorylated by mass spectrometry sequence analysis (Glass et al. 2003).
A model was proposed by Bertolotti-Ciarlet et al. (2003) (figure 8) to 
demonstrate the difference in stability between NV rVLPs made either of VPl 
and VP2 together or VPl only. The latter construct was more susceptible to 
modifying factors such as heat, pH, and change in ionic concentration which 
expose more cleavage sites and facilitates the action of proteases. However, the 
VP2 may be required in only small amount to have such a stabilizing effect on 
viral particles and this is presumably regulated by its unusual mechanism of 
translation in cis from the VPl inRNA. If over-expressed it may destabilise the 
particles (Glass et al. 2000).
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Figure (8) Role of VP2 in Norwalk Virus capsid stability
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Figure (8) Proposed model for the mechanism of the VP2 stabilizing effect on 
NV VPl capsid protein. Particles composed of both VPl and VP2 proteins are 
more stable than those composed only of the VPl capsid protein. Therefore, 
particles composed only of VPl (A) could be more sensitive to various 
treatments (such as pressure, heat, pH, or changes in ionic concentration; 
represented by the shaded arrow) that cause disassembly of the particles 
compared to particles that also contain VP2 (B). Once the particles disassemble, 
the soluble VPl capsid protein may be more sensitive to protease degradation 
(solid arrows) because of the exposure of more cleavage sites (Bertolotti- 
Ciarlet et al. 2003).
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1.3.6 Antigenic diversity
Genetic diversity of NoVs has been studied by RT-PCR and sequencing 
of different strains. NoVs have been classified into 31 genotypes which are 
distributed in five genogroups (Wang et al. 2005; Zheng et al. 2006), of these 
about 26 genotypes are in the three human genogroups (GI, II and IV) (Tu et al. 
2008a).
Comparisons of NoV capsid proteins have shown that sequence similarity 
was only 8% and 11% between P2 and PI subdomains respectively and reaches 
up to 30% in S domains (Chakravarty et al. 2005). Several studies identified 
regions of the NoV capsid protein that differ between most strains, and 
presumably represent those regions subject to host immune pressure. These are 
located largely in the PI and P2 subdomains with P2 being the most variable. It 
is assumed that these areas must elicit a large part of the host immune response 
and are thus responsible for the bulk of the antigenicity of NoVs (Kitamoto et 
al. 2002).
It has not been possible to identify the “neutralising” epitopes of human 
NoVs since cell culture systems are not available and conventional 
neutralisation tests can not be performed. This has meant that the relationship of 
sequence to functional antigenicity has been unclear. However, it could be 
approximated by seeking antibodies against VLPs which can reflect the binding 
properties of the authentic particles (Lochridge et al. 2005). Studies depended 
on the in vitro assessment of the ability of convalescent sera taken from infected 
volunteers to inhibit carbohydrate binding and hemagglutination by VLPs 
(Hutson et al. 2003).
Parker et al. (2005) tried to map cross-reactive epitopes using a group of 
monoclonal antibodies (MAbs) generated using NV rVLPs. These MAbs were
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cross-reactive within specific genogroups (Kitamoto et al. 2002). Antibodies 
NV3901 and NV3912 were found to react with the same epitope present in all 
GI strains and NS14 reacted with several GII strains. These MAbs remain the 
most important capture antibodies used in commercial NoV diagnostic ELISA 
kits (Burton-MacLeod et al. 2004). These workers also used deletion and site- 
directed mutagenesis to produce mutants that were not recognised by the MAbs. 
They showed the existence of unexpected conformational epitopes for MAbs 
NV3901 and NV3912 between amino acid 454 and 520 with high degree of 
similarity (about 90%) among GI NoVs. In spite of this conformational nature of 
the epitope, MAb NV3901 reacted with denatured capsid protein in Western 
blotting and so it was thought to be continuous epitope (Hardy et al. 1996). 
However, they attributed this discrepancy to the possibility that there is a 
minimal binding region in these epitopes which renatures during Western 
blotting allowing their reaction with the MAbs (Harper et al. 1990), this also 
explains the large size of the epitope characterised for MAb NV3901.
A comparison of the epitope sequences recognised by GI and Gll-specific 
MAbs revealed an overlapping region between the epitope of MAb NS14 and 
the N-terminal region of the ‘minimal binding domain’ of MAb NV3901 which 
also included the conserved glutamic acid residue at position 472. This indicates 
that there is cross-reactivity between GI and GII (Parker et al, 2005). The 
common epitope that was recognized by both MAbs of this study was mapped 
within the C-terminal PI subdomain of the NoV capsid protein. Similar findings 
were reported by Yoda et al. (2001) who mapped a GI epitope for the cross­
reactive MAb (8c7) to a region within the C-terminal PI subdomain overlapping 
the epitope described by Parker et al. (2005). Yoda et al. (2001) also showed 
that the binding sites of most of the antibodies that have been produced lie 
within the first 70 amino acids of the capsid protein. Most of these antibodies 
were type-specific, but two GI and GII cross-reactive MAbs (1B4, IF6) which
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also found to bind here were mapped to eleven amino acids within the N- 
tenninus of the capsid protein. This also suggests that many antigenic epitopes 
should be located within the S domain of the capsid. This result contradicts 
results of other studies in which MAbs produced against NV rVLPs (Hardy et 
al. 1996). Parker et al. (2005) have attributed this discrepancy to the different 
immunogens used for production of MAbs or different routes of administration, 
but it remains possible that the S domain is indeed antigenic and that antibodies 
raised to this domain could be broadly reactive. Indeed this is to be expected 
since the S domain contains the greater sequence conservation of the virus 
capsid protein although antibody access may be sterically hindered.
Shiota et al. (2007) could identify a MAb 14-1 with the broadest reactivity 
between GI and GII NoV rVLPs ever detected. They precisely identified the 
location of the epitope of MAb 14-1 on the C-terminal PI subdomain which 
shows more sequence conservation than N-terminus PI and P2 subdomains. 
Further analysis showed that the C-terminal PI subdomain is involved in the 
conformation of the minimal binding region.
Generally, broad-reactive MAbs detected against different NoV epitopes 
could be classified into two types depending on epitope characteristics; those 
with cross-reactivity to linear epitopes in different genogroups (Yoda et al. 
2001; Kitamoto et al. 2002; Yoda et al. 2003; parker et al. 2005), and those 
with cross-reactivity to conformational epitopes in similar genorgoups (Yoda et 
al. 2003; Parker et al. 2005).
The production of MAbs against NoVs rVLPs (Hardy et al. 1996) has 
allowed the investigation of the ability of these antibodies to block specific 
VLPs-cellular interaction. NV rVLPs bound to various mammalian cell types 
but most efficiently to the differentiated Caco-2 cells (human colonic carcinoma
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cells) as concluded by White et al. (1996). They used MAbs to the virus which 
blocked VLPs binding to Caco-2 cells; these experiments suggested that the 
virus capsid binding site resides between residues 300-384. Their results were in 
agreement with subsequent research that showed P2 subdomain of NoV capsid 
to contain the attachment site important for interaction with cellular receptors 
(figure 9) (Neill et al. 2000; Matsuura et al. 2001).
However, Caco-2 cells do not support NV growth and thus lack of 
receptors is not the only obstacle to virus replication in these cells. A 
requirement for a potential co-receptor has been suggested (Hutson et al. 2004). 
However, transfection of virus RNA leads to highly inefficient growth of virus 
suggesting that an intracellular effect is also at work. Although some progress 
has been made it remains at this time impossible to culture human NoV in usual 
cell culture systems. However, advance was made in the study of different 
NoVs. A murine NoV was recovered from interferon-deficient mice which was 
able to grow in a murine macrophage-like cell lines (Wobus et al. 2004). Later 
on, Asanaka et al. (2005) reported for the first time the replication of NV viral 
RNA in mammalian cells (Human Embryonic Kidney ‘HEK293T’) with 
successful packaging into viral particles by intracellular expression of NV 
cDNA using a modified (replication-deficient) vaccinia virus strain ‘Ankara’ 
encoding the bacteriophage T7 RNA polymerase (MVA)-T7. However, this did 
not involve the actual productive replication of virus RNA by virus-specified 
mechanisms. Chang et al. (2006) have also reported the expression of self- 
replicating NV RNA (NV replicon) in human hepatoma (Huh-7) cells and 
hamster (BHK21) cells which could overcome the requirement of a helping 
virus. However, Guix et al. (2007) have studied replication of NV following 
transfection by large amounts of virus RNA extracted from NV particles 
obtained from human volunteers stool samples. This was able to replicate in 
Huh-7 cells leading to capsid protein synthesis, but replication was highly
43
General Introduction
inefficient compared with the number of cells that are known to take up RNA by 
transfection.
Figure (9) P2 viral attachment site
Figure (9) A computational prediction (done by Rasmol visualization 
program) of the binding pocket on the surface of the NV capsid protein, on top 
of the P2 subdomain and is composed of a conserved RGD-like motif (R291) 
and 3 strain-specific hot spots, N300, F335, and N368, that are close to each 
other. Ball-and-stick models of the side chains indicate the critical residues 
surrounding the putative binding pocket. The oval represents the PI subdomain 
of the capsid protein. The S domain is not shown (Tan et al. 2003).
1.3.7 Human resistance and susceptibility
Human strains of both NoVs and SaVs can cause gastroenteritis, however, 
SaVs affect mainly children (Nakata et al. 1985) while, NoV gastroenteritis 
affect both children and adults, but is followed by the production of poor short 
lasting strain specific immunity (Matsui and Greenberg 2000).
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Children less than five years of age have a high prevalence of antibody to 
NoV due to early life exposure (Talal et al. 2000). Antibodies to NoVs are low 
in the first year as maternal antibodies win, but start to increase almost 
immediately (Peasey et al. 2004). Adult studies also showed high NoV antibody 
prevalence (Pelosi et al. 1999). Similar results were obtained by Kriston et al. 
(1996). Seroprevalence of astrovirus types 1 and 6 in London was determined 
using recombinant virus antigen. This study used NoV to compare with 
astrovirus and showed early exposure well before adolescence.
Variation in susceptibility of individuals to NoV infection was first shown 
by Parrino et al. (1977) in a series of sequential challenge experiments. Persons 
fell into two groups; those who were naturally resistant and were not infectable 
and those who were infectable and in whom multiple challenges were required 
to induce effective immunity. The bulk of the resistance to infection can now be 
attributed to lack of suitable receptors. The virus is known to attach to the Lewis 
and blood group antigens. Lewis antigens are thought to be synthesised in the 
epithelial cells of the gut and then secreted into different body secretions such as 
saliva and also into the blood where they become adsorbed to the red blood cells 
(Marcus and Cass 1969; Oriol et al. 1986). These antigens are the 
carbohydrate products of genetically specified enzymes (Lindesmith et al. 
2003), and their expression depends on the presence of a certain 
glycotransferase enzyme; «(1,3/1,4) fucosyltransferase (Lewis enzyme ‘Le 
enzyme’, FUT-3) while their secretion into the saliva depends on another 
enzyme; «(1,2) fucosyltransferase (secretor enzyme ‘Se enzyme’, FUT-2). Most 
individuals possess the FUT-2 gene and are termed ‘secretor positive’ whilst 
about 20% of the European (Marionneau et al. 2001) and African (Ravn and 
Dabelsteen 2000) populations have a mutation in this gene resulting in ‘secretor 
negative’ phenotype. The FUT-2 enzyme produces the H-type 1 antigen by 
adding a fucose (Fuc) residue in a(l,2) linkage of the terminal galactose (Gal)
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residue, while the FUT-3 enzyme which is expressed in Lewis positive 
individuals modifies the H-type 1 or its precursor to produce either Le^ or Le^ 
Lewis antigens respectively. Functional FUT-3 gene is absent in about 10% of 
Europeans representing the ‘Lewis negative’ phenotype with absence of Le^ or 
Le^ antigens from mucosal surfaces. The A and B enzymes of the ABO system 
modify the H antigen by adding ‘N-acetyl galactosamine’ or ‘galactose’ 
producing “A” and “B” antigens respectively (figure 10). Volunteer studies of 
NV cellular binding have shown that the ‘secretor negative’ individuals lacking 
the Le*’ antigen were not susceptible to NV infection (Lindesmith et al. 2003), 
also blood group ‘O’ and ‘A’ individuals were at more risk than group ‘B’ 
individuals (Hutson et al. 2002).
Figure (10) Biosynthesis of ABH and Lewis antigens
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Figure (10) Pathways of ABH and Lewis antigens synthesis (Kudo et al. 1996).
46
General Introduction
Furthermore, even if infectable, levels of antibody appear to be poorly 
protective even against homologous challenge (Wyatt et al. 1974; Parrino et 
al. 1977). Given the genetic diversity of NoV strains in circulation it is not 
surprising that susceptible persons suffer serial bouts of infection (Caul and 
Appleton 1982).
1.3.8 Detection and diagnosis
The provision of diagnostic reagents has been challenging due to the 
genetic and antigenic diversity of NoVs (Hale et al. 1996). Recently, the 
production of broadly cross-reactive antibodies has helped the production of 
effective first generation ELISA kits for detection of NoVs in clinical samples. 
Although these assays are more simple and economic than PCR, their use in 
diagnosis of NoV infections is still limited (Tanaka et al. 2006), also some 
strains are not detected and so further improvement is required (Parker et al.
2005).
The production of a wide variety of antibodies to different NoV VLPs 
using Baculovirus or other expression systems (Hutson et al. 2003) has allowed 
the production of new generations of ELISA assays with a broader range of 
reactivity. These assays remain of limited sensitivity due to continuous 
appearance of new NoV strains, however, their high specificity increases their 
usefulness in confirming outbreaks depending on results from only few cases 
(Gray et al. 2007). Nevertheless, negative ELISA results should be confirmed 
by RT-PCR test (Patel et al. 2009).
MAbs production if achieved by hybridoma formation is greatly affected 
by the immunisation route of the animal from which the sensitized lymphocytes 
are extracted prior to fusion with myeloma cells (Holmdahl et al. 1985). Tanaka 
et al. (2006) investigated the effect of oral antigen administration on the
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efficiency of the hybridomas-produced. Their experiment showed effective 
mucosal lymphocyte priming even with low doses of oral NV rVLPs which 
allowed the production of highly efficient MAb-secreting hybridomas. They 
have also noticed a significant increase in the frequency of IgA production by 
hybridomas obtained after oral immunisation of mice compared with that 
observed when MAbs were created following the more conventional intra- 
peritoneal route. Furthermore, they concluded that oral immunisation (which 
mimics the natural infection pathway) leads to the production of antibodies with 
broader reactivity since the MAbs produced by intra-peritoneal immunisation 
were less cross-reactive than those obtained following oral administration.
Detection of NoV by RT-PCR really began very soon after the first 
sequences were obtained (Xi et al. 1990). As time has passed more and more 
sequences have been added to the database and the primers used have been 
redesigned several times to achieve the broadest possible cross-reactivity. Even 
so some NoV strains still escape detection (Trujillo et al. 2006), In 
epidemiologic studies, RT-PCR is usually followed by nucleotide sequencing 
for accurate identification of related infections and exclusion of wrongly 
connected cases (Dowell et al. 1995). For increasing the sensitivity of the test, a 
quantitative real time RT-PCR has been recently developed which allowed rapid 
detection during epidemic and endemic gastroenteritis (Trujillo et al. 2006).
1.3.9 Clinical management
As long as the case is not complicated, oral rehydration is sufficient to 
replace essential electrolytes and introduce sugars. If a patient can not tolerate 
oral fluids or dehydration is regarded as severe, parenteral administration should 
be used. According to the patients’ ability, foods can be added as early as 
possible and this accelerates symptomatic recovery. Antibiotics were found to 
have no role in treatment of uncomplicated cases. Also, no reduction in
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intestinal fluid losses has been noticed with anti-diarrhoeal agents (which 
decrease intestinal motility) such as loperamide which can sometimes harm 
children under three years of age (Li et al. 2007),
1.3.10 Prevention
There are currently no effective vaccines or drugs to combat NoV 
infection; interference with the transmission cycle is cuiTently the most effective 
way to stop spread of infection. This relies mainly on raising awareness of virus 
modes of transmission and promoting strict personal hygiene to prevent 
secondary transmission from person to person (Patel et al. 2009).
Good food hygiene is essential and has been found to be protective both 
in the home and in commercial catering (de Wit et al. 2003), avoidance of high 
risk foods can also help. Food handlers are required to cease work if they 
contract NoV illness and to remain away from work for 48 hours after the 
cessation of symptoms. Extending this period to 72 hours (Parashar et al. 2001) 
or even longer (Rockx et al. 2002) can be beneficial (Patel et al. 2009).
Better control of water contamination in oyster-harvesting areas can be 
achieved by restricting overboard dumping of faecal waste from boats 
(Parashar et al. 2001) and by introduction of tertiary treatments at sewage 
works.
Disinfection of environmental surfaces after contamination with faeces or 
vomitus is very important preventive measure (Parashar et al. 2001) especially 
in institutions (camps, cruise ships) where an outbreak can be extended by an 
influx of new susceptible visitors. This effect can sometimes lead to the need to 
close the facility to stop propagation of infection (Patel et al. 2009).
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There is thus a requirement for an effective vaccine against this virus and 
this project is loosely concerned with such a process, furthermore, we also wish 
to see whether such an engineered vaccine might be developable as a base- 
vehicle for the presentation of antigens derived from other agents. Work cited 
above indicates that the route of antigen presentation will affect the nature of the 
immune cells and response induced with enteric immunisation being the more 
natural route. This approach has been used in the past and we wished to hirther 
explore this possibility using yeast as a presentation system.
1.3.10.1 Vaccine Development
Developing an effective NoV vaccine is restricted by several challenges 
including the highly evolving nature of the viruses, lack of full understanding of 
the crucial immune responses to NoV infection and the short-lived homologous 
immune response induced to the infecting strain (Tacket et al. 2003).
The observation of stable self-assembling NV rVLPs has prompted their 
investigation as possible vaccines. It has been found that the size of the VLPs 
facilitates their uptake by the dendritic cells (DCs) through macropinocytosis 
which then has a critical role in activating both innate and adaptive immune 
responses by presentation of processed antigen to CD4 and CDS T-cells with 
subsequent production of effector cells including plasma cells which produce 
specific antibodies and cytotoxic T lymphocytes (CTL) (Demi et al. 2005) 
(figure 11). Several viruses are tackled by VLP-based vaccines including 
parvovirus (Sedlik et al. 1997), RHDV (Laurent et al. 1994) hepatitis B virus 
and human papilloma virus vaccines (reviewed by Chackerian, 2007; Spohn 
and Bachmann, 2008).
Recombinant VLPs present repeating epitope patterns to the immune 
system and are often highly immunogenic by parenteral administration (Ball et
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al. 1998; Guerrero et al. 2001; Noad and Roy 2003). Recent work with human 
papilloma virus has led to the introduction of a successful vaccine to protect 
against cervical cancer (Lowy and Schiller 2006). Similar trials to develop a 
NV vaccine using NV rVLPs have been put into place (Tacket et al. 2003).
So far it has been shown that NoV VLPs were able to stimulate both local 
and systemic immune responses in mice in different studies (Ball et al. 1998; 
Guerrero et al. 2001; Xia et al. 2007) with current trials ongoing to evaluate 
their immunogenicity in humans (Ball et al., 1999; Tacket et al., 2003).
Figure (11) Virus like particles-mediated immune response
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Figure (11) DC maturation upon uptake of VLPs/Baculovirus which induces 
danger signal followed by cellular activation and upregulation of maturation 
markers. Mature DCs present processed VLPs antigens to naiive CD4^ and 
CD8^ T-cells via MHC class-II and class-1 respectively. Cytokines secreted by 
DCs result in differentiation into effector B and T-cells with production of 
antibodies and T-cell mediated cytotoxicity (Ludwig and Wagner 2007).
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As NV causes a localized intestinal infection, the ability of a vaccine to 
induce local antibodies appears to be of great importance as the first line of 
defence that can limit the disease in early stages, and this further suggests that 
oral vaccination might be the most appropriate means of administration in order 
to promote effective mucosal immunity (Estes et al. 2000). However, if the 
local immune response can last for only short time, then simultaneous induction 
of a systemic immune response is also necessary for longer-term protection 
(Bernstein et al. 1989). Also, the particulate nature of NV rVLPs facilitates 
their sampling transport across the mucosal barrier by the ‘M ’ cells overlying 
the gut associated lymphoid tissue (Jiang et al. 1992). It is not therefore 
surprising that NV rVLPs have been assessed as candidate vaccines for 
administration by both conventional and oral routes.
Conventional perenteral administration has concentrated on increasing 
effectiveness through adjuvant choice (Lycke et al. 1983), and administration 
regime (Ball et al. 1999). Vibrio cholera toxin (CT) was found efficient in 
enhancing both mucosal and systemic immune response despite of its toxicity 
(Kateley et al. 1975; Holmgren and Lindholm 1976). Trials are underway to 
reduce this toxicity, hopefully without altering the adjuvant flmction (Pizza et 
al. 2001). A genetically modified CT ‘CT-E29H’, produced by a single amino 
acid substitution, was tested as adjuvant for a NV rVLP vaccine in mice 
(Periwal et al. 2003) This modified CT has lower toxicity, but the same 
adjuvant power as the native toxin. Intranasal administration of the vaccine- 
adjuvant combination resulted in enhanced production of both local and 
systemic immune responses than those produced without adjuvant (Tebbey et 
al. 2000).
52
General Introduction
1.3.10.2 Resistance of virus like particles to gastrointestinal conditions
A knowledge of the mechanisms of stability, assembly and disassembly of 
NV rVLPs can help in the design of an effective vaccine formula (Ansar et al.
2006). Using several analysis tools including microscopy, colorimetry, and 
spectroscopy Ausar et al. (2006) studied behaviour of NV rVLPs in solutions as 
pH and temperature were changed. This showed various changes in the 
secondary, tertiary, and quaternary structure of the rVLPs. They used pH values 
similar to the normal range found in the gut. NV rVLPs were found to be stable 
(by spectroscopic analysis) at both neutral and acidic pH in contrast to alkalinity 
(pH 8.5) which caused them to disrupt as previously shown in a study by White 
et al. (1997). At pH 8, few intact NV rVLPs were preserved (as shown by 
TEM), and those which persisted were smaller at 24 nm in diameter, and these 
were attributed to be smaller T=1 structures created from the capsid protein.
Survival at acidic pH has been reported for other viruses which infect the 
gut such as adenovirus type-5 (Rexroad et al. 2006) and poliovirus type-I. This 
particle stability can be explained as an adaptation of viruses to their natural 
route of infection (Krell et al. 2005).
Oral administration thi'ough ingestion of transgenic plants expressing 
virus proteins has also been investigated. This approach has significant 
advantages including convenient administration, low cost, and protection of NV 
antigens by plant cells and cell debris during their passage through the stomach 
(Mason et al. 2002). The transgenic potato has been assessed for effectiveness 
following administration to mice. A study using raw, recombinant potatoes 
expressing NV rVLPs induced an IgG response in 100% of the murine recipients 
even at low doses (Tacket et al. 2000). However, mucosal IgA was induced 
only in 30-40% of responders. Ball et al. (1999) also investigated oral rVLP 
administration in humans using VLPs expressed in tomato. Thr ee (60%) of five
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sero-positive volunteers displayed a rise in serum antibody after receiving a 
single low dose (lOOpg) of rVLPs orally. On raising the dose, fifteen (100%) of 
the volunteers tested developed a four-fold antibody rise after two weeks of 
immunisation. Both of these experiments demonstrate that such an 
administration route can succeed; at present the induced antibody titres are low 
compared with those induced by other routes and protection has not been 
demonstrated, but the advantages of this type of administration mean that it 
deserves continued attention.
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A great deal of attention has been given to the development of NV vaccines both 
due to the emerging understanding of the true extent of the NoV problem, and 
also to the clear emergence of strains of increased pathogenicity which 
demonstrated an active and ongoing threat from this source (Matsui and 
Greenberg 2000). However, the observed genetic diversity of these viruses 
implies that such vaccines could suffer horn limited cross-reactivity and might 
require constant re-engineering in response to virus emergence. Further, the 
opportunity for oral administration demands consideration as a cheap, 
acceptable and potentially effective route of administration. There is however a 
need to consider alternative methods of vaccine presentation, since induction of 
gnenetically engineered plants is relatively slow and labour intensive. Further, 
production of large amounts of edible vaccine could require large scale 
agricultural activity at a time when food production is already under thr eat hom 
increasing use of facilities for biofuel production. It would seem that a simpler 
system, more readily altered and updated, and which could be produced on an 
industrial scale might offer advantage.
Finally the structure of the NV capsid (which consists of independently folded 
domains) offers the opportunity for insertion of foreign domains in the backbone 
of an acid stable particle which could open the route for the production of 
enterically administrable vaccines presenting a variety of antigens that do not 
usually infect via this route. This project will address some of these issues:
1. We will attempt to delete the major source of strain-specific variation 
(namely the antigenic loops on the surface of the virus) in order to 
promote a more cross-reactive antigenicity directed predominantly at the
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S domain. This could provide improved diagnostic reagents and could 
also point the way to a more pan-reactive vaccine.
2. Previous attempts have found that simple deletion mutants may fail to 
produce particles at all. We will attempt to replace the missing sections 
with short stretches of poly-glycine to recover particulate forms.
3. We will attempt to replace the P2 subdomains with independently folded 
regions obtained from other viruses using influenza as our initial model.
4. Creation of transgenic plants and edible products offers a cheap 
production method, but the work required to create these transgenics in 
the first place is considerable. We will examine a different means of 
enteric delivery; ingestion of whole yeasts expressing recombinant 
antigens for the following reasons:
• Such a system is readily engineered and cheap to produce.
• Incorporation of umelated antigens (Above) could increase its 
applicability.
• Such a means of administration provides not only vaccine antigens, but 
yeast cells ftequently used as nutritional supplements and thus useful in 
promoting response in those who may be otherwise undernourished.
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Chapter 2: General Materials & Methods
2.1 Cells and Viruses
2.1.1 Insect cells
Sf21 cells, derived from Spodoptera frugiperda (Sf) [the fall army worm], were 
grown in non-vented tissue culture flasks using TC-lOO medium (GIBCO, 
Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum 
(FBS) (Clontech, France), 2 mM L-Gutamine (GIBCO, Paisley, UK), 100 U/ml 
penicillin, and 100 pg/ml streptomycin (GIBCO, Paisley, UK) at 28°C for 4-5 
days. Passage was performed at a split ratio of 1:4. Old medium was discarded 
and confluent cells were detached by shaking with sterile glass beads before 
they were recovered by aspiration of the liquid and centrifugation (2500 rpm, 5 
minutes) in Centurion centrifuge-1000 series (Centurion Scientific, west Sussex, 
UK). Cell pellets were resuspended in fresh medium.
For heezing, the cells were detached as above, collected by centrifugation (2500 
rpm, 5 minutes) and resuspended in 1ml heezing medium (10ml TC-lOO, 1ml 
FBS, 1ml Dimethylsulfoxide ‘DMSO’) per 75cm^ flask harvested cells. Cells 
were aliquoted into 1.8ml cryovials and slowly frozen at -80°C overnight. The 
cryovials were then transferred to liquid nitrogen for prolonged storage.
For resuscitation, the cells were thawed rapidly in a 37°C water bath and were 
spun through 10ml of fresh growth medium at 2500 rpm for 5 minutes to 
remove the DMSO. The cells were resuspended in fresh growth medium and 
seeded into a 25 cm^ flask. Growth medium was changed after 24 hours for 
removal of residual DMSO.
2.1.2 Production of high titre viral stock of recombinant Baculovirus
Recombinant viruses were initially obtained by picking a single plaque of 
recombinant virus obtained by plaquing the transfection yield. This was
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introduced to a 25cm^ flask of Sf21 cells and allowed to grow for 4 days. At the 
end of this time the medium and cells were harvested and stored at -80°C and 
designated {clone) stock PL A high titre viral stock was generated by several 
rounds of viral growth starting with the PI stock. The PI stock was used to 
produce the R1 stock (titre usually in the range 1-5 x lO^pfu/ml). This was then 
used to produce the R2 high titre stock (approximately 5 x 10  ^- 2 x 10^  ptu/ml) 
which is required to obtain sufficient multiplicity of infection (m.o.i) for high 
level of expression of recombinant proteins. In some cases titre was not 
sufficient and an additional round of amplification was required. These rounds 
of growth were performed as follows:
Sf21 cells were grown in I S q v c i  flasks to 70% confluence (as in 2.1.1). Old 
growth medium was discarded and the recombinant Baculovirus inoculum (R1 
stock) was added at m.o.i = 1 -2  pfii/cell. The flask was rocked for 1 hour at 
room temperature to allow virus adsorption to the cells. 10 ml of fresh growth 
medium was added to each flask, and then the flasks were incubated at 28°C for 
4-5 days till cytopathic effect was obvious. The medium was then clarified at 
2500 rpm for 5 minutes and the supernatant containing the Baculovirus (R2 
stock) was aliquoted into sterile bijoux vials and stored at -80°C.
2.1.3 Baculovirus Plaque Assay
Plaque assays were performed in 6 well (3.5 cm^) tissue culture plates which 
were seeded with Sf21 cells in 2ml growth medium/well. The plate was 
incubated overnight at 28®C or to 50% confluence. The Baculovirus stock to be 
assayed was serially diluted (ten fold) in serum-free TC-lOO medium, Old 
growth medium was discarded and 0.2ml of each dilution was plated per well. 
Plates were rocked for 1 hour at room temperature, before the inoculum was 
removed and the cell sheets overlaid with 2ml 1% seaplaque agarose in TC-lOO 
growth medium. When the agarose was set 1ml of growth medium was applied 
to the surface. The plates were incuhated at 28°C in a humidified box for 5 days.
60
General Materials and Methods
Plaques were stained by adding 1ml of 1:10 neutral red stock (0.33% w/v) in 
growth medium to the 1ml of the medium already present in each well. 
Incubation was continued for 4 hours when the stain was removed and 
incubation continued for a further 1 hour to allow the stain to clear. Neutral red 
is a vital stain and does not inactivate the viruses. Thus it could be used to obtain 
viral clones by plaquing recombinant virus following transfections and selecting 
individual plaques for subsequent culture.
2.2 Molecular biology
2.2.1 Polymerase chain reaction (PCR)
All primers used in our study were designed according to Apte and Daniel 
(2003) (Appendix III). PCR was used to amplify the target sequences of the 
Hawaii virus capsid gene and also to screen plaques of recombinant 
Baculovirus. A lOOpl PCR reaction typically contained lOpl lOx PCR buffer 
(Appendix I), 10pi 2mM deoxyribonucleotide triphosphate (dNTP) mixture, 
lOpl 2.5pM forward primer, lOpl 2.5pM reverse primer, 58pl Milli-Q 
(Millipore Corporation Quality) water, and 2pl of the target DNA. 5 units of Taq 
polymerase enzyme were added to the mixture, overlaid with 100pi liquid 
paraffin in reaction tubes and placed in a thermal cycler (TECHNE, Cambridge, 
UK). The machine was adjusted according to the amplified sequence size and 
the melting temperatures ‘Tm’ of the primers, as a rough guide extension times 
were calculated at 1 minute per 1000 bases and annealing temperatures were 5- 
10°C below the predicted Tm of the oligo primers concerned. DNA was 
precipitated from the reaction mixture (after removal of paraffin) by the addition 
of 2 volumes of absolute ethanol and 1/30^ ^^  volume sodium acetate solution 
(3M, pH 5.0). Precipitation mixtures were allowed to stand at -20°C overnight 
(or for 2 hours at -80°C) before the DNA was collected by spinning at 13000 
rpm for 10 minutes in a microcentrifuge (Eppendorf-5415C, California, USA). 
The supernatant was carefully removed and the pellet was washed twice with
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70% ethanol, dried at 37°C for 3 minutes in a dry heat block and resuspended in 
20pl Milli-Q water.
2.2.2 Electrophoretic separation of DNA in agarose gel
1.2% agarose (1.2g agarose, 10ml lOx Tris Borate EDTA (TBE) buffer 
(Appendix I), 90ml Milli-Q water, and 5 pi ethidium bromide ‘lOmg/ml stock’) 
was used to resolve the DNA samples according to their size. lOpl of each DNA 
sample was mixed with 10pi 2x TBE sample buffer (Appendix I) and loaded 
into the gel, with 10pi of Ikb DNA ladder (Promega, Madison, USA). 
Electrophoresis was proceeded at 125 volts for about 1 hour using running 
buffer (Appendix I). DNA bands were visualised and images were recorded 
using a UV trans-illuminator machine (UVi-Tec, EEC).
2.2.3 Cloning of PCR products
2.2.3.1 DNA extraction from agarose gel
DNA bands were excised from agarose gels under UV illumination and the 
DNA was recovered using QIAquick Gel Extraction Kit_ (QIAGEN, Crawley, 
UK) according to the manufacturer’s instructions. The concentration of the 
recovered DNA was assessed by agarose gel analysis using standard 
concentrations of lambda DNA (Promega, Madison, USA). PCR products were 
cloned by ligation to the commercial vector pGEM T-easy (Promega, Madison, 
USA) (Appendix II).
2.2.3.2 Ligation reactions
Reactions usually included 20ng of the appropriate vector and sufficient insert 
DNA to achieve a 3:1 molar excess of insert to vector. A lOpl ligation reaction 
included Ipl lOx ligase buffer (Appendix I), Ipl 25% polyethylene glycol, 20ng 
of the vector, and the calculated volume of the insert. Milli-Q water was added 
to bring the total volume to lOpl. The reaction components were mixed and
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allowed to stand for 2 minutes on ice. Then, Ipl of T4 DNA ligase (Promega, 
Madison, USA) was added and mixed. The mixture was overlaid with 30pl of 
liquid paraffin and incubated overnight at 14°C in a water bath placed in a 4°C 
room. After this time the ligation mixture was diluted and the enzyme detached 
by addition of Ipl 0.2M EDTA (SIGMA, USA) and 9pl Milli-Q water. Ligation 
mixtures were stored at -20°C until they were used in transformation.
2.23.3 Transformation of competent Æ coli ‘DH5a’ by plasmid DNA
Ligated vectors were introduced into pre-prepared frozen competent E. coli cells 
strain ‘DH5a’. Bacterial cell suspensions were thawed on ice and 50pl aliquots 
were transferred to pre-cooled 1.5ml Eppendorf tubes. 10pi of diluted ligation 
mixture was added per tube and the E, coli cells were mixed gently and left to 
stand on ice for 30 minutes. The transformation mixture was then heat shocked 
at 40°C for exactly 45 seconds and returned to ice for 5 minutes. 200pl of 2x YT 
(Yeast extract Tryptone) medium was added and mixed. Cells were then 
incubated at 37°C in heating block for 1 hour with gentle mixing every 15 
minutes to allow phenotypic expression. The transformation mixture was then 
divided between 2x YT agar plates containing appropriate selection antibiotic 
(ampicillin ‘200pl/100mP when using pGEM T-easy or zeocin UOOpg/mP 
when using pPICZ plasmid vectors in transformation), X-GAL ‘5-bromo 4- 
chloro 3-indolyl p-galactosidase’ (Melford laboratories, Chelsworth, UK) 
(500pi/100ml) and IPTG ‘isopropyl p-D-thiogalactopyranoside’ (NBL GENE 
sciences, Cramlington, UK) (250pi/100ml). The later two components permit 
blue/white screening of recombinant colonies. Four plates were used per tube of 
transformation mixture. Plates were allowed to dry at room temperature and 
incubated in a 37°C incubator overnight.
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2.23.4 Purification of plasmid DNA
The well-separated white colonies were picked from the transformation plates 
and grown separately overnight in 5ml 2x YT medium with vigorous shaking at 
37°C in an orbital shaker incubator (Gallenkamp, UK). Samples of each culture 
were stored separately at 4°C, whilst the bulk of the culture was sedimented in 
an Eppendorf tube by using microcentrifuge (Eppendorf-5415C, California, 
USA) at 14000 rpm for 1 minute. As cultures exceeded 1.5 ml, supernatants 
were removed and a fresh 1.5ml added to the pellet and respun to collect all the 
cells in the same tube. Plasmid DNA was isolated using QIAprep Spin Miniprep 
Kit_(QIAGEN, Crawley, UK) according to the manufacturer’s instructions. This 
kit relies on alkaline lysis of bacterial cells, followed by adsorption of the 
plasmid DNA onto a silica membrane. Purified plasmid DNA was eluted with 
50jLil elution buffer supplied by the manufacturer.
2.2.3.S Restriction enzyme digestions
When required e.g. to screen plasmid DNA for the presence of a target insert or 
to prepare DNA bands for ligation, DNA was digested using restriction 
enzymes. For analysis, reactions were typically 10pi in volume and contained 
Ipl lOx bovine serum albumin (lOmg/ml) (Promega, Madison, USA), Ipl lOx 
appropriate enzyme buffer (as recommended by the manufacturer), 2 pi plasmid 
DNA sample (e.g. DNA prepared by the Miniprep kit) and 6pi Milli-Q water. 
The solution was mixed and lOU of each restriction enzyme (Promega, 
Madison, USA) was added, mixed again, spun briefly to recover the mixture 
which was then incubated at the appropriate temperatuie for the enzyme in use 
in a heating block for 1-2 hours. For cloning, these reactions were scaled up in 
volume and we used 5-1 OU restriction enzyme per Ipg of DNA. Digestion was 
checked by agarose gel electrophoresis analysis of a small sample after 1 hour 
and if it was incomplete fresh enzyme was added and incubation continued for a 
ftirther hour. The digest was then reanalysed by agarose gel electrophoresis.
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2.23.6 Sequencing
lOpl Samples of plasmid DNA (lOOng/pl) were sent to CoGenics (UK) for 
automatic sequencing using universal M l3 forward and reverse primers to 
sequence across the insertion site in the pGEM T-easy vector in both directions. 
Later in the project sequencing used synthetic primers derived from virus 
sequences to address particular regions of relevant constructs.
2.3 Protein expression
2.3.1 Baculovirus rescue and screening of recombinants
DNA to be expressed was recloned from the pGEMT-easy cloning vector using 
restriction sites appropriate for transfer into the recombination shuttle vector 
pVL1393 (Invitrogen, USA) (Appendix II). These excisions and reclonings were 
made with great attention to reading frame and orientation was forced when 
possible. Sf21 cells were grown in 3.5 cm  ^dishes to 50% confluence in TC-lOO 
growth medium. The cell monolayer was washed with TC-lOO without serum 
and 0.8ml of TC-lOO (serum and antibiotic free) was added to each dish. 
Meanwhile, the transfection mixture was prepared in a sterile plastic universal, 
0.4pg Baculovirus linear DNA (BD BaculoGold, BD Biosciences Pharmingen) 
and 2pg pVL1393 vector containing the target insert were added and adjusted to 
lOOpl (In general a molar ratio of 5:1 shuttle vector DNA: Baculovirus linear 
DNA was sought). lOpl lipofectin (GIBCO, Paisley, UK) was diluted in 90pi of 
serum and antibiotic free TC-lOO for each transfection. Then, the diluted 
lipofectin was added to the DNAs, mixed gently, and allowed to stand at room 
temperature for 15-20 minutes to allow the association between liposomes and 
DNA to take place. 200pl of the transfection mixture was then added to each 
dish dropwise and rocked gently for mixing. Dishes were incubated at 28°C for 
5 hours, then the transfection mixture was removed and replaced with 2ml TC- 
lOO growth medium (containing 10% FBS) and incubation continued in a 
humidified atmosphere at 28°C for 4-5 days, or until cytopathic effect was
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apparent. The medium was harvested and clarified by centrifugation at 2500 rpm 
for 4 minutes, and then stored at -80°C. Recombinant virus was screened by 
plaque assay in SfZl cells under agarose overlay. Plaques were visible after 5 
days at which time 1.5ml of TC-lOO containing X-gal (10%) was added above 
the agarose to allow the chromogen to diffuse down to the cells overnight. 
Recombinant plaques did not express lac-Z enzyme and remained colourless 
whilst non-recombinant plaques lacking an insert turned blue.
2.3.2 Large scale preparation of recombinant protein from Sf21 cells
Large scale expression of Hawaii capsid protein was attempted using 
recombinant Baculovirus. Infections were carried out at high m.o.i (5-10 
pfu/cell) using 6 large (175cm^) flasks seeded with Sf21 cells and grown to 70% 
confluence. The viral inoculum was added in 4ml TC-lOO fresh growth medium 
per flask and the flasks were rocked at room temperature for 1 hour. Following 
this adsorption period the cell monolayer was briefly washed with serum-free 
SF-900 medium (GIBCO, Paisley, UK), and 40ml of the medium was added to 
each flask. Flasks were incubated at 28°C for 6 days when cells were detached 
using cell scrapers into the medium. Cells were then collected by centrifugation 
at 2500 rpm for 5 minutes and both cell pellet and culture supernatant were 
saved. Supernatants were pooled in 250ml conical flask. Both supernatant and 
cells were sampled for polyacrylamide gel electrophoresis screening for the 
expected protein.
2.3.3 Sodium dodecyl sulfate-PoIyacrylamide Gel Electrophoresis ‘SDS- 
PAGE’
A 10% resolving gel was made containing 4.6ml distilled water, 10ml Ax2 
resolving buffer (Appendix I), 5ml 40% acrylamide-bisacrylamide (Appendix I), 
and lOOfil 20% SDS (SIGMA, Japan). Polymerisation of acrylamide was 
induced by addition of 200pl 10% ammonium persulphate and 50pl TEMED
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(N,N,N’,N’-Tetramethylethylenediamine) (SIGMA, China) which acts as a 
catalyst for the polymerisation. The resolving gel was immediately poured 
between the glass plates of a BioRad minigel apparatus using a pipette to a level 
just below the expected level of the comb. Water-saturated butanol was overlaid 
to exclude oxygen (an inhibitor of polymerisation) and to ensure a smooth 
surface to the gel. The gel was left to set when the water-saturated butanol was 
discarded and the gel top was washed with distilled water. A filter paper was 
used to dry the inside surfaces of the glass plates above the resolving gel, but 
without touching the gel itself. A 4% stacking gel was made containing 3.75ml 
distilled water, 5ml Bx2 stacking buffer (Appendix I), 1ml 40% acrylamide- 
bisacrylamide, and 50pi 20% SDS. Again, polymerisation was induced by 
addition of 100pi 10% ammonium persulphate and 30pl TEMED and then the 
gel was poured immediately on top of the resolving gel. The comb was 
positioned in the stacking gel which was left to set and the comb was then 
carefully removed and the well pockets were washed in running buffer 
(Appendix I) to remove acrylamide tags. The gel tank was assembled and both 
reservoirs were filled with running buffer. The protein samples were mixed with 
sample buffer (liquid samples were mixed with an equal volume of 2x sample 
buffer (Appendix I) and pellets were resuspended directly in Ix sample buffer) 
and boiled for 2 minutes for dénaturation. Prestained wide range (6-175 kDa) 
protein marker (BioLabs, Hitchin, UK) was boiled. 15 pi samples were loaded 
into the wells and one well was loaded with lOpl of the marker. Electrophoresis 
was proceeded at 150 volts for 1-2 hours. The gel was carefully removed and 
stained with Coomassie blue stain (Appendix I) for about 1 hour on a desktop 
shaker and then destained in several changes of destaining solution (Appendix I) 
until bands could be seen.
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2.3.4 Protein assay
The concentration of the expressed purified proteins was determined by using 
BioRad protein assay kit (BioRad, UK). Bovine serum albumin standard 
dilutions of 1.6, 0.8, 0.4, 0.2, and 0.1 mg/ml were prepared by 1:2 serial dilution 
of the first concentration (25 pi each). The sample was prepared by adding 2,5 pi 
of the purified protein to 22.5pl distilled water. Blank was a 25pl of distilled 
water. 2ml reagent A and 40pl reagent S were mixed by vortex and 125 pi was 
added to each of the blank, standard and sample tubes. 1ml reagent B was added 
and mixed immediately to all tubes which were incubated at room temperature 
for 15 minutes. The absorbance was measured at 750 nm using Biotech 
photometer (UV 1101, Cambridge, UK) and results were plotted to derive a 
standard curve using Microsoft Excel software.
2.3.5 Protein blotting & staining
2.3.5.1 Semi-dry Western Blot
After running the protein samples on a polyacrylamide gel, the gel was 
equilibrated in three changes of transfer buffer (25mM Tris, 192mM glycine, 
and 20% methanol) for 5 minutes each, by rocking it gently at room 
temperature. For each gel, 8 sheets of 3MM Whatman paper and one sheet of 
Immobilon PVDF membrane (Millipore, Bedford, UK) were cut to the same 
size as the gel. The Whatman papers were soaked in transfer buffer, while the 
membrane was soaked first in methanol for 15 seconds and then in transfer 
buffer. Arrangement of the blot layers in the electroblotting apparatus 
commenced by stacking 4 pieces of Whatman paper on the bottom plate 
electrode of BioRad semi-dry blotter apparatus (Trans-Blot SD, UK). These 
were followed by the membrane upon which the gel was carefiilly placed. At all 
stages care was taken to avoid trapping bubbles between layers of the stack. 
Finally, the remaining 4 pieces of Whatman paper were laid carefully on the top. 
Any air bubbles that may have been present were removed by gentle rolling
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from the centre outwards with an empty 50ml falcon tube. The upper electrode 
plate was put in position and the apparatus was closed. Proteins were blotted 
from the top ‘negative electrode’ towards the bottom ‘positive electrode’ at 10- 
15 volts for 40 minutes with maximum current limit of 5.5Amp/cm^.
2.3.5.2 Immunostaining of Western blots
The capacity of the membrane to bind protein non-specifically was blocked after 
blotting by overnight immersion of the blot in blocking solution containing 5% 
dried milk protein in Ix tween 20 wash buffer at 4°C. The blot was then placed 
carefully inside a 50ml falcon tube ensuring that the protein side was facing the 
centre of the tube. 5ml blocking buffer containing the appropriate dilution of 
primaiy antibody (Appendix V) was then added, and the tube was rolled at the 
appropriate temperature for 1 hour on a roller mixer SRTl (Stuart scientific, 
UK). Most antibodies were allowed to bind at room temperature, but in some 
cases suppliers specified 4°C for this step in which case the rolling was carried 
out in the cold room. The blot was then removed and washed twice in Ix tween 
20 wash buffer (30 seconds each wash), and then twice for 10 minutes each time 
in the same buffer. It was then transferred to another 50ml falcon tube 
containing 5mls of blocking buffer as above in which the appropriate dilution of 
the secondary antibody (horse radish peroxidase (HRP) conjugate) (Appendix 
V) had been prepared. Rolling incubation continued at room temperature for 1 
hour. The blot was washed again as above before it was removed from the box, 
excess liquid carefully removed by scraping it gently across the edge of the box 
and a chemiluminescent substrate (Super Signal West Pico, Thermo Scientific, 
Rockford, USA) was then applied on its protein side and distributed by gentle 
pipetting and left on the blot for 5 minutes. The blot was then removed, briefly 
wiped on the side of the box and wrapped in cling film. The wrap was then 
placed in X-ray cassette (protein side uppermost) and held in place with a tag of 
masking tape. A fresh X-ray film (Fuji) was then placed on the blot wrap and the
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cassette closed. An initial exposure was developed after 1-2 minutes to check 
the intensity of the signal and a fresh film was then placed. This was exposed for 
periods of a few minutes to an hour depending on the intensity of the bands 
generated in the initial exposure.
2,4 Annealing reactions for synthetic inserts
When complete sequence replacement was necessaiy sections of the DNA to be 
inti'oduced were synthesised as oligomers in both positive and negative senses. 
These were then annealed to create a double stranded molecule with protruding, 
single-stranded, sticky ends compatible with the restriction enzyme cleaved 
acceptor molecule into which the synthetic DNA was to be inserted. A lOOpl 
annealing reaction was used containing lOjal lOx annealing buffer (Appendix I), 
45 pi sense strand and 45 pi antisense strand in 1.5ml Eppendorf tube which was 
exposed to heat in boiling bath for 2 minutes and then transferred to 65°C 
heating block for 5 minutes and finally transfened to 44°C water bath for 2 
hours. The samples were left to cool overnight in the water bath after it was 
turned off. The DNA strands were precipitated (as in 2.2.1) and resuspended in 
90pi Milli-Q water. The strands were phosphorylated using lOOpl reaction 
containing the 90pl DNA sample, lOpl lOx kinase buffer (Appendix I), Ipl 
ImM ATP and 2pi kinase enzyme (which catalyzes the transfer of a phosphate 
group from ATP to the free terminus of the polynucleotides) and mixed. The 
mixture was incubated at 37°C for 45 minutes. The annealed DNA strands were 
extracted fi*om the solution by addition of equal volume (100pi) of phenol- 
chloroform-isoamyl alcohol to the sample followed by vortex mixing for 2 
minutes. Phases were separated by centrifugation (13000 rpm for 2 minutes) and 
the upper (aqueous) layer was haiwested to a fresh Eppendorf tube. The DNA 
was re-extracted and precipitated (as in 2.2.1), and resuspended in 50pi Milli-Q 
water.
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Chapter 3: Production of engineered Hawaii capsid protein
The Hawaii virus capsid protein (VPl) was selected for engineering. This is the 
prototype GII virus and was selected since GII viruses are currently reported as 
responsible for the bulk of outbreaks. If our approach was to succeed with GII 
then this would be of greater significance as this success may transfer to the 
other genogroups.
3.1 Methods
3.1.1 Cloning strategy
The strategy was to clone Hawaii VPl protein in two sections: left hand (LH) 
and right hand (RH) separately and then to combine them to yield a product in 
which unique terminal sites can be used to force the orientation of cloning, 
whilst distinct, but also unique sites would be present internally flanking the P2 
region destined for replacement. P2 itself was removed in this process and 
replaced with a short stuffer of unrelated sequence (but with compatible termini) 
derived from Lambda phage. This can easily be removed for replacement with 
sequences of interest. Restriction enzyme sites were chosen to flank the 5’ and 
3’ ends of the each segment as follow: (BamHI and Xhol) to flank the LH 
segment and (Hindlll and PstI) to flank the RH segment, and Hindlll to flank 
both ends of the stuffer segment which is incorporating a native Xhol site in the 
center. Each segment was cloned separately in pGEM T-easy plasmid vector. In 
order to create the artificial constructs for evaluation the stuffer segment was 
removed by Hindlll digestion and ligated at the end of the RH clone using the 
newly created Hindlll site in the forward primer used to amplify this region. 
Then, the left hand end of the stuffer segment was removed by digesting this 
vector with Xhol (at the site contained within the stuffer segment) and PstI at the 
3’ end of the RH segment. This separated the RH segment plus part of the 
lambda stuffer (terminating in PstI and Xhol restriction sites). Finally, this
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segment could be ligated in the LH clone after its digestion with Xhol flanking 
the 3’ end of the LH segment and PstI which exists in the pGEM T-easy vector 
to form the final construct. For use, the remaining part of the stuffer was 
removed by digestion with Xhol and Hindlll to allow the insertion of any 
desired sequence between these sites. Initially, we replaced the stuffer section 
with short length of synthetic DNA specifying poly-glycine amino acid chain to 
reform a plasmid containing the desired inserts (figure 12).
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Figure (12) Cloning strategy in pGEM T-easy
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Figure (12) Showing the cloning strategy 
of engineered Hawaii VP 1 into 
pGEM T-easy plasmid. Different 
nucleotide fragments are shown in 
specific colours as follows: RH: blue, 
LH: green, Lambda: red, poly-glycine 
chain: yellow. The used Restriction 
enzymes are shown above the arrows for 
different digestion reactions.
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3.1.2 Primers
Three PGR primers were designed and purchased (SIGMA Proligo, UK); two to 
amplify the LH and RH segments of Hawaii VPl gene (Accession number: 
U07611.2): LH(Hawaii) primer and RH(Hawaii) primer, and one to amplify a 
segment of Lambda phage DNA as a stuffer (table 3) (figure 13) (Appendix III). 
Restriction enzyme sites were added at the 5’ end of each primer to allow easy 
manipulation of the amplified segments.
Table (3) PCR Primers
Primer/Orientation/Genomic 
location/Accession number
Sequence
LH(hawaii)/Forward/5085-5104 
[Hawaii ORF2 - U07611.21
5 ’ - AG AGGATCC ATG A AG ATGGCGTCG A ATG A-3 ’
LH(hawaii)/Reverse/5895-5912 
[Hawaii 0RF2 - U07611.21
5 ’ -G ACTCG AGCCCGTGGTGCCC A AC AATTC-3 ’
RH(hawaii)/Forward/ 6246-6265 
[Hawaii ORF2 - U07611.21
5 ’ -GC AAGCTTGGGTCTGTTT A AC ACTG ACC A-3 ’
RH(hawaii)/Reverse/ 6672-6689 
[Hawaii ORF2 - U07611.21
5’-GCCTGCAGTTACTGCACTCTTCTGCGCCC-3’
Lambda stuffer/Forward/ 33301-33319 
[Lambda phase - V00638.ll
5 ’ -GC AAGCTT AGTCTGG AT AGCC AT A AGT-3 ’
Lambda stuffer/Reverse/33831-33850 
[Lambda phase - V00638.1]
5’-GCAAGCTTATTGAAATCGACCATGACGT-3’
Table (3) Showing the nucleotide sequences, orientations and genomic locations 
of the designed primers with the added restriction enzyme sites (underlined) at 
the 5’ ends. BamHI and Xhol were chosen to flank the LH segment, Hindlll and 
PstI to flank the RH segment and Hindlll to flank both sides of the Lambda 
stuffer. Extra bases are shown in bold and stop codon is boxed.
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Figure (13) Primers sites and directions 
5085-5104 p 2  6246-6265
5 -  - 3 ’
5895-5912 6672-6689
Figure (13): Schematic representation of Hawaii capsid gene ‘ORP2’ (shown in 
red) showing the site and direction of the designed primers; LH segment primers 
(represented by green arrows) and RH segment primers (represented by blue 
arrows).
3.1.3 Determination of poly-glycine chain length
We studied the X-ray structure of the NV rVLP (as a model for No Vs) using 
Swiss pdb viewer software, and found that the chains entering and leaving P2 
were approximately 28Â apart. This gap could be bridged using a short chain of 
poly-glycine, an amino acid chosen for simplicity and flexibility and relatively 
low immunogenicity, and which itself may not promote drastic structural 
alteration. A minimum of 8 residues would be required if the chain is extended, 
and up to a maximum of 18 residues if in flexible a-helical conformation. 
Accordingly, these artificial sequences were synthesised as sense and antisense 
strands (SIGMA Proligo, UK). The complementary strands of each chain were 
annealed together (as in general methods) to form a dsDNA with sticky termini 
appropriate for the restriction enzymes used (table 4). Each of the annealed 8 
and 18 poly-glycine segments were then used to replace the stuffer segment after 
it had been removed to produce the final clones in pGEM T-easy vector 
containing the modified Hawaii capsid gene (8-Hawaii and 18-Hawaii).
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Table (4) Synthetic poly-glycine chains
Name Nucleotide sequence
Annealed 8 
poly-glycine 
‘Sense’ & 
‘Antisense’ 
strands
5’-TCGAGTGGAGGAGGAGGAGGAGGAGGAGGA3’
3 ’- CACCTCC TCC TCC TCC TCC TCCTCC TTCGA-5 ’
Annealed 18 
poly-glycine 
‘Sense’ & 
‘Antisense’ 
strands
5’-TCGAGTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGA-3’
3 CACC TCCTCC TCC TCC TCC TCC TCC TCC TCC TCCTCC TCC TCC TCC TCC TCCTCCTTCGA-5'
Table (4) Nucleotide sequences of the synthetic 8 and 18 poly-glycine chains 
with complementary ends (underlined) to those cut with Xhol and Hindlll for 
replacement of the Lambda stuffer.
3.1.4 Purification of the engineered Hawaii capsid protein
Several methods for the purification of VLPs have appeared in the literature 
(Jiang et al. 1992; Hutson et al. 2003). These make use of the density and 
sedimentation coefficients of the VLPs, but since our goal was to alter the size 
and shape of the VLPs produced it was possible that no previous method would 
be immediately applicable. We therefore attempted several different procedures 
and modifications thereof.
3.1.4.1 First purification method
This method was derived from Jiang et al. (1992). Polyethylene glycol ‘PEG’ 
was used to precipitate protein from the pooled SfZl culture supernatants. Solid 
PEG (Grade 6000) was added to final concentration of 8% and dissolved by 
stirring. The flask stood on ice for 1 hour before proteins were pelleted at 1500 
rpm for 30 minutes in Mistral-3OOOi centrifuge (Sanyo, Japan). The supernatant 
was discarded and the pellet was resuspended thoroughly by syringing in 5ml 
NT buffer (0.1 M NaCl, 0.01 M Tris pH 7.4) using needles of progressively 
finer bore (21G, then 25G). Higher speed spinning at 10000 rpm for 10 minutes
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then pelleted the large protein aggregates and debris and the resulting 
supernatant was diluted using NT buffer and overlaid onto a 5ml cushion of 
20% sucrose/NT buffer in a sw28-Ti rotor tube. The samples were spun at 
28000 rpm in Beckman ultracentrifuge (J2-21M/E, Beckman Coulter, USA) for 
5 hours, then the supernatant was discarded and the pellet below the cushion was 
resuspended in 100 pi NT buffer. In this method protein should not pellet 
through the sucrose unless particulate, while soluble protein will remain in 
solution above the sucrose.
3.1.4.2 Second purification method
This method was derived from Hutson et al. (2003), and has the advantage that 
PEG was not used since this could result in the formation of aggregates which 
might not be readily broken up. This could lead to a loss of desired material 
during clarifications. In this approach the cell culture supernatant was harvested 
and clarified by centrifugation at 2500 rpm for 5 minutes in centurion 
centrifrige-1000 series. Higher speed centrifugation at 10000 rpm for 10 minutes 
excluded the larger cell debris. The supernatant was directly spun in sw28-Ti 
rotor tubes at maximum speed for 2 hours in Beckman ultracentrifuge (J2- 
21M/E) to pellet any VLPs. The pelleting time was calculated according to the 
formula: T = K/S, where T= pelleting time in hours, K = K-factor of the rotor 
(246 for sw28-Ti rotor) and S = sedimentation coefficient of the target protein 
(170-187s for No Vs, according to the ICTV database description). The pellet 
was resuspended in 1ml NT buffer by syringing, and resuspended in 1.34 g/cm^ 
CsCl as the reported buoyant density of No Vs in CsCl is 1.33-1.41 g/cm^ 
(Kapikian et al. 1996). This was placed into a Beckman sw55-Ti rotor tube 
which was spun to equilibrium overnight at 50000 rpm in Beckman 
ultracentrifuge (L-8M) to separate different components on the basis of their 
densities. Any potential VLP band was aspirated by micropipetting and then 
pelleted again through NT buffer to remove the CsCl.
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3.2 Results
3.2.1 Screening of PCR products
The cDNA specifying Hawaii virus VPl was obtained by PCR from a 
recombinant Baculovirus kindly supplied by Dr Kim Green of NI AID, Bethesda, 
USA. This was then recloned into pGEM T-easy. This clone had been prepared 
and sequenced by a previous student at Surrey (Grace W. Kuria; University of 
Surrey MPhil thesis 1999), and was used as the source of DNA from which to 
engineer the proteins. PCR was performed as described in general materials and 
methods chapter. Products were analysed on agarose gels (figure 14) which 
shows the following band sizes: 549bp, 443bp, and 827bp for lambda, RH, and 
LH segments respectively. Each PCR product was extracted from an agarose gel 
and cloned separately in pGEM T-easy plasmid. After transformation, plasmids 
carrying each insert were prepared and used in the cloning strategy.
Figure (14) PCR products
1 2  3 4
lOOObp
827bp
.  ^-----  549bp
SOObp --------- ^  4 4 3 b „
Figure (14) Agarose gel (1.2%) showing the PCR products. (1) Ikb DNA ladder. 
(2) Lambda stuffer [549bp]. (3) RH segment [443bp]. (4) LH segment [827bp].
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3.2.2 Confirmed constructs in pGEM T-casy vector
The two constructs (8- and 18-Hawaii) should differ by a length of 30 bases (18- 
8 amino acid codons), but this difference is too small to be apparent without 
excision. Accordingly, insertion into pGEM T-easy vector was checked by 
cutting out the section of the construct including the poly-glycine insertion using 
two sets of restriction enzymes, (BamHI and Hindlll) and (Xhol and PstI). The 
restriction fragments of the first enzyme set consist of two bands; one 
corresponds for the vector and the other for LH segment plus 30 or 60bp (for 8 
or 18 amino acids) giving final sizes of 857bp and 887bp respectively, while, the 
other enzyme set gives band corresponding for the vector and band for RH 
segment plus 30 or 60bp (for 8 or 18 amino acids) giving final sizes of 473bp 
and 503bp with a small, but detectable difference in mobility on the gel (figures 
15, 16).
Figure (15) Modified Hawaii VPl in pGEM T-easy
XholLHBamHI Hindlll
PstI
pGEM T-easy 
(3015bp)
Figure (15) Schematic diagram showing the final clone of the Hawaii capsid 
protein after substitution of the P2 subdomain with poly-glycine chain in pGEM 
T-easy plasmid vector and showing different restriction enzyme sites used for 
screening of the correct insertion of the constructed nucleotide sequence in that 
vector.
80
Production of Engineered Hawaii Capsid Protein
Figure (16) Screening of 8- and 18-Hawaii capsid gene in pGEM T-easy
(BamHI & Hindlll) (Xhol & PstI )
1 2  3 4
lOOObp -------
8 5 7 b p _ ^  I------  887bp
750bp-------
SOObp 503bp473bp
Figure (16) Agarose gel (1.2%) showing the restriction fragments confirming 
the correct cloning of the modified Flawaii capsid gene in pGEM T-easy. (1) & 
(2) Restriction fragments of (BamHI & Hindlll) of the 8- and 18-Hawaii clones 
respectively (3) & (4) Restriction fragments of (PstI & Xhol) of the 8- & 18- 
Hawaii clones respectively. The slight increase in size of the 18 amino acid 
insert construct is visible (tracks 2 and 4) compared with the 8 amino acid insert 
(tracks I and 3).
3.2.3 Confirmed constructs in Baculovirus shuttle vector (pVL1393)
Once the construct had been confirmed it was excised from the pGEM T-easy 
vector using the terminal enzymes (BamHI and PstI) and recloned into the 
Baculovirus shuttle vector (pVL1393). Sites had been chosen to permit easy 
cloning to produce a final construct in that vector. Once clones had been 
obtained the presence and orientation of the modified ORF2 insert in pVL1393 
vector was confirmed by restriction enzyme digestion using the enzyme pairs 
(BamHI and Bglll) and (PstI and Xhol). The inserts released by these treatments 
were assessed on an agarose gel. The first enzyme pair shows restriction 
fragments of the following sizes: 566bp (segment between BamHI and Bglll in
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the LH fragment), 738bp and 768bp for the segment between the two Bglll 
enzymes including the remaining part of LH, poly-glycine chain and RH in 8- 
and 18-Hawaii constructs respectively, and a third band (fragment between 
Bglll and BamHI including the remaining part of the vector) (figures 17, 18, 
19), while, the second enzyme pair shows restriction fragments of the following 
sizes: 473bp and 503bp including the RH and the poly-glycine chain in 8- and 
18-Hawaii constructs respectively, 3055bp (segment between the two Xhol sites 
including the LH fragment), and a third band representing the remaining part of 
the vector. Size difference due to the insertion of the extra 30 bases in 18- 
Hawaii construct is visible in the shift of the 473bp band in the Xhol and PstI 
digest to 503bp as seen in tracks 4 and 5 in figures (18) and (19) respectively.
Figure (17) Modified Hawaii VPl in Baculovirus shuttle vector
Bglll [566]
XholBamHI
(4129)
LH
lindlll
Xhol
(1901)
PVL1393
(9639bp)
PstI (4165) 
Bglll (4169)
Figure (17) Schematic diagram showing the Baculovirus shuttle vector carrying 
the modified Hawaii capsid gene and showing different restriction enzyme sites 
that were used for screening of the correct insertion of the constructed 
nucleotide sequence in that vector.
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Figure (18) Screening of the 8-Hawaii capsid gene in pVL1393
(BamHI & Bglll) (PstI & Xhol)
5
10,000bp 
3000bp------ ►
750bp
SOObp
3055bp
738bp
566bp
473bp
Figure (18) Agarose gel (1.2%) showing the restriction fragments confirming the correct 
cloning of the 8-Hawaii capsid gene into the Baculovirus shuttle vector (pVL1393). (1) Ikb 
DNA ladder. (2) & (3) Restriction fragments of (BamHI & Bglll) of clones 1 and 2 of 8- 
Hawaii construct respectively. (4) & (5) Restriction fragments of (PstI & Xhol) of clones 1 
and 2 respectively.
Figure (19) Screening of the 18-Hawaii capsid gene in pVL1393
(BamHI & Bglll) (PstI & Xhol)
1 2 3 4 5
lO.OOObp----- ►
3.000bp ----- ►
lOOObp------- ►
750bp --------►
SOObp ------- "
3055bp
768bp 
566bp 
503 bp
Figure (19) Agarose gel (1.2%) showing the restriction fragments confirming the correct 
cloning of the 18-Hawaii capsid gene into the Baculovirus shuttle vector (pVL1393). (1) Ikb 
DNA ladder. (2) & (3) Restriction fragments of (BamHI & Bgll) of clones 1 and 2 of 18- 
Hawaii construct respectively. (4) & (5) Restriction fragments of (PstI & Xhol) of clones 1 
and 2 respectively.
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3.2.4 Sequencing of the final clones
The 5’ and 3’ sections of the cloned constructs were checked in pGEM T-easy 
vector by using the universal M l3 forward and reverse primers. To confirm the 
identity of each clone prepared with synthetic insert two new internal primers: 
Hawaii-junct-seq. and Left-Hawaii-seq. (table 5) were designed and purchased 
(SIGMA Proligo, UK) to sequence across the 3’or 5’ end of the inserted poly­
glycine chain respectively and also to check the correct ORE. Two samples were 
sent to CoGenics Company for each construct, obtained data confirmed presence 
of the expected sequences (Appendix IV).
Table (5) Internal sequencing primers
Primer/Genomic location Sequence
Hawaii-junct-seq./6315-6294 
[Hawaii 0RF2 - U07611.21
5 ’-TGTTTAGGGTTAATCTTCCAGA-3 ’
Left-Hawaii-seq./5793-5812 
[Hawaii 0RF2 - U07611.21
5 ’ -TTGTC AA ATTCT AG ATTCCC-3 ’
Table (5) Nnucleotide sequence and genomic location of the internal primers 
that were designed to sequence across the inserted poly-glycine chain.
3.2.5 PCR-confirmed recombinant Baculovirus plaques
Clones yielding the expected restriction digest pattern and sequencing result 
were selected and used in co-transfection of Sf21 cells with Baculovirus linear 
DNA. During this reaction Baculovirus cannot be rescued unless the linear virus 
DNA supplied is returned to a circular form. This is only achieved if it can 
recombine with the cDNA provided in the Baculovirus shuttle vector. This 
recombination inserts the engineered recombinant construct into the Baculovirus 
DNA under the control of the polyhedrin promoter. The transfection medium 
was harvested and plaqued in Sf21 cells. Recombinant “white” Baculovirus
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plaques were picked and tested for the presence of inserted sequence by PCR 
using the LH(Hawaii) forward and the RH(Hawaii) reverse primers. The 
expected sizes are 1300bp and 1330bp for 8- and 18-Hawaii constructs 
respectively, four out of five tested plaques were proved positive for 8-Hawaii 
insert, and three out of five for 18-Hawaii (figures 20, 21).
Figure (20) PCR screening of recombinant Baculovirus 
(Containing 8-Hawaii capsid gene)
1 SOObp ---------►!__________________________________________________
1 SOObplOOObp  H
Figure (20) Agarose gel (1.2 %) showing PCR screening of the picked plaques 
of the recombinant Baculovirus with the 8-Hawaii capsid gene. (1) Ikb DNA 
ladder. (2) Negative control. (3) Positive control. (4), (5), (6), (7) and (8) PCR 
products of five different plaques with expected size band (1300bp) shown in 
lanes 4, 5, 6, and 7.
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Figure (21) PCR screening of recombinant Baculovirus 
(Containing 18-Hawaii capsid gene)
1 SOObp ---------------------------------------------------------------------------------------------- —  13 3 0 b p
lOOObp ---------
Figure (21) Agarose gel (1.2 %) showing PCR screening of the picked plaques 
of the recombinant Baculovirus with the 18-Hawaii capsid gene. (1) Ikb DNA 
ladder. (2) Negative control. (3) Positive control. (4), (5), (6), (7) and (8) PCR 
products of five different plaques with expected size band (1330bp) shown in 
lanes 4, 6, and 7.
3.2.6 Purified 8- and 18-Hawaii proteins
Plaques which yielded the correctly sized PCR product were then grown on (as 
described before) to produce high titer stocks in order to assess the induction of 
any recombinant proteins.
The expected molecular weights of the engineered 8- and 18-Hawaii capsid 
proteins were calculated using OMIGA software (kindly provided by Dr. Mike 
Carter) to be 47.5kDa and 48kDa respectively. Yields of recombinant proteins 
appeared highly variable from experiment to experiment. The first attempt using 
either the first or second method for purification yielded a surprisingly pure 
preparation of virus protein; a single prominent band of the expected molecular 
weight (47.5kDa for the 8-Hawaii capsid protein) was observed on Coomassie 
staining after polyacrylamide gel electrophoresis (figures 22 and 23).
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Purification of the 18-Hawaii capsid protein was tried by both methods, while 
the first method failed to show any VLPs, by using the second method we could 
reveal a specific band of expected molecular weight (48 IcDa) on a Western blot 
immunostained with rabbit anti-Hawaii capsid protein antibodies (kindly 
provided by Kim Green, USA) after CsCl (L34g/cm^) density gradient 
centrifugation (figure 24). In the second purification method of both 8- and 18- 
Hawaii proteins we measured the densities of four different layers obtained after 
overnight spin in 1.34g/cm^ CsCl (at 50000 rpm) by densitometer and were 
found to be as follow: 1.17g/cm^ -  1.19g/cm^ -  1.28g/cm^ -  1.49g/cm^ for 
layers ‘T to ‘4’ respectively from up- downwards. The highly pure protein 
bands of both expressed constructs shown in figure 23 (lane number 4) and 
figure 24 (lane number 6) were found in CsCl layer number ‘3’ with density 
measuring 1.28g/cm^ which is less than the density of the wild NoVs and this 
was expected as the expressed VLPs are devoid of nucleic acid.
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Figure (22) Purified 8-Hawaii VLPs ‘First purification method’
1 2
175kDa 
83kDa 
62kDa 
47.5kDa
32kDa
47.5 kDa 8-Hawaii 
VLPs
Figure (22) SDS polyacrylamide gel. (1) Prestained broad range protein marker. 
(2) Purified 8-Hawaii capsid protein with the expected size ‘47.5 kDa’ (first 
purification method).
Figure (23) Purified 8-Hawaii VLPs ‘Second purification method’
175kDa
83kDa
62kDa
47.5kDa
32kDa
L
47.5 kDa 
8-Hawaii VLPs
Figure (23) SDS polyacrylamide gel. (1) Prestained broad range protein marker. 
(2), (3) and (4) Different CsCl ‘1.34 g/cm^’ density layers [number 1,2,3] of 
which layer [3] (lane 4) with density measuring 1.28g/cm^ contains the 8- 
Hawaii capsid protein with the expected size ‘47.5 kDa’ (second purification 
method).
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Figure (24) Purified 18-Hawaii VLPs ‘Second purification method’
175kDa 
83kDa 
62kDa
47.5kDa 
32kDa
48 kDa 18-Hawaii 
VLPs
Figure (24) Western blot immunostained with rabbit anti-FIawaii capsid protein 
antibodies, showing the purification steps of the 18-FIawaii capsid protein from 
Sf21 cells. (1) Non-infected Sf21 cells. (2) Supernatant of infected SfZl cells 
(with recombinant Baculovirus-18-Hawaii). (3) Cell lysate of infected SfZl 
cells. (4) 28000 rpm spin supernatant. (5) 28000 rpm spin pellet. (6) VLP band 
after 50000 rpm spin in CsCl (1.34g/cm^) showing the purified 18-Hawaii 
capsid protein with the expected size ‘48kDa’ (second purification method).
3.2.7 EM-detected particulate forms
A sample of the purified 8-Hawaii capsid protein was sent to Pirbright I AH 
(Institute for Animal Health) where it was observed under the EM by Dr Paul 
Monahagn. The preparation examined with the EM revealed numerous 
particulate structures (figure 25). Many of these were small ring-like structures 
as frequently observed in preparations of both viable virus and VLPs (Jiang et 
al. 1995; White et al. 1996; White et al. 1997). Scattered amongst these were 
occasional smooth round structures approximately 30nm in diameter (accurate
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sizing was not performed). In addition some larger aggregates (also rounded) 
were observed representing attached multiple VLPs.
Figure (25) EM of the expressed 8-Hawaii VLPs
Ring 
Larger structure
VLPs
Figure (25) Electron micrograph of the purified 8-Hawaii capsid protein 
showing potential VLPs, small protein rings and also larger structures 
representing attached multiple VLPs.
3.3 Discussion
Previous work at Surrey University had generated deletion constructs in which 
the variable region (P2) was removed. The resulting protein failed to form 
particles and instead adopted a denatured conformation (N. Smith, University 
of Surrey, MPhil thesis) that induced serum reacting only with denatured 
protein. In order to promote more faithful protein folding, possibly even particle 
formation, we sought to replace the missing P2 subdomain with poly-glycine to 
bridge the gap between the emergent and returning polypeptide chains entering 
and leaving the PI subdomain and thus allow these chains to move easily to the 
required distance apart. At this stage data obtained supported the concept that 
bridging the gap where P2 had been removed was permitting some form of 
structural assembly (figure 25). However, later preparations failed to yield 
significant virus proteins. This was attributed to poor growth of the recombinant
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virus in the SfZl cells. During this period the host cells themselves were not 
growing well and protein yields were generally low in the Baculovirus system.
Thus, in an attempt to both improve protein yield and to move on towards the 
second goal of developing an enterically administrable form of the engineered 
proteins it was decided to change the expression system to yeast. Whole yeast 
cells could serve as a vehicle to introduce the relatively conserved antigenic 
domains of Hawaii capsid protein to the gastrointestinal tract, simulating the 
natural infection pathway resulting in gut immune stimulus that might result in 
better cross-reactive local and systemic immune responses. Although it was 
generally assumed that NoV VLPs might provide a serviceable acid-stable 
carrier for the expression of such epitopes, it was not necessarily a requirement 
that any particle formed should be faithful full-size VLP assembled in the same 
way as intact virus in order to perform this role. Furthermore, administration of 
antigens within yeast cells is expected to exert some protection of the antigens 
from the adverse conditions in the stomach and so full acid stability of the VLPs 
or other structures may not be an absolute requirement. Consequently, the 
observation of some structural components in the engineered protein was at least 
promising. Also, we sought to create a chimeric protein containing the left and 
right sections of the Hawaii capsid protein, but incorporating an unrelated 
antigenic domain.
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Chapter 4: Yeast expression system as an edible vaccine candidate
4.1 Introduction
Constraints on different aspects of vaccine manufacture and delivery have 
been responsible for exclusion of about 20% of infants from the compulsory 
immunisation programme with the result of 2 million deaths all over the world 
every year (Langridge 2000). The fear of spread of infectious diseases from un­
immunized persons makes it necessary to find an alternative that is easy to 
deliver, cost effective, safe and socially acceptable to provide protection (Fifis 
et al. 2004). Diarrhoeal viruses in particular wreak their greater damage in the 
developing world. Deaths are increased by malnourishment and this also reduces 
the capacity of the body to mount an immune response (Keiisch and 
Scrimshaw 1986).
Parenteral immunisation does not lead to efficient stimulation of the 
mucosal immune system in which direct presentation of the antigen to the 
mucosal surface is essential (Czerkinsky et al. 1993). As Tanaka et al. (2006) 
observed in their comparative experiment of different immunisation routes, the 
production of IgA was significantly higher in case of hybridomas produced after 
oral immunisation of mice than those produced after using intraperitoneal route. 
Body mucosal surfaces, especially the intestine, act as a potential access route 
for a large variety of pathogens. Local immune control is essential and >60% of 
the antibodies secreted daily are produced in the gastrointestinal (GI) tract. 
Consequently the GI tract may be regarded as one of the largest immunological 
organs of the human body (Pouwels et al. 1998). Edible vaccines may prove 
particularly suited to protection against organisms that usually invade via the 
enteric tract as this is the natural route for virus challenge to the body and it is 
here that effective local immunity may offer protection (Mestecky and Mcghee 
1987). Vaccination by the same route may thus offer the potential for induction
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of a more “natural” type of immunity. Furthermore, due to the integration of the 
mucosal immune system, remote priming of other mucosal surfaces may result 
(Ruedl and Wolf 1995) representing an advantage for producing an effective 
multivalent oral vaccine canying antigens from different pathogens with 
variable mucosal entry routes. Also, oral immunisation frequently stimulates 
both local and systemic immune responses with effective pathogen restriction 
(Pouwels et al. 1998).
Edible vaccines can overcome the pitfalls accompanying parenteral 
vaccination such as high production cost and poor patient compliance since 
some healthy individuals will avoid presenting themselves for immunisation 
(Cripps et al. 2001). Production of herd immunity by oral immunisation of a 
small proportion of community individuals can represent an advantage when 
applied in less industrialized countries (Bloom 1989; Husband 1993). The easy 
administration of edible vaccines minimizes the need for medically trained 
personnel. Also, they can be efficiently prepared by relatively low-technology 
processes (akin to agriculture for plant based expression, or perhaps more 
similar to brewing in the yeast-based system as proposed) and do not require 
purification or extensive downstream processing. All of this makes enteric 
vaccines cheap to produce and administer. A final advantage is that engineered 
foodstuffs are relatively stable, obviating the need for cold chain maintenance 
(Walmsley and Arntzen 2000).
The effect of providing a potential vaccine and a simultaneous nutrition 
supplement has not yet been assessed, but this is readily achievable by using 
edible vaccines in which the vaccine carrier is not an inert matrix but of 
nutritional value itself. Repeated and prolonged administration may be necessary 
to induce response by this route but this does not pose the same problems if  it 
were necessary to achieve repeat administration of a parenteral or conventional
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vaccine. Finally, such a process of repeat administration provides opportunity to 
improve the nutritional status of the vaccinee during the course of a vaccination 
regime.
Production of edible vaccines has to date largely concentrated on plants 
(fruits or leaves in particular) to deliver antigenic proteins to the digestive tract. 
The genes of interest are transferred to create a transgenic plant with the ability 
to manufacture the encoded protein. Several plants have been used for 
production of antigenic proteins such as tobacco, tomato and potato through 
their infection with recombinant plant virus as the tobacco mosaic virus (Santi 
et al. 2006; Gleba et al. 2007). These transgenic plants have proved to be 
immunologically active when orally ingested (Huang et al. 2005), however, 
their actual use to produce a commercial vaccine has been delayed due to 
limitation of the expressed antigen amount which is usually <1% of total soluble 
protein (Santi et al. 2008).
However, although it has not been evaluated for this puipose killed and 
dried yeast preparations could be a good candidate for developing enteric 
vaccines. Yeast is readily grown and is known to dry well, retaining protein 
(enzyme) activity and nutritional value (e.g. in bakers yeast or yeast dietaiy 
supplements). Yeast is commonly found both in and on animal bodies; most 
animals exhibit some foim of sero-reactivity to yeast antigens which must 
indicate that exposure to yeast antigens occurs in the body. Further, the cells are 
readily manipulated by established processes to create and express recombinant 
proteins, whilst yeasts themselves are recognised as a food component and even 
used as a beneficial dietary supplement in man and livestock across the world. 
Finally, yeast feiinentation and culture is a well-established technology available 
on an industrial scale across the world. The approval of some yeast as edible 
food supplements for human use such as S. cerevisiae due to its GRAS status
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‘Generally Regarded As Safe’ has allowed its use in the pharmaceutical field 
(Schreuder et al. 1996).
Eukaryotic proteins expressed in their native hosts must undergo a post- 
translational stage of modification adding some molecules [such as 
carbohydrates] or bonds [such as disulfide bonds] to fold the protein into its 
final form (Romanos et al. 1992). Prokaryotic expression systems such as 
Escherichia coli (Baneyx 1999) and lactic acid bacteria which have been 
recommended for many years (Daly and Hearn 2005) mostly lack the ability to 
make such modifications resulting in production of mis-folded insoluble 
proteins which accumulate intracellularly as inclusion bodies (White et al. 
1994; Cole 1996). If intended for vaccine use, potentially toxic cell and cell wall 
components must be carefully removed by purification (Robinson et al. 1984) 
and the expressed proteins may require further Solubilisation and refolding 
(Marston and Hartley 1990). All of this reduces yield and increases expense 
(Wang et al. 2000; Daly and Hearn 2005). Yeast shares many of the useful 
aspects of bacterial expression systems but also offers advantages in better 
folding of expressed proteins.
A study done by Lueking et al. (2000) compared the expression of 29 
different cDNA clones of the human foetal brain proteins in E. coli and the yeast 
Pichia pastoris (P. pastoris) cells as heterologous protein expression systems. 
While E. coli could express only 24 clones (of which only nine were soluble and 
the remaining fifteen were produced as inclusion bodies) P. pastoris as a 
eukaryote expressed all as soluble proteins (Mason et al. 1996a). For these 
reasons yeast has been extensively used to produce antigens used in 
conventional vaccination procedures. These include for instance the first 
licensed recombinant subunit vaccine to protect against human hepatitis B virus, 
and human papilloma virus (reviewed in Spohn and Bachmann 2008), while
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many others are currently in trial such as dengue virus and HCV (Mune et al.
2003).
The stable genetic engineering of yeast cells is relatively simple due to 
well characterized site-directed homologous recombination processes (Blanquet 
et al. 2004). Transformants of yeast such as P. pastoris are genetically stable as 
they result from integration of the expression cassette into the chi'omosome of 
the cell through homologous recombination (Cregg and Higgins 1995). This 
stability abolishes the need for using media containing selective substance such 
as antibiotic which is required to isolate transformants in case of plasmid 
expression and in turn increases the production costs. Also, depending on 
plasmids for heterologous protein expression can not be guaranteed for long 
because plasmids are susceptible to be lost upon repeated passages (Romanos et 
al. 1992; Thiry and Cingolani 2002).
Although live attenuated vaccines are efficient immunogens, they carry a 
pathogenicity risk due to different virulence factors (Streatfîeld et al. 2001). 
There are currently some live-attenuated bacterial and viral vaccines which are 
administered either intradermally such as BCG vaccine (Colditz et al. 1994) or 
parenterally. However, there are few licensed oral vaccines based on live 
attenuated organisms (Tacket and Mason 1999).
A protective immune response was obtained in animals orally immunised 
with live recombinant avirulent Salomnella typhimiirium expressing 
pneumococcal surface protein ‘A ’ (Nayak et al. 1998) and Lactococcus lactis 
expressing tetanus toxin fragment ‘C’ (Robinson et al. 1997; Chatel et al. 
2001). Other trials are continued to assess the efficiency of oral vaccines 
produced against different strains of Salmonella typhi in humans (Bumann et al. 
2000).
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In a study by Schi'euder et al. (1996) who used the baker’s yeast 
Saccharomyces cerevisiae (S. cereviciae) as a matrix to deliver Hepatitis B 
surface antigen to mice by intraperitoneal administration, the immune response 
to yeast itself was stronger than that induced by the delivered antigen leading 
them to propose yeast as a good edible vaccine candidate (Blanquet et al.
2004).
Living S. cerevisiae has been used orally to protect against and treat some 
illnesses such as Clostridium defficile diarrhoea in man (Schellenberg et al. 
1994). Another yeast that has been commonly used for years to treat the 
antibiotic-associated diarrhoea is the Saccharomyces boulardii which was 
proved to be safe for human use (Mcfarland and Bernasconi 1993). Both types 
of yeast are considered fungal probiotics (Edwards-Ingram et al. 2007) 
allowing their use as food supplement. Also, they were proved to be promising 
as vaccine candidates capable of expressing immunogenic proteins (Schreuder 
et al. 1996).
To study the ability of living yeast given as oral vaccine to survive 
digestive tract conditions and actively secrete the protein of interest in different 
parts of the tract Garrait et al. (2009) conducted their study using S.cerevisiae 
expressing recombinant glutathione-S transferase protein in rats. They showed 
that 43% of the ingested yeast could be recovered alive from the upper part of 
the digestive tract.
Adjuvant-boosting of the safer inactivated vaccines can overcome their 
less potent immunogenicity which becomes worst on oral administration 
(Tacket and Mason 1999; Langridge 2000). When these vaccines are given 
through the oral route they are mostly affected by the harsh gastric conditions 
and enzymatic activity which dramatically distorts the structure and hence the
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immunogenicity of the delivered antigenic determinants allowing only few 
intact antigens to pass through the epithelium. Therefore, higher doses of orally 
administered inactive vaccines are usually required to compensate for this 
antigen loss (Lamm 1997).
Protection of the antigen from the adverse external environment can 
circumvent its loss before inducing an immune response (Lauterslager and 
Hilgers 2002). Antigen protection can be achieved by expressing the antigen in 
transgenic plants as the wall of plant cells offers an effective barrier in front of 
the acidic pH of the stomach and the other proteolytic enzymes in the 
gastrointestinal tract (Tacket and Mason 1999; Langridge 2000). Yeast cells 
can similarly offer the advantage of antigen protection as they are proved to be 
highly resistant to gastric and small intestinal secretions (Blanquet et al. 2003). 
The ability of recombinant yeast to survive rat gastric and intestinal environment 
was also reported by Garrrait et al. (2007).
Furthermore, using VLPs (or other repetitive particle structures) can add 
more advantages besides using yeast cells for external protection of the antigen 
(Jennings and Bachmann 2008). Their particulate nature and repetitive antigen 
display to the immune cells enhances the immune response with better induction 
of cytotoxic T-lymphocytes than other soluble and denatured proteins which can 
induce immunotolérance with suppression of the immune response (Garside 
and Mowat 1997) and thus VLPs can decrease both the need for co­
administration of adjuvants and also the number of required boosters (Grgacic 
and Anderson 2006).
Ball et al. (1996) obtained an exciting result in their study which involved 
oral immunisation of mice with purified NY rVLPs, significant serum and 
intestinal antibody responses were detected. Their results appeared surprising
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because they did not use adjuvants with the administrated antigen which 
consisted of non-replicating particles in contrast to data obtained earlier using 
poliovirus which emphasized the significance of using live attenuated virus for 
better production of mucosal responses after oral immunisation (Ogra et al. 
1968).
In addition to production of homologous immunity to the particle 
proteins, VLPs have been successfully used as earners for foreign epitopes 
(chimeric VLPs) with dual immune response production (Sedlik et al. 1997; 
Neirynck et al. 1999; Langeveld et al. 2001; Netter et al. 2001; Varsani et al. 
2003; Woo et al. 2006).
Recombinant proteins can be expressed either intra- or extracellulaiiy. 
Protein purification is required in intracellular expression to get rid of various 
contaminants. However, if the vaccine carrier is proved safe for human 
consumption such as some yeasts, then whole cells with intracellularly 
expressed antigens can be used thus removing the need for purification steps 
(Fames et al. 2005; Xia et al. 2007). As shown in the results of a study which 
compared capsid protein variants of RHDV expressed in P. pastoris, there was 
an insignificant difference between the immune response obtained when orally 
vaccinating rabbits with soluble purified protein and the protein associated with 
the raw disrupted yeast pellet (Farnos et al. 2006).
As a conclusion, yeast has been used successfully as expression bench for 
heterologous proteins. When thinking of VLPs as possible vaccines, it is most 
important to keep the correct folding of the expressed protein subunits which 
helps natural assembly of viral protein subunits into particles which by turn are 
known to be excellent immune response inducers than separate proteins. Yeast 
as eukaryote has the ability to perform post-trnaslational modification and fold
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the expressed proteins in a way similar to the native form, an advantage that is 
not possible in prokaryotes in which mis-folded proteins are usually produced. 
Several trials were done to use recombinant bacteria as oral vaccines which 
proved the importance of that route, however. Yeast should be considered more 
seriously due to their added advantages on the expressed protein. Parenteral 
administration of purified proteins expressed in yeast has been proved protective 
such as the hepatitis B surface antigen expressed in P. pastoris and 
commercially licensed for use. Repeated booster injections are usually required 
to enhance the immune response which represents a burden on the vaccinee. 
However, the advantages of the oral route over parenteral administration due to 
production of effective local immunity makes it veiy essential to evaluate its 
efficiency in restricting infections. Trials of oral recombinant yeast expressing 
antigenic proteins showed success in protecting immunised animals (Farnos et 
al. 2005; Xia et al. 2007). Yeast can also prove economically superior to plants 
which are commonly investigated nowadays as edible vaccines. Therefore, we 
set out to transfer previous constructs fi'om baculo to yeast in order to try 
recombinant Hawaii-yeast as oral vaccine and also to construct chimeric protein 
containing influenza sequences.
4.2 Methods
4.2.1 Yeast expression system
P. pastoris was selected for large scale expression of the study proteins. P. 
pastoris is a methylotrophic yeast; capable of metabolizing methanol as its sole 
carbon source. The parent type strain ‘X-33’ which is phenotypically methanol 
utilization positive (Muf^) was used through out our experiment. There are two 
genes in Pichia pastoris coding for the alcohol oxidase enzyme; AOXl and 
AOX2, however, most of the enzyme activity in the cells is accounted for by the 
AOXl product. The AOXl gene is highly induced by methanol and its product 
may account for >30% of the total soluble protein in cells growing in the
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presence of this compound. This efficient promotion has prompted the use of the 
AOXl promoter to drive heterologous protein expression in Pichia. The inducer 
(methanol) is critical (Koutz et al. 1989). We used two different yeast shuttle 
vectors in our study: one for intracellular expression (pPICZ-A) and the other 
for secreted expression (pPICZ a-A) (Appendix II). The later was used through 
out most of the experiment and hence its features were considered in details in 
figure (26) and table (6). Yeast strains, shuttle vectors and sequencing enzymes 
used in this study were included in the EasySelect Pichia Expression Kit which 
was purchased from Invitrogen Company (California, USA, Cat. No. K1740- 
01).
Figure (26) pPICZ a-A Pichia expression vector
a-factor Multiple Cloning Site c-myc epitope 6x His stop
5’AOXl AOXl TT region
PTEF-1
pUC origin
PEM7
Zeocin resistance gene
Figure (26) Diagram of pPICZa-A vector showing its features.
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Table (6) Features of pPICZ a-A Pichia expression vector
Feature Function
5’ AOXl - A 942 bp fragment containing the 
AOXl promoter.
- Targets plasmid integration to the 
AOXl locus.
- 5’ AOXl priming site: bases 855-875
Native Saccharomyces cerevisiae 
a-factor secretion signal
Efficient protein secretion from 
Pichia
Multiple cloning site with 10 
unique restriction sites
insertion of gene of interest into the
expression
vector
C-terminal myc epitope tag detection of the fusion protein by the Anti- 
myc Antibody
C-terminal polyhistidine tag is the epitope for the Anti-His(C-term) 
Antibody
AOXl Transcription Termination 
(TT)
- Native transcription termination and 
polyadenylation signal from AOXl gene 
(-260 bp): bases 1341-1682
- 3’ AOXl priming site: bases 1423-1443
TEFl promoter Transcription elongation factor 1 gene 
promoter
from S. cerevisiae that drives
expression of the zeocin resistance gene in
Pichia
EM7 (synthetic prokaryotic 
promoter)
promoter that drives expression of the 
zeocin resistance gene in E. coli
Zeocine resistance gene Zeocin resistance
pUC origin Allows replication of the plasmid in E. coli
Table (6): Functional structure of pPICZa-A Pichia shuttle vector.
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4.2.2 Cloning strategy: Construction of the chimeric protein
The antigen chosen for production of chimeric protein was influenza vims 
hemagglutinin (HA) which was proved to contain most of the epitopes targeted 
by neutralising antibodies and T-cell responses in influenza ‘A ’ viruses, with 
available monoclonal antibodies (reviewed in Rajnavolgyi et al. 1994) that 
would allow detection of the expressed protein. As the deleted P2 subdomain 
consists of 126 amino acids accurate selection of a suitable part of the HA 
domain was a necessity; too large section could prevent the S domains of the 
Hawaii VPl from coming together and thus prevent particle formation. We 
selected the globular head domain of HAl domain consisting of 243 amino acids 
and which starts and ends in a stem-like structure that should allow insertion 
into our constructed Hawaii vector.
To constmct a Hemaglutinin-Hawaii (HA-Hawaii) clone, the selected HA 
segment was amplified from a clone of the HA gene from Influenza ‘A’ fowl 
plague virus (FPV) strain ‘Dobson’ (H7N7) (Accession number: CY014992.1) 
kindly provided by Institute for Animal Health, Compton, UK. This was 
amplified using designed primers (HA primers) (table 7) (Appendix III) which 
added Xhol and Hindlll restriction sites to the 5’ and 3’ ends of the PGR 
product respectively. The product was cloned in pGEM T-easy vector. The 
correct HA insert was then recovered from pGEM T-easy and inserted into one 
of our previously created clones in the pVL1393 vector between the LH and RH 
segments after excision of the poly-glycine chain (by Xhol and Hindlll 
digestion reaction).
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Table (7) Hemagglutinin primers
Primer/Orientation/ 
Genomic location/ 
Accession number
Sequence
HA/Forward/177-194 
[H7N7,influenza/A]/ CY014992.1
5 ’-AAAACTCGAGGCGGACAAACATCCCCAA-3 ’
H A/Reverse/886-905 
[H7N7,influenza/A]/ CY014992.1
5 ’-TTTAAGCTTCCTCCACTGTGGTAGCATTC-3 ’
Table (7): Nucleotide sequences, orientations and genomic locations of the primers that were 
used to amplify the selected segment of influenza HA domain with the added restriction sites 
underlined.
4.2,3 Primer design for recloning the constructs into pPICZ-A vector 
(For intracellular expression)
Two primers were designed to amplify the same constructs (8-Hawaii, and 18- 
Hawaii) that we had previously expressed in Baculoviruses by PCR horn the 
pVL1393 vector in which they had been assembled. We also amplified the 
unmodified (wild) Hawaii VPl gene and the HA-Hawaii construct from their 
own vectors in order to introduce all to yeast. As we were aiming to express the 
engineered proteins intracellularly in yeast, we designed primers (left hand- 
intracellular, and right hand-intracellular) (table 8) (Appendix III) to permit 
recloning into the yeast shuttle vector ‘pPICZ-A’ which contains no secretion 
signal, by adding SacII and Apal restriction sites to the N- and C-temini of the 
LH and RH Hawaii flanking sequences respectively. We also included an 
initiation codon ‘ATG’ as a part of yeast consensus sequence 
[(G/A)NNATGTCT] as recommended (Hamilton et al. 1987).
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Table (8) Yeast cloning primers ‘Intracellular expression’
Primer/Orientation/Genomic 
location/Accession number
Sequence
Left hand-intracellular/Forward/
5088-5106 [Hawaii ORF2 - U07611.21
5’-ATCCGCGGAAAAATGTCTAAGATGGCGTCGAATGACG-
3’
Right hand-intracellular/Reverse/
6672-6689 [Hawaii ORF2 - U07611.21
5-ATGGGCCC TTA CTGC ACTCTTCTGCGCCC-3 ’
Table (8) Nucleotide sequences, orientations and genomic locations of the 
primers that were used to clone the constructs in pPICZ-A yeast shuttle vector 
with addition of SacII and Apal restriction enzyme site (underlined) to 5’ end of 
the forward and reverse primers respectively in order to facilitate cloning into 
that vector. Yeast consensus sequence is bold. The stop codon is boxed.
4.2.4 Primer design for recloning the constructs into pPICZa-A vector 
(For secreted expression)
Two primers were designed to allow cloning of the amplified genes in frame and 
downstream of the N-terminal secretory a-factor signal sequence and in frame 
with the C-terminal His-tag sequence in the Pichia expression vector ‘pPICZ-a- 
A’. The new primers (left hand-secreted, and right hand-secreted) (table 9) 
(Appendix III) were designed to permit recloning into the yeast shuttle vector 
for subsequent transfer into that host. Primers were designed to add Sfil 
restriction site to the N-terminus of the LH Hawaii flanking sequence and a 
SacII restriction site at the C-terminus of the RH Hawaii flanking sequence.
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Table (9) Yeast cloning primers ‘Secreted expression’
Primer/Orientation/Genomic 
location/Accession number
Sequence
Left hand-secreted/Forward/ 
5085-5100 [Hawaii ORF2 - U07611.21
5’-AAAGGCCCAGCCGGCCAATGAAGATGGCGTCG-3’
Right hand-secreted/Reverse/ 
6668-6689 [Hawaii ORF2 - U07611.21
5'-CGCCGCGGGATACTGCACTCTTCTGCGCCC-3'
Table (9) Nucleotide sequences, orientations and genomic locations of the 
primers that were used to clone the constructs in pPICZa-A yeast shuttle vector 
with addition of Sfil and SacII restriction enzyme sites (underlined) to 5’ end of 
the forward and reverse primers respectively in order to facilitate cloning into 
that vector.
4.2.5 PCR
The Pfu polymerase enzyme (Promega, Madison, USA) was used for all 
amplifications since this enzyme offers fidelity of amplification. PCR was 
performed in a lOOpl reaction as described in general methods. The thermal 
cycler was adjusted to run 20 cycles of dénaturation [95°C, 1 minute], annealing 
[68°C, 1 minute], and extension [73°C, 3 minutes for 8-, 18-, and wild-Hawaii, 
and 4 minutes for HA-Hawaii], after initial dénaturation at 95°c for 5 minutes. A 
final extension period of 7 minutes at 73°C was allowed to permit completion of 
incomplete product. Extension time was calculated at 2 minutes per 1000 bases 
as Pfu enzyme is slower than Taq polymerase. Also, Pfu enzyme does not add a 
poly-adenosine to the final products (Hu 1993), thereof the products are not 
cloned readily into vectors such as pGEM T-easy. Thus a final reaction was 
conducted in which Ipl of Taq polymerase enzyme was added to the completed 
PCR reaction mixtures and incubated at 72°C for 10 minutes to permit this 
residue to be added. Samples were taken from different PCR reactions and 
analysed by running on agarose gels to confirm the expected sizes. DNA was
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then concentrated by precipitation and run on an agarose gel for excision of the 
required bands and cloning into pGEM T-easy as has been described.
4.2.6 Preparation of competent P. pastoris ‘X-33’ cells
Solutions used for preparation of competent P. pastoris ‘X-33’ cells were 
included in EasyComp Pichia Transformation Kit (Invitrogen, California, USA, 
Cat. No. K1730-01) which was also used for transformation of competent cells. 
P. pastoris was grown on YPD agar plates (Appendix I) by streaking a single 
colony on the surface of the medium. Plates were incubated at 30°C overnight, 
and then kept at 4°C for up to 1 month. To prepare competent cells, 10ml of 
YPD medium were inoculated with single colony of P. pastoris strain ‘X-33’ 
and grovm overnight at 30°C in shaking incubator (250 rpm). The overnight 
culture was diluted (-1:5) to ODgoo = 0.1-0.2 in 10ml YPD medium and grown 
at 30°C with shaking till ODeoo = 0.6-1.0 (about 6 hours). The cells were 
pelleted at 500x g for 5 minutes at room temperature and the supernatant was 
discarded. The cell pellet was then resuspended in 10ml of solution-I which is a 
sorbitol solution containing ethylene glycol and DMSO (storage temperature: 
4°C) after being equilibrated to room temperature and the cells were pelleted 
again without incubation at 500xg for 5 minutes at room temperature and the 
supernatant was discarded. The cell pellet was finally resuspended in 1ml of 
solution-I. Competent yeast cells were aliquoted in 50|l i1 fractions in 1.5ml 
sterile Eppendorf tubes and frozen slowly after wrapping the tubes in cotton 
wool and placing them in an expanded polystyrene box which was allowed to 
stand at -80°C overnight. After slow freezing the tubes were removed form the 
box and stored at -80°C for future use.
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4.2.7 Transformation of competent P. pastoris ‘X-33’ cells
After final screening of the clones by sequencing, DNA was then prepared on a 
slightly larger scale using QIAGEN Plasmid Midi Kit_(QIAGEN, Crawley, UK) 
according to the manufacturer instructions. The prepared pPICZa-A plasmids 
were then linearized by S ad restriction enzyme and gel-extracted to prepare the 
DNA for yeast transformation. EasyComp Pichia Transformation Kit was used 
for transformation of competent cells. For each transformation one tube of 
competent ‘X-33’ cells was thawed at room temperature and cells were 
transferred (50pl) to a sterile Eppendorf tube. The linearized pPICZa-A plasmid 
(with different constructs) was added in concentration not less than 3pg in 
volume not more than 5 pi. 1ml of solution-II which is a PEG solution was added 
to the DNA/cell mixture and mixed by flicking the tube. The transformation 
mixture was incubated for 1 hour at 30°C in water bath with ftequent mixing 
every 15 minutes to ensure efficient transformation. The mixture was then heat 
shocked in 42°C water bath for 10 minutes and the cells were split into two 
Eppendorf tubes ( -  527pl/each). 1ml of YPD medium was added to each and 
then incubated for 1 hour at 30°C to allow zeocin resistance expression. The 
cells were pelleted at 3000xg for 5 minutes at room temperature and the 
supernatant was discarded. Cells in each tube were resuspended in 500pl of 
Solution-Ill which is a salt solution for cell washing and then cells were 
recombined in one tube and pelleted again at 3000xg for 5 minutes at room 
temperature and the supernatant was discarded. Finally, the cell pellet was 
resuspended in lOOpl of solution-III. The transformation mixture was divided 
between two YPD agar plates with zeocin final concentration [lOOpg/ml] and 
plated using sterile spreaders. Zeocin selection plates were incubated at 30°C 
after covering with foil (as zeocin is light-sensitive) for 3-10 days.
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4.2.8 Expression of recombinant proteins
To determine the expression level of the recombinant proteins, three clones were 
selected from each transformant (after confirmation by PCR screening of many 
clones of each construct) and grown separately in 20ml of Buffered Glycerol- 
complex medium (BMGY) (Appendix I) which helps to generate yeast biomass 
(for increasing the protein yield) before induction in 250ml flask at 28-30°C 
with shaking (250-300 rpm) until culture reached an optical density ODgoo ^  2.0- 
6.0 (overnight). Cells were pelleted by centrifugation at 1500-3000xg for 5 
minutes at room temperature and resuspended to an ODsqq = TO in 100ml of 
Buffered Methanol-complex Medium (BMMY) (Appendix I) which contained 
methanol to induce expression. Cells were grown on in 1 liter baffled flasks at 
28-30°C with shaking (250-300 rpm). 100% methanol was added every 24 hours 
to a final concentration of 0.5% to maintain induction of the AOXl promoter. 
1ml sample of each culture was transferred to sterile Eppendorf tube every day 
for five consecutive days. Cells were separated from the medium by 
centrifugation at 14000 rpm for 2-3 minutes in a microcentrifuge (Eppendorf- 
5415C, California, USA). Supernatants and cell pellets were stored at -80°C for 
future assay. Larger scale expression was then undertaken by growing the 
selected clones in 200-3 00ml BMMY medium in 1 liter baffled flasks using the 
same growth conditions. Six such cultures were carried out for each antigen and 
the cell pellets were combined and kept at -80°C. 300ml from the growth 
medium were spun down and the pellet was kept frozen for protein purification 
later on.
4.2.9 Purification of expressed His-tagged recombinant protein
4.2.9.1 Sample preparation
The yeast pellet (obtained from 300ml growth medium) was resuspended using 
a suitable volume of lysis-Y kit (Roche, Mannheim, Germany) after the addition 
of PMSF (phenylmethylsulphonyl fluoride) as a protease inhibitor replacing the
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PI tablets provided with the kit. This was necessary since the tablets supplied 
contain EDTA which can interfere with efficient purification (Scopes 1994). 
The samples were shaken for 15 minutes at room temperature to lyse the yeast 
cells. The binding buffer (Appendix I) was added to the cell lysate to reach the 
required concentration of imidazole (20mM).
4.2.9.2 Column preparation
HisTrap FF crude kit (GE Healthcare, UK) affinity chromatography was used to 
purify the His-tagged expressed proteins according to the manufacturer’s 
instructions.
4.2.9.3 Sample application
The yeast cell lysate was applied to the column using a syringe and the flow­
through was collected. The column was then washed with 10ml binding buffer 
with collection of this as the wash fraction. Finally, the captured His-tagged 
protein was eluted with 5ml elution buffer (Appendix I) (containing 500mM 
imidazole) collected in 1ml fractions in 1.5ml Eppendorf tubes. A sample of 
each collected fraction was analysed on SDS-PAGE and the column was 
regenerated by washing with 10ml binding buffer. Elution fractions of each 
protein were pooled and kept at -80°C.
4.2.10 Preparation of samples before mouse immunisation
4.2.10.1 Purified proteins
The 5 elution fractions of each of the purified 8- and 18-Hawaii proteins were 
ffeeze-dried overnight at -40°C in Eppendorf tubes, the resulting dry protein 
powders were pooled for each protein.
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4.2.10.2 Non-purified intracellular proteins
Pooled yeast pellets obtained from methanol-induced expression (5x 200ml 
cultures for each protein) of the four different clones and also the control X-33 
Pichia strain were pooled separately in sterile Milli-Q water and adjusted to a 
final volume of 20ml each in falcon tubes. Freeze-drying does not inactivate 
yeast cells and although yeast expressing the recombinant proteins was not 
considered harmful, it was felt essential to inactivate cells before they were 
administered to mice orally. Inactivation consisted of two cycles of cobalt (60) 
irradiation of yeast cells while in the falcon tubes of 11.9 kGy and 2.1 kGy 
(conducted at a rate of 0.7 kGy per hour for 17 hours and 3 hours respectively) 
using the irradiator maintained by Brunei University (London). Irradiation levels 
were estimated according to Frazier and Westhoff (1988) who estimated the 
killing dose of fermentative yeasts to range between 4 and 9 kGy. The first 
session was anticipated to be sufficient to achieve total cell death. However, 
when cell viability was checked by rehydrating a sample of irradiated pellets and 
spreading this onto appropriate plates, 1-2 colonies were still observed in 2 of 
the irradiated cell preparations. Accordingly, a second irradiation step was 
implemented and after this no viable cells were recovered from any sample. 
Samples were frozen at -80°C while tilting the falcon tubes at 45° horizontally 
to increase the exposed surface area before they were put in a freeze diyer and 
allowed to dry overnight at -40°C after replacing tube caps with parafilm. Dry 
yeast pellets were weighed and their weights were: 5.5 grams for each of the 8-, 
18-, and HA-Hawaii, 6.0 grams for wild-Hawaii, and 6.7 grams for X-33 control 
Pichia.
4.2.11 Immunisation protocols
Immunisation was to be performed by both parenteral route (using purified 
antigens) and also enteric route (using whole cell inactivated pellets). The 
animal used (mouse) and the experiment regime were decided based on the scale
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of protein purification we could obtain and the suggestions of Saurev Chemicals 
Company staff (Bangalore, India) who performed the experiment according to 
the Indian regulations for animal welfai'e or exposure of genetically modified 
proteins.
4.2.11.1 Oral immunisation
Ten mice were used for oral immunisation using two mice for each of the four 
different protein constiucts and the umnodified yeast. Dried yeast was given 
orally at a dose of 1% of mouse average body weight (assumed to average 20 
grams) mixed with mouse food powder using 6.0 gram of dry yeast on 24 gram 
mice food to make a total of 30 grams sufficient for the whole study period. 
Each mouse was fed 1 gram of the mixture per day for 14 consecutive days. 
According to the estimated protein expression level, the amount of the antigen 
contained in each dry yeast oral dose was predicted to be 0.1 mg (contained in 
0.2 gram yeast pellet). In each case regular food was added to the cages after the 
dosed food had been consumed. Faeces were collected from the cages on days 7 
and 28. Mice were sacrificed on the day 28 of the experiment (14 days after the 
last feed) and bled out. Sera and faces were then shipped to the UK on cardice 
for assessment in ELISA.
4.2.11.2 Parenteral immunisation
For parenteral immunisation the purified antigens were administered in Freund’s 
adjuvant using the company standard immunisation scheme. This consisted of a 
primary injection of SOpg of antigen emulsified in Freund’s complete adjuvant 
and three booster doses at weekly inteiwals of 50pg emulsified in Freund’s 
incomplete adjuvant. Two mice were used for each purified antigen available, 
however, as we were not able to recover all antigens in this form, only 8-Hawaii 
and 18-Hawaii were used for this step. Mice were bled out at the end of the 
experiment (1 month) and sera were shipped to the UK for analysis by ELISA.
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In order to use our engineered protein in a reasonable amount (to compensate for 
the deleted antigenic determinants) and also to be comparable with others work, 
we preferred to immunise only two mice with each protein with oral dose of 
0.1 mg (estimated) and parenteral dose of 50pg.
4.2.12 ELISA for serum samples
Microimmune plates (Nunc-Maxisorp, Demnark) were used for antigen coating. 
Antigens used consisted of Baculovirus infected SfZl cells. The positive control 
antigens were Sf21 cells infected with recombinant BBaculovirus expressing the 
unmodified Hawaii VPl protein. Negative control samples consisted of Sf21 
cells infected with a wild Baculovirus that expressed no additional antigens, but 
was also polyhedrin negative. The positive control samples thus also contained 
Baculovirus proteins as well as cell proteins, but differed only in the presence of 
the Hawaii protein.
4.2.12.1 Preparation of control antigens
To prepare either positive or negative control antigens, SfZl cells were infected 
with appropriate Baculovirus at m.o.i = 5pfu/cell, for 5 Days. SfZl cell pellets 
were ffeeze-thawed and then resuspended in 5ml of PBS before sonication (5 
times, 30 seconds each with gaping of 30 seconds) on ice. Cell lysates were kept 
at -80°C before use and protein concentration of each lysate was assessed using 
the BioRad protein assay kit. Both positive and negative control antigen lysates 
were then adjusted to a final concentration of lOmg/ml with more PBS and 
stored at -80°C until used. Protein concentration of each stock was then tested 
again to ensure that they were similar.
4.2.12.2 Coating ELISA plates
Plates were coated using a procedure developed at central HP A Colindale (Dr. 
Jim Gray, HP A, personal communication). In brief, wells were coated using
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lOOjil of antigen sample per each well (diluted in PBS as explained below), and 
holding them at 4°C overnight covered in cling film. The plates were then 
washed once with PBS-0.05% tween-20 (Appendix I) and dried at 37°C. 
Blocking of excess capacity for protein adsorption was achieved by adding 
lOOpl of Soloupro gelatinous solution (Microimmune, Brentford, UK) to each 
well followed by incubation at 37°C for 2 hours, followed by drying at 37°C 
incubator.
4,2.12.3 ELISA checkerboard plan
In order to determine the most appropriate match of serum dilution and antigen 
concentration a checkerboard titration was carried out for the wild-Hawaii serum 
(supposed to show positive reactivity). Antigen was serially diluted and the 
dilution series was plated horizontally across the plate using concentrations of 
(1, 0.5, 0.1, 0.01 mg/ml). Serum was then diluted (1:200, 1:500, and 1:1000) and 
the dilution series was tested down the columns of the plate. This formed a set of 
12 wells. The serum was tested against the positive and negative control 
antigens (SfZlcell lysates from Baculo-Hawaii and wild Baculovirus infected 
cells). Tests were performed in duplicate at this stage i.e. two sets of 12 wells 
(see plan in figure 27). Plates were incubated for 1 hour at 37°C, and then 
washed 3 times with PBS-T-20. lOOjil (1:2000 dilution) of goat anti-mouse IgG, 
IgM, IgA horseradish peroxidise conjugate (Millipore, catalogue no: AP501P) 
was added to each well in the plate and incubated for 1 hour at 37°C and then 
plates were washed 3 times with PBS-T-20. lOOpl of TMB substrate ‘1.25mM’ 
(Millipore, California, USA) was added to each well and incubated for 15 
minutes at room temperature. Change in colour was measured in an ELISA 
reader (BIO-TEK, Winooski, USA) at 630mn. To show the actual difference 
between the positive and negative control antigens, we used the Norovirus- 
specific ‘GIT polyclonal detector antibody conjugated to horseradish peroxidase 
and supplied with the Norovirus Dakocytomation Detection Kit as a positive
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control. This antibody was used alone and in these wells no serum was added. 
Results were averaged for the duplicates and expressed as a ratio of OD reading 
against Baculo-Hawaii positive control antigen divided by OD reading against 
wild Baculovirus negative control antigen. A value of 1 thus indicated no 
specific reaction. Analysis of experimental sera was conducted in triplicate wells 
(for each determination) using optimum checkerboard conditions. Average OD 
reading was determined and expressed as a ratio as described above. Control 
sera used here were derived from animals that had been fed unmodified yeast X- 
33 containing no virus proteins (although it was methanol induced in the same 
way as the recombinant cells). The cut off value was calculated for each sample 
separately as the average of OD readings against the negative control antigen 
plus three standard deviations.
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Figure (27) ELISA checkerboard plan
Baculo-Hawaii (mg/ml) Wild Baculo (mg/ml)
1.0 0.5 0.1 0.01
1 2  3 4 7 8
1.0 0.5 0.1 0.01
9 10 11 12u  ^ 1:200 A o o o o oo o o oo o oa 1:500 B o o o o oooo oooo11a ^ 1:1000 C o o o o o o o o o o o o
D o o o o o o o o o o o o
 ^ 1:200 E o o o o o o o o o o o o1- 1:500 F o o o o oo o o o o o oP  ^ 1:1000 G o o o o o o o o o o o o
H o o o o oo o o o o o o
Figure (27) Showing plan of ELISA with the different concentrations of positive 
and negative control antigens and serum dilutions used for each sample, 
according to the results obtained from this checkerboard the best representative 
concentration and dilution were selected to be done for all the samples in 
triplicates.
4.3 Results
4.3.1 Confirmed insertion of HA segment into pGEM T-easy vector
The insertion of the HA segment into pGEM T-easy vector was checked by 
restriction enzyme digestion by freeing it with the two flanking enzymes (Xhol 
and Hindlll) and the correct size (728bp) was detected by agarose gel 
electrophoresis of digest sample (figures 28, 29).
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Figure (28) HA segment in pGEM T-easy vector
Xhol
llndlllHA
MCS
pGEM T-easy 
(3015bp)
Figure (28) Schematic diagram showing the pGEM T-easy plasmid vector 
carrying the HA segment and showing the two flanking restriction enzyme sites 
that were used for screening the correct insertion of that segment.
Figure (29) Screening of the HA segment in pGEM T-easy vector
1 2 3
3000bp
750bp 728bp
Figure (29) Agarose gel (1.2%) showing the restriction fragments confirming 
the correct cloning of the PCR-amplifled HA segment in pGEM T-easy vector. 
(1) Ikb DNA ladder. (2) & (3) Restriction fragments of (Xhol & Hindlll) of two 
different HA clones respectively.
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4.3.2 Correct HA-Hawaii construct in pVL1393 vector
The HA-Hawaii construct was then checked in pVL1393 vector by two 
digestion reactions using (BamHI and Bglll) and (PstI and Xhol) restriction 
enzyme pairs. The first enzyme pair shows restriction fragments of the following 
sizes: 566bp (segment between BamHI and Bglll in the LH fragment), 1436bp 
for the segment between the two Bglll enzymes including the remaining part of 
LH, HA fragment, and RH fragment and a third band (fragment between Bglll 
and BamHI including the remaining part of the vector). While, the second 
enzyme pair shows restriction fragments of the following sizes: 1171 bp 
including the RH and the HA fragment, 3 05 5bp (segment between the two Xhol 
sites including the LH fragment), and a third band representing the remaining 
part of the vector (figures 30, 31). The construct was also confirmed by 
sequence determination.
Figure (30) HA-Hawaii VPl in pVL1393 vector
Bglll [566]
XholLHBamHI
(4129) llndlll
PstI (4165) 
Bglll (4169)
pVL1393
(9639bp)Xhol(1901)
Figure (30) Schematic diagram showing the pVLI393 vector carrying the HA- 
Hawaii capsid gene and showing different restriction enzyme sites that were 
used for screening the correct insertion of the constructed nucleotide sequence in 
that vector.
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Figure (31) Screening of HA-Hawaii VPl in pVL1393 vector
(BamHI & Bglll) (PstI &XhoI)
1 2 3 4 5
3000bp
ISOObp
lOOObp
750bp
500bp
 <-------- 3055bp
^ ----------------- 1436bp
 <-------- 1171bp
(443bp + 728bp)
566bp
Figure (31) Agarose gel (1.2%) showing the restriction fragments confirming 
the correct cloning of the ‘HA-Hawaii’ capsid gene into the pVL1393 vector. (1) 
Ikb DNA ladder. (2) & (3) Restriction fragments of (BamHI & Bglll) of clones 
1 and 2 respectively. (4) & (5) Restriction fragments of (PstI & Xhol) of clones 
1 and 2 respectively.
4.3.3 Screening of PCR products amplified by yeast cloning primers (for 
secreted expression)
The following band sizes were obtained as expected after running samples of the 
PCR products on agarose gel; 1300bp, 1330bp, 1648bp, and 1998bp for 8-, 18-, 
wild-, and HA-Hawaii constructs respectively (figure 32).
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Figure (32) PCR products obtained by yeast cloning primers ‘Secreted
expression’
2000bp ----- ^
ISOObp ----- ►
lOOObp ----- ►
1998bp
1648bp
1330bp
1300bp
Figure (32) Agarose gel (1.2%) showing the PCR products (for cloning in yeast 
expression vector pPlCZa-A). (1) Ikb DNA ladder. (2) 8-Hawaii, (3) 18- 
Hawaii, (4) wild-Hawaii, (5) HA-Hawaii constructs.
4.3.4 Confirmed constructs in pGEM T-easy vector
Recombinant clones were checked for the insertion of DNA into pGEM T-easy 
vector by Notl restriction enzyme digestion since this site flanks the multiple 
cloning site in that vector. The expected restriction fragment sizes obtained 
include the insert size of each construct plus 34bp representing the distance 
between the Notl sites on both sides of each insert (figures 33, 34).
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Figure (33) Modified Hawaii VPl in pGEM T-easy
Sfil
LHNotl
(43) 1 , 18, HA, or wild-Hawaii
SacII
Notl
(77)
pGEM T-easy 
(3 015bp )^
Figure (33) Schematic diagram showing the final clone of the modified Hawaii 
capsid protein with different inserts in pGEM T-easy.
Figure (34) Screening of of 8,18, wild and HA-Hawaii in pGEM T-easy
3000bp--------^2000bp--------►
ISOObp--------►
lOOObp--------►
Vector band
1998bp + 34bp 
1648bp + 34bp
1330bp + 34bp
1300bp + 34bp
Figure (34) Agarose gel (1.2%) showing the restriction fragments confirming 
the correct cloning of the 8, 18, wild and FIA-Hawaii constructs into the pGEM 
T-easy vector using Notl restriction enzyme digestion. (1) Ikb DNA ladder. (2), 
(3), (4), and (5) Restriction fragments of 8, 18, wild and HA-Hawaii clones 
respectively.
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4.3.5 Confirmed constructs in pPICZa-A vector
After confirmation of the correct constructs they were cut out of the pGEM T- 
easy vector by Sfil and SacII restriction enzymes and ligated to pPICZa-A yeast 
shuttle vector digested with the same enzymes and gel-extracted to remove the 
small fragment released. Ligation mixtures were then used to transform E. coli 
DH5-U cells as above, but since pPICZ a-A carries a zeocin resistance marker, 
this antibiotic was used to select transformants with a final concentration of 
lOOjLig/ml. Recombinant pPICZa-A plasmids were checked for the expected 
inserts using EcoRI and SacII restriction enzymes. These two enzymes were 
selected to allow one-step digestion reaction as they share the same buffer for 
efficient cutting. EcoRI enzyme (in the vector) precedes Sfil site (which flanks 
the 5’ end of the constructs) by 17 bases and another EcoRI site exists at 
position 186 in the Hawaii ORF2, thus tlii'ee bands are expected in each 
digestion reaction; 203bp (segment between the two EcoRI sites), segment 
between the EcoRI and SacII sites including the construct (1114bp, 1144bp, 
1462bp, and 1812bp for 8-, 18-, wild and HA-Hawaii respectively), and a 
segment representing the remaining part of the vector (figures 35, 36 and 37). 
Due to longer electrophoresis duration the small band (203bp) was lost as in 
figure (36).
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Figure (35) Modified Hawaii VPl in pPICZ a-A
Sfil EcoRI (186) (1229L,
EcoRI
(1212
5’ AOX
pPICZ a-A 
(3593bp)
18, HA, or wild-Hawaii 
H
SacII
AOXlTT  
> PTEF-1
Zeocin resistance gene
Figure (35) Schematic diagram showing the final clone of the modified Hawaii 
capsid protein with different inserts in pPICZ a-A.
Figure (36) Screening of 8,18, HA-Hawaii clones in pPICZ a-A
1 2 3 4 5 6 7I4000bp
1114bp
2000bp 1812bp
1oOObp
1144bp
1OOObp
Figure (36) Agarose gel (1.2%) showing the restriction fragments confirming the correct 
cloning of the 8, 18, and HA-Hawaii capsid gene into the yeast expression vector (pPICZ a- 
A) using EcoRI and SacII restriction enzyme digestion. (1) Ikb DNA ladder. (2) & (3) 
Restriction fragments of clones 1 and 2 of 8-Hawaii respectively. (4) & (5) Restriction 
fragments of clones 1 and 2 of 18-Hawaii respectively. (6) & (7) Restriction fragments of 
clones 1 and 2 of HA-Hawaii respectively.
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Figure (37) Screening of wild-Hawaii clone in pPICZ a-A
1 2
3000bp
1500bp
1OOObp
1462bp
203bp
Figure (37) Agarose gel (1.2%) showing the restriction fragments confirming the correct 
cloning of the wild-Hawaii capsid gene into the yeast expression vector (pPICZ a-A) using 
EcoRI and SacII restriction enzyme digestion. (1) Ikb DNA ladder. (2) Restriction fragments 
of wild-Hawaii clone.
4.3.6 Sequencing of the constructs
Screening was done by sequencing the constructs in pGEM T easy vector using 
M l3 forward and reverse primers or pPICZa-A vector using AOXl forward and 
reverse primers (table 10) which are included in the EasySelect Pichia 
Expression Kit (Invitrogen, California, USA), and all constructs were sequenced 
by the previously ordered ‘right hand-secreted primer’ which we used to check 
the sequence across the insert. Obtained data showed correct sequences 
(Appendix IV).
Table (10) AOXl sequencing primers
Primer Sequence
AOXl forward primer 5 -GACTGGTTCCAATTGACAAGC-3 '
AOX 1 reverse primer 5 -GCAAATGGCATTCTGACATCC-3 '
Table (10) Nucleotide sequences of forward and reverse AOXl primers that 
were used to verify the final yeast clones in pPICZa-A vector.
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4.3.7 Integrated constructs into yeast chromosomes
Direct PCR screening of three yeast clones of each construct was performed 
before proceeding to protein expression. Lyticase solution (Invitrogen) was used 
to lyse the yeast cell walls (Appendix I). A 50pl PCR reaction was set up as 
before for each clone using AOXl forward and reverse primers. A lOjal sample 
was analyzed by agarose gel electrophoresis. After insertion of the expression 
cassette (introduced in the pPICZ a-A plasmid) by cross-over recombination 
into yeast genome, we should expect two bands for each PCR: one coiTesponds 
to the AOXl gene (normally exists in yeast genome) which is approximately 2.2 
kb and the other band corresponds to the insert size plus 588bp (representing the 
promoter and transcription termination sequences between the AOXl 5’ and 3’ 
sites in the pPICZ a-A) giving a final sizes of 1888bp, 1918bp, 2236bp, and 
2586bp for 8-, 18-, wild-, and HA-Hawaii inserts respectively (figures 38, 39, 
40), The two bands appear overlapping in case of wild-Hawaii in figure (40) as 
they are very close in size (2200bp and 2236bp). The pPICZa-A vectors 
containing the 8-Hawaii or wild-Hawaii inserts before yeast transformation were 
used separately as positive controls for two PCR reactions which do not show 
the AOXl band as in figures 38 and 40.
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Figure (38) PCR of 8-Hawaii transformants
2000bp ------- ►
1500bp ------- ►
AOXl gene (2.2 kb)
8-Hawaii 
(1300bp + 588bp)
Figure (38) Agarose gel (1.2%) showing the PCR products of three different 8- 
Hawaii clones after transformation into Pichia ‘X-33’ with the expected sizes as 
indicated on the image. (1) Ikb DNA ladder. (2) Negative control. (3) Positive 
control (8-Hawaii in pPICZa-A before yeast transformation). (4), (5), and (6) 
are three different clones of 8-Hawaii recombinant yeast.
Figure (39) PCR of 18 and HA-Hawaii transformants
18-Hawaii 
(1330bp + 588bp)
2500bp ------- ►
2000bp ------- ►
1500bp
HA-Hawaii 
(1998bp + 588bp)
AOXl gene bands 
(2.2 kb)
Figure (39) Agarose gel (1.2%) showing the PCR products of three different 18- 
and HA-Hawaii clones after transformation into Pichia ‘X-33’ with the expected 
sizes as indicated on the image. (1) Ikb DNA ladder. (2), (3) and (4) are three 
different clones of 18-Hawaii recombinant yeast. (5), (6), and (7) are three 
different clones of HA-Hawaii recombinant yeast.
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Figure (40) PCR of wild-Hawaii transformants
1 2 3 4 5 6
2500bp ------- ►
2000bp ------- ►
1500bp ------- ►
Wild-Hawaii 
(1648 + 588)
Overlapping AOXl 
gene band (2.2 kb)
Figure (40) Agarose gel (1.2%) showing the PCR products of three different 
wild-Hawaii clones after transformation into Pichia ‘X-33’ with the expected 
sizes as indicated on the image. (1) Ikb DNA ladder. (2) Negative control. (3) 
Positive control (wild-Hawaii in pPICZ a-A before yeast transformation). (4), 
(5), and (6) are three different clones of wild-Hawaii recombinant yeast showing 
overlapping bands of wild-Hawaii insert and AOXl gene due to very close 
sizes.
4.3.8 Expressed proteins by recombinant Pichia pastoris
Since our aim was to derive whole cells that could be used for immunisation it 
was logical to arrange for expression of the protein intracellularly. Later we 
reverted to expression as a secreted protein using plasmid pPICZa-A in an 
attempt to clearly demonstrate recombinant protein synthesis.
4.3.8.1 Intracellularly expressed HA-Hawaii chimeric protein
As we proceeded in the steps of detecting the intracellularly expressed proteins 
in either the cell pellet lysates (as expected) or the growth media, we could 
detect only the HA-Hawaii protein in one clone of the many checked in a 
Western blot of yeast cell lysates (lane number 4, figure 41) immunostained
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with rabbit anti-Hawaii capsid protein antibodies (kindly provided by Kim 
Green, USA). We thought about association of the expressed proteins with the 
yeast cell walls as previously reported by Famos et al. (2005) with resultant 
difficulty in their detection.
Figure (41) HA-Hawaii chimeric protein expressed ‘intracellularly’ by 
recombinant yeast transformed with ‘pPICZ-A’ vector
1 2 3 4 5 6 7 8 9
175kDa
83kDa
62kDa
47.5kDa
Figure (41) Western blot immunostained with rabbit anti-Hawaii capsid protein 
antibodies showing intracellular expression of HA-Hawaii chimeric protein 
using pPICZ-A vector. (1) Parent non-induced X-33 Pichia strain. (2) Induced 
X-33 Pichia strain. (3), (4), (5), (6), (7), (8), and (9) are yeast cell lysates of 
seven different clones of HA-Hawaii construct, with only one clone (lane 
number 4) showing a different pattern from the controls and also has the 
expected size (~74kDa).
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4.3.S.2 Expressed proteins by P. pastoris (secreted expression system)
The clone that best expressed its recombinant protein was identified by SDS- 
PAGE (as in general methods) using samples of both supernatants and cell 
pellets and including parent yeast control samples: non-transformed X-33 Pichia 
strain as a negative control, and GS115 Pichia strain expressing (3-galactosidase 
which is a 119kDa fusion protein as a positive control. Proteins in the gel were 
electrotransferred onto a PVDF membrane using semi-dry Western blotting (as 
in general methods). Blots were immunostained using anti-His tag mouse 
antibodies (Millipore, California, USA) (diluted: 3pl/5ml blocking buffer), and 
HRP-conjugated anti-mouse secondary antibodies (Dako, Demnark) (1:1000 
dilution) and chemiluminescent substrate for detection of positive signals using 
X-ray film. Although all constructs are in frame with the pPICZa-A ‘secretion 
signal’ as was confirmed by sequence aligmnent with ‘OMIGA’ software, no 
signals were detected in the supernatant samples (as was expected), however, 
strong signals were obtained in all cell pellet samples, with different band 
pattern from the parent yeast control samples. Prominent bands were detected 
near the expected sizes (-48kDa for 8- and 18-Hawaii, 74kDa for HA-Hawaii, 
and 58kDa for wild-Hawaii proteins) in all clones checked. The larger and 
smaller bands which appear in each sample could be attributed to glycosylation 
and degradation of the originally expressed protein respectively (figures 42, 43 
and 44). The clone with the best signal was selected, and the optimum time of 
protein expression was identified (figures 45 and 46). Surprisingly although we 
did detect protein synthesis of all constructs in this system the proteins were 
retained intracellularly. Clear time courses were obtained for 8- and 18-Hawaii 
proteins, however, it was proved difficult to obtain clear time courses for FIA- 
and wild-Hawaii proteins.
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Figure (42) Expression of 8- andl8-Hawaii capsid proteins by recombinant
yeast
1 2 3 4 ^5 6 7 8
p-galactosidase 175kDa
(119kDa) 83kOa 
62kDa 
47.5kDa 48 kDa
Figure (42) Western blot immunostained with anti-His tag antibody showing 
expression of His-tagged proteins which are corresponding in size to 8- and 18- 
Hawaii capsid proteins. (1) Negative control (parent non-transformed X-33 
Pichia strain). (2) Positive control (GS115 Pichia strain expressing P- 
galactosidase). (3), (4), and (5) Three different clones of 8-Hawaii construct. (6), 
(7), (8) Three different clones of 18-Hawaii construct.
Figure (43) Expression of HA-Hawaii capsid protein by recombinant yeast
74 kDa
175kDa
83kDa
62kDa
Figure (43) Western blot immunostained with anti-His tag antibody showing 
expression of His-tagged proteins which are corresponding in size to HA-Hawaii 
capsid protein. (1,) Negative control (parent non-transformed X-33 Pichia 
strain). (2) Positive control ‘loaded into 2 lanes for confirmation’ (GSl 15 Pichia 
strain expressing P-galactosidase). (3), (4), (5), (6), (7), and (8) Six different 
clones of HA-Hawaii construct.
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Figure (44) Expression of wild-Hawaii capsid protein by recombinant yeast.
175kD
83kDa
62kDa
47.5kDa
32.5kD
58 kDa
Figure (44) Western blot immunostained with anti-His tag antibody showing 
expression of His-tagged proteins which are corresponding in size to wild- 
Hawaii capsid protein. (1) Negative control (parent non-transformed X-33 
Pichia strain). (2) Positive control ‘2 lanes’ (GSl 15 Pichia strain expressing p- 
galactosidase). (3), (4), (5), (6), (7), and (8) Six different clones of wild-Hawaii 
construct.
Figure (45) Time course for the expressed 8-Hawaii capsid protein by
recombinant yeast
1 2 3 4 5 6 7
175kDa
83kDa
47.5kDa
32.5kDa
Figure (45) Western blot immunostained with anti-His tag antibody showing 8- 
Hawaii capsid protein expressed by recombinant yeast and harvested over five 
consecutive days. (1) Negative control (parent non-transformed X-33 Pichia 
strain). (2) Positive control (GS115 Pichia strain expressing p-galactosidase).
(3), (4), (5), (6), and (7) pellets of 8-Hawaii recombinant yeast harvested on day 
1, 2, 3, 4, and 5 respectively.
132
Yeast Expression System as an Edible Vaccine Candidate
Figure (46) Time course for the expressed 18-Hawaii capsid protein by
recombinant yeast
1 2 3 4 5 6 7I p #  m
175kDa
83kDa
62kDa
47.5kDa
32.5kDa
k
Figure (46) Western blot immunostained with anti-His tag antibody showing 18- 
Hawaii capsid protein expressed by recombinant yeast and harvested over five 
consecutive days. (1) Negative control (parent non-transformed X-33 Pichia 
strain). (2) Positive control (GSl 15 Pichia strain expressing P-galactosidase).
(3), (4), (5), (6), and (7) pellets of 18-Hawaii recombinant yeast harvested on 
day 1, 2, 3, 4, and 5 respectively.
4.3.9 Purified 8- and 18-Hawaii proteins
A good purification was obtained for both 8- and 18-Hawaii proteins (figure 47 
and 48) with the highest concentration in the second elution fraction as indicated 
in the manufacturer manual. Confirmation of the specificity of the purified 
proteins was done by running samples from the flow-through and the second 
elution fraction of 8- and 18-Hawaii on SDS-PAGE gel which was then blotted 
to a PVDF membrane and the Guinea pig anti-Hawaii capsid protein antibody 
(kindly provided by Kim Green, USA) was used to detect specific signals on X- 
ray film. The Western blot shows bands with similar sizes to those appeared on 
the polyacrylamide gel during purification (figure 49). In contrast, the difficulty 
to purify the HA- and wild-Hawaii construct proteins is possibly due to incorrect
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folding which renders them water-insoluble and thus difficult to elute from the 
column or masking of the His tag itself causing the proteins to pass out of the 
column without binding, a sample from the column pass-through fi*action was 
run on a polyacrylamide gel, but the lane was loaded with different proteins so 
as we could not recognise them.
Figure (47) Purification of His-tagged 8-Hawaii capsid protein
1 2 3 4 5 6 7 8
175kDa 
83kDa
62kDa 47.5kDa
32.5kDa
Figure (47) SDS polyacrylamide gel showing different steps of purification of 
the 8-Hawaii capsid protein using His-tag column. (1) Prestained broad range 
protein marker. (2) Yeast lysate passed through the column. (3) Column wash.
(4), (5), (6), (7), and (8) Five consecutive elution fractions of the 8-Hawaii 
capsid protein.
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Figure (48) Purification of His-tagged 18-Hawaii capsid protein
1 2 3 4 5 6 7 8
175kDa “
83kDa
62kDa
47.5kDa
32.5kD
Figure (48) SDS polyacrylamide gel showing different steps of purification of 
the 18-Hawaii capsid protein using His-tag column. (1) Prestained broad range 
protein marker. (2) Yeast lysate passed through the column. (3) Column wash.
(4), (5), (6), (7), and (8) Five consecutive elution fractions of the 18-Hawaii 
capsid protein.
Figure (49) Confirmation of the purified His-tagged proteins
1 2  3 4
175kDa 
83kDa 
62kDa
47.5kDa
32.5kDa
Figure (49) Western blot immunostained with Guinea pig anti-Hawaii capsid 
protein antibodies confirming the specificity of the purified 8- and 18-Hawaii 
capsid proteins. (1) and (3) Yeast lysate passed through the column for 8- and 
18-Hawaii capsid proteins respectively. (2) and (4) Second elution fraction of 8- 
and 18-Hawaii capsid proteins respectively.
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4.3.10 Determined protein concentration
Protein concentrations of the pooled elution fractions obtained for both 8- and 
18-Hawaii (pooled from two column purifications) were determined using 
BioRad protein assay kit (BioRad laboratories, UK) as in general methods. The 
total protein concentrations are 600pg and 820pg for 8- and 18-Hawaii elutions 
respectively. We could roughly estimate the level of recombinant Hawaii protein 
expression in P. pastoris (depending on the amounts that we could purify from 
certain volumes of growth media in case of 8- and 18-Hawaii proteins) to be 
about 2.7mg/liter.
4.3.11 ELISA checkerboard result
The results of ELISA checkerboard done in duplicate for the wild-Hawaii 
serum, presented in table (11) show that there is a general trend towards positive 
reactivity in the lower right sector of the plate. We therefore selected the 
conditions of 0.1 mg/ml antigen concentration and 1:500 serum dilution to 
evaluate response in the other samples. This value was in the centre of the 
positive region and also preserved reasonable economy of reagents. The tested 
control and preimmune sera all gave response ratios between 0.9 and 1.2, while 
the positive control anti-NoV antibody gave ratio of 2.6.
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Table (11) Wild-Hawaii serum checkerboard ratios
A ntigen concentration
1 1.0mg/ml 0.5mg/ml 0.1mg/ml 0.01mg/ml 1.0mg/ml 0.5mg/ml 0.1mg/inl 0.01mg/ml 1.0nig/ral 0.5mg/ml 0.1mg/ml 0.01mg/ml1 Average of duplicate OD readings against the ‘positive’ 
control antigen
Average of duplicate OD 
readings against the ‘negative’ 
control antigen
Ratios of average OD readings 
[against positive control antigen: 
negative control antigen]
1:200 2.18 2.16 2.22 2.04 2.60 2.18 2.12 2.03 0.84 0 .9 9 1.05 1
1:500 1.79 1.87 2.09 1.92 1.85 1.78 1.68 1.76 0 .9 7 1.05 1.25 1.09
1:1000 1.26 1.39 1.22 1.18 1.42 1.307 1.00 1.59 0.89 1.07 1.21 0.75
Table (11) Showing averages of duplicate OD readings obtained with different 
dilutions of wild-Hawai serum against different concentrations of Baculo- 
Hawaii antigens (positive control) and wild Baculovirus antigens (negative 
control). It also shows the ratios of these averages (against positive control : 
negative control). The table also shows a general trend towards positive 
reactivity (shown in green) in the lower right sector of the plate.
4.3,12 ELISA results of experimental sera
Results obtained of study sera (done in triplicates) are shown in table (12) and 
figures (50, and 51). As all preimmune serum samples were tested separately 
from the immune serum samples i.e. in separate plates and session, some of the 
preimmune samples show higher OD readings than their corresponding immune 
samples which is simply due to difference in manual mixing of the plates (which 
affect the intensity of the developed colour) before reading in the ELISA reader, 
however, this does not affect the results of the test which depend on comparing 
the readings of the immune samples against the positive control antigens with 
the cut off points calculated from the readings of the immune samples against 
the negative control antigens, and both readings were done on the same plate.
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According to the calculated cut off values the following antigens were 
considered to have stimulated immune reaction towards the engineered Hawaii 
capsid proteins by inducing a response in both of the immunised mice including 
parenterally-injected 8-Hawaii and orally-fed 8-Hawaii, 18-Hawaii, HA-Hawaii 
or inducing a response in only one mouse including parenterally-inj ected 18- 
Hawaii and orally-fed wild-Hawaii. The main reason behind using the parenteral 
route was to confirm that the constructs we have expressed are actually 
immunogenic in case we could not detect any response when using the whole 
yeast by the oral route, and as we could not purify all constructs, only 8- and 18- 
Hawaii were tried by parenteral route, and both proved immunogenic although 
the 18-Hawaii induced response in only one of the two immunised mice which 
can be attributed to the low antigenic dose in comparison to the better result 
obtained with oral route. Using only two mice in the immunisation experiment 
for each protein did not enable us to do statistical analysis of the ELISA results 
as the small number of samples could reduce the sensitivity of statistical tests, 
instead we relied on the ‘cut off point’ as a judge for appearance of reactivity. 
As obseiwed there is indication of an immune response in most of antigens 
delivered orally which could be attributed to gradual induction by repeated 
administration (daily). In this work we were able to administer only over a short 
time period (14 days) and these results, although small, may indicate potential 
for greater response if administration could be prolonged. Moreover, the fact 
that the engineered Hawaii capsid protein used for antibody production in mice 
is lacking the most antigenic part (P2 subdomain) let us expect such low 
reactivity of those antibodies with the Baculovirus-expressed wild Hawaii 
capsid protein which was used (while mixed with Sf21 cell proteins) in the 
ELISA test to coat the plates as a positive control antigen. This low purity also 
increased the background of the test results.
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In this analysis we have been able only to determine reactivity of experimental 
serum samples towards the Hawaii virus VPl protein. Reactivity towards 
influenza hemagglutinin segment included in the HA-Hawaii chimeric protein is 
clearly of interest and will be considered in the future. Assessment of these sera 
can include not only ELISA, but also determination of any neutralizing activity.
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Table (12) ELISA results
Serum sa m o le s  
obtained after: 
Parenteral 
Im m unisation
OD readings 
against positive 
controi antigen
Average
OD
readings
OD readings 
against negative 
controi antigen
Average
OD
readings
Ratio of 
averages
Cut off 
vaiue
1 2 3 1 2 3
8[1]preimmune 0 .9 6 5 0 .9 2 0 .8 8 4 0 .9 2 3 0 .7 6 3 0 .7 4 4 0 .8 3 6 0 .781 1 .1 8 1 8 1 8
8[1]immune 0 .6 6 4 0 .8 9 1 .0 4 4 0.866 0.51 0 .5 5 8 0 .5 1 8 0 .5 2 8 6 6 7 1 .6 3 8 0 8 3 0 .6 0
8[21preimmune 0 .7 4 5 0 .8 1 3 0 .7 7 7 0 .7 7 8 3 3 3 0 .6 7 2 0 .7 2 4 0 .7 2 3 0 .7 0 6 3 3 3 1 .1 0 1 9 3 5
8[2]]lmmune 0 .6 8 4 0 .4 4 6 0 .5 1 9 0.549667 0 .3 0 2 0 .3 3 3 0 .3 1 9 0 .3 1 8 1 .7 2 8 5 1 2 0 .3 6
18[1lpreimmune 0.861 0 .8 0 9 0 .8 8 3 0 .851 0 .6 8 7 0 .7 4 6 0 .8 2 8 0 .7 5 3 6 6 7 1 .1 2 9 1 4 6
18[1]]immune 0 .7 8 3 0 .6 1 2 0 .7 3 8 0 .711 0 .5 7 4 0 .4 1 8 0 .5 5 8 0 .5 1 6 6 6 7 1 .3 7 6 1 2 9 0 .7 7
18[2]preimmune 0 .8 0 8 0 .8 2 5 0 .6 3 9 0 .7 5 7 3 3 3 0 .641 0 .7 8 2 0 .7 5 2 0 .7 2 5 1 .0 4 4 5 9 8
18[2]]immune 1 .1 1 4 1 .3 7 3 1 .0 8 4 1.190333 1 .0 0 6 0 .9 0 2 0 .8 8 5 0 .931 1 .2 7 8 5 5 4 1 .12
Oral im m unisation
8[11 preimmune 0 .681 0 .581 0 .6 3 8 0 .6 3 3 3 3 3 0 .6 1 6 0 .6 0 3 0.691 0 .6 3 6 6 6 7 0 .9 9 4 7 6 4
8[1l]immune 0 .881 0 .6 1 2 0 .5 5 3 0.682 0 .4 5 0 .3 8 3 0 .4 6 8 0 .4 3 3 6 6 7 1 .5 7 2 6 3 6 0 .5 6
8[2] preimmune 0 .8 4 4 0 .7 1 2 0 .8 1 9 0 .7 9 1 6 6 7 0 .8 4 0 .7 6 8 0 .8 4 8 0 .8 1 8 6 6 7 0 .9 6 7 0 2
8[21]immune 0 .5 3 4 0 .6 0 3 0 .6 6 6 0.601 0 .4 6 3 0.41 0 .3 4 6 0 .4 0 6 3 3 3 1 .479081 0 .5 8
18[1]preimmune 0 .6 3 0 .5 6 0 .4 7 4 0 .5 5 4 6 6 7 0 .5 9 2 0 .5 7 6 0 .5 9 0 .5 8 6 0 .9 4 6 5 3
18[1]limmune 0 .8 9 5 0 .8 9 9 0 .9 5 3 0.915667 0 .5 8 5 0.61 0 .5 1 4 0 .5 6 9 6 6 7 1 .6 0 7 3 7 3 0.71
18[2]prelmmune 0 .5 9 7 0 .5 3 0 .541 0 .5 5 6 0 .4 2 8 0 .4 2 6 0 .4 4 7 0 .4 3 3 6 6 7 1 .2 82091
18[2]]immune 0 .9 7 5 1 .1 2 4 0 .8 8 3 0.994 0 .4 3 4 0 .4 2 7 0 .4 0 6 0 .4 2 2 3 3 3 2 .3 5 3 5 9 1 0 .4 6
HA[1]preimmune 0 .571 0 .531 0 .5 5 4 0 .5 5 2 0 .4 9 2 0 .4 9 2 0 .5 0 2 0 .4 9 5 3 3 3 1 .114401
HA[1l]immune 0 .6 7 5 0 .831 0 .8 3 3 0.779667 0 .4 8 3 0 .5 4 3 0 .5 7 3 0 .5 3 3 1 .4 6 2 7 8 9 0 .6 7
HA[2]preimmune 0 .5 2 3 0 .501 0 .5 1 2 0 .5 1 2 0 .4 5 3 0 .4 5 8 0 .5 2 4 0 .4 7 8 3 3 3 1 .0 7 0 3 8 3
HA[21immune 0.871 1 .0 4 6 0 .9 6 0.959 0 .5 9 6 0 .6 1 6 0 .6 2 2 0 .6 1 1 3 3 3 1 .5 6 8 7 0 2 0 .6 5
W[1]preimmune 0 .9 6 5 0 .9 8 6 0 .9 3 6 0 .9 6 2 3 3 3 0 .8 9 7 0 .8 5 4 0 .931 0 .8 9 4 1 .0 7 6 4 3 5
W[1]immune 0 .8 6 6 0 .8 6 4 0 .9 0 5 0.878333 0 .4 4 8 0 .4 5 4 0 .561 0 .4 8 7 6 6 7 1 .8 0 1 0 9 4 0 .6 7
W[2]preimmune 0 .7 1 3 0 .7 3 0 .7 1 4 0 .7 1 9 0 .6 7 8 0 .6 8 7 0 .7 2 0 .6 9 5 1 .0 3 4 5 3 2
WI2]limmune 0 .6 0 .4 4 7 0 .5 7 5 0 .5 4 0 6 6 7 0 .3 7 4 0 .4 7 2 0 .3 5 4 0 .4 1 .3 5 1 6 6 7 0 .5 8
X-33[1] ‘control negative’ 1 .0 8 7 1.001 0 .9 6 2 1 .0 1 6 6 6 7 0 .9 5 2 0 .7 2 6 0 .7 5 5 0 .811 1 .2 5 3 5 9 6
X-33[2] ‘control negative’ 1 .0 1 3 1 .0 0 9 1 .0 5 6 1 .0 2 6 0 .9 6 7 0 .9 7 4 0 .9 4 5 0 .9 6 2 1 .0 6 6 5 2 8
NoV-detector antibody 
‘control positive’
1 .26 1 .15 1.11 1 .17 0 .3 7 5 0 .5 2 0 .4 8 3 0 .4 5 9 2 .6
Table (12) showing the triplicate ELISA OD readings o f  all the experimental and control serum 
samples obtained after administration o f  engineered proteins by different routes (parenteral and oral) 
to mice. Two mice were used for each o f  the four used antigens (8-, 18-, HA-, and Wild-Hawaii) and 
also the parent yeast ‘X -33’ which was used as a negative control. Each antigen is indicated by the 
first one or two digits o f  its name, and the mouse number is written between brackets. The table shows 
the average value for each sample and the ratio between these averages against positive and negative 
control antigens (coated on the plate at a concentration o f  0.1 mg/ml). In all the preimmune sera and 
the control sera (mice immunised with the parent yeast ‘X -33’) the ratio ranges between 0.9 and 1.2 
which means no specific reactivity as expected. Cut o ff  value was calculated for each sample 
separately (as the average o f  the OD readings against the negative control antigen plus three standard 
deviations) to detect the reactivity o f  different serum samples. OD readings o f  the immune serum 
samples indicating specific reactivity are shown in red.
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Figure (50) Immune serum samples of parenteral immunisation
■ Positive control 
Ag
□ Negative control 
Ag
8[2]
■ Positive control 
Ag
□ Negative control 
Ag
18[1]
■ Positive control 
Ag
□ Negative control 
Ag
18[2]
■ Positive control 
Ag□ Negative control] 
Ag
Figure (50) Shows the average value of triplicate ELISA OD readings for each 
immune serum sample (obtained after parenteral immunisation of mice with 8- 
or 18-Hawaii protein) against positive and negative control antigens. Error bars 
represent three standard deviations above the averages i.e. the cut off values.
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Figure (51) Immune serum samples of oral immunisation
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Figure (51) Shows the average values of triplicate ELISA OD readings for each immune 
serum sample (obtained after oral immunisation of mice with 8-, 18-, HA-, or wild-Hawaii 
protein) against positive and negative control antigens. Error bars represent three standard 
deviations above the averages i.e. the cut off values.
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Chapter 5: General discussion
In contrast to the capsids of most animal viruses, which consist of 
multiple structural proteins, the capsids of the Caliciviridae are formed by the 
assembly of multiple copies of a single structural protein. An important 
discovery was that these capsid proteins have the intrinsic ability to self- 
assemble into VLPs that resemble authentic virions in both morphology and 
antigenicity (Jiang et al. 1992; Green et al. 1993; Laurent et al. 1994; Jiang 
et al. 1999; Chen et al. 2004; Di Martino et al. 2007).
NV rVLPs are similar to wild NV virions as shown in the results of 
ELISAs and immunoprécipitations with cross-reactivity when using NV-specific 
hyperimmune antisera, MAbs and antipeptide antisera (Jiang et al. 1992; Green 
et al. 1993; Hardy et al. 1996). Also, data obtained from comparison studies of 
computer-processed images (at 22nm resolution) of NV rVLPs and primate 
calicivirus virions (containing genomic RNA) showed similar domain 
aiTangement despite the absence of nucleic acid from the recombinant particles 
(Prasad et al. 1994a; Prasad et al. 1994b).
For production of an efficient VLP vaccine, the integrity of the particles 
should be maintained while exposing the antigenic domains in a proper way for 
induction of an immune response (Gerlich et al. 1996). Several attempts have 
been made to produce chimeric particles for the purpose of iimnunisation such 
as the study of Nagesha et al. (1999); these workers replaced the 30 amino acid 
N-terminal of the RHDV capsid protein with a six-residue epitope from 
bluetongue virus capsid protein YP7. The modified protein assembled to form 
modified VLPs. Their study thus showed retention of particle assembly whilst 
both RHDV and bluetongue virus sections were found to be antigenic. Other 
workers also found minimal effect on particle formation after the addition of
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exogenous epitopes (36 amino acids from HCV) introduced to the Hepatitis B 
surface antigen VLPs as a carrier (Netter et al. 2001), However, in this work 
inserted regions have been around 6-36 amino acids in maximum size.
Our first aim in this study was to modify the Hawaii capsid protein by 
removing the hypervariable region responsible for strain-specificity (P2 
subdomain) and to bridge the resulting gap by inserting poly-glycine in an 
attempt to maintain folding and assembly capability in VPl. We also sought to 
replace the entire P2 domian which forms an independently folded domain on 
the virus surface as a potential means of increasing the carrying capacity of 
potential VLP based vaccines. Modified foims would then be expressed in the 
Baculovirus expression system and examined by EM (White et al. 1996; White 
et al. 1997). However, the protein yield was limited and our EM examination 
was restricted.
Although NoV rVLPs have been expressed in a variety of different 
systems such as bacterial (Tan et al. 2004), Baculovirus (Jiang et al. 1992; 
Green et al. 1993; White et al. 1997), and Venezuelan equine encephalitis 
virus (VEE) (Baric et al. 2002; Harrington et al. 2002), each of these systems 
have limitations and we are not alone in obtaining poor yields from Baculovirus 
expression, it is also expensive and time-consuming and many workers have 
reported the continuing contamination of purified VLPs by Baculovirus or insect 
cell components. The bacterial system can provide high yields but no particle 
formation occurs presumably because proteins are not folded correctly. The 
VEE system is not commonly used because it shares the same technical 
difficulties as the Baculovirus system. Most of these systems have been 
evaluated as potential production methods for VLPs which are then purified 
extensively before evaluation as antigens, however, in all of these systems the 
expressed protein is often contaminated with host components (Xia et al. 2007).
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The theory explored in this work is that enteric vaccination may offer a 
simpler and cheaper route in this context. Yeast offers multiple advantages as 
possible candidate for oral vaccination; the cell wall may provide extra 
protection of labile antigenic determinants when ingested, yeast itself has 
nutritive value which may assist response in the malnourished and has been well 
documented as providing potentially at least a high yield of expressed 
heterologous proteins. Xia et al. (2007) have also recommended tlie Pichia 
expression system in particular for other reasons including its wide use in 
pharmaceutical applications, easy scale-up for large-scale production, and 
natural protein folding and modification. Finally efficient cloning and 
expression techniques are already established. P. pastoris is considered the most 
economic expression system for production of high yield of a recombinant 
protein due to the highly active and inducible AOX promoter and this can 
compensate for the higher doses usually required for oral immunisation (Cregg 
et al. 1987; Cregg et aï. 1993; Canales et al. 1997).
We also attempted the construction of a chimeric protein based on Hawaii 
VLPs and incorporating antigenic determinants from influenza virus HA domain 
(as a model virus). As the length and the sequence of the inserted peptide can 
seriously affect protein folding and hence particle formation and their secretion- 
competence (Lee et al. 1996), we proposed in our study a novel insertion site in 
the Hawaii VPl protein which was produced by deleting the 126 amino acids of 
the P2 subdomain which represent the outermost, independently folded, domain 
on the viral capsid and hence providing greater space for heterologous epitopes 
than the few amino acids inserted hitherto in VLPs. We were able to insert a 243 
amino acid chain of the HA globular head domain from an influenza A virus.
Since we sought to prepare a VLP that was contained within the yeast cell 
for enteric immunisation our first experiments sought intracellular expression of
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our engineered proteins in yeast using the vector (pPICZ-A). However, this 
provided poor yields and we were able to detect expression of only one 
construct (HA-Hawaii) which was thought to be associated with the yeast cell 
wall. This association was also reported by Farnos and his group (2005) in the 
expression of another calcivirus capsid protein; RHDV VP60. Both to confirm 
that our constructs did express and in an attempt to increase yields we 
transferred them to the yeast shuttle vector (pPICZ a-A) which allows secretion 
of the expressed protein. Although this did allow us to detect expression of all of 
the proteins we were surprised in that all appeared to be intracellular and were 
not secreted free in the medium. Famos et al. (2005) also used a secretion signal 
in the expression cassette, but found that secretion of the VP60 protein did not 
occur which they attributed to the inefficiency of the secretion signal (sucrose- 
invertase secretion signal, from S. cereviciae) and association of the protein with 
the yeast cell walls. Inefficient secretion induced by this signal has been 
reported elsewhere (Rodriguez et ai. 1994; Garcia-Garcia et al. 2000). 
Interestingly, the expression of RHDV VP60 was detected in yeast as multiple 
bands in Western blots. There was a wide range of band sizes which matches 
our results in Hawai protein expression. P. pastoris is known to add mainly N- 
linked oligosaccharide to the expressed proteins (Montesino et al. 1998), and 
O-glycosylation is not excluded as evidenced by Gonzalez et al. (2004). It is 
therefore likely that this variation in size can be attributed to glycosylation and 
Famos and colleagues were able to show this directly in the case of RHDV by 
enzymatic deglycosylation (Farnos et al. 2005). We attribute our observations 
to a similar process, but have not investigated this directly. Fortunately, we 
could use the dried whole yeast pellets for oral immunisation of mice which 
means that all glycosylated forms (as well as any breakdown or prematurely 
tenninated peptides) will be present in the immunogen. However, as we could 
not be certain that oral administration would induce any antibody response at all, 
we also carried out conventional parenteral administration of some of our
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antigens to demonstrate that these constructs are antigenic (ie, as a form of 
positive control). We succeeded in purifying the 8- and 18-Hawaii engineered 
proteins while HA- and wild-Hawaii were not purified by this method.
Live-attenuated bacteria and viruses have been considered as likely 
candidates for orally administered vaccines. Their capacity to induce antigen 
expression in the gut is likely to promote a good immune response compared 
with inactivated antigens introduced by the same route. However, VLPs are 
capable of inducing a response even if administered as inert particles and non­
replicating NV rVLPs produced in insect cells, induced a significant response 
when delivered through mucosal routes (Ball et al. 1998; Guerrero et al. 
2001), The unique acid-resistant nature of the NoV VLPs favours their use as 
edible vaccines since they can resist the harsh effect of the stomach pH more 
than other proteins (Ball et al. 1996).
We tried both oral and intravenous administration of our constructed proteins to 
determine the induction of a specific immune response in mice. The oral 
immunisation included four different expressed proteins administered in dried 
whole yeast cells: 8-, 18-, HA-, and wild-Hawaii proteins and also the parent 
yeast (strain X-33) as a control. The intravenous immunisation employed only 
the 8- and 18-Hawaii purified proteins. We could detect a low reactivity in the 
sera produced by most of the engineered proteins to the native Hawaii capsid 
protein by ELISA. However, the test antigen used here was the complete Hawaii 
virus VPl. This contains the immunodominant P2 domians that were lacking in 
all our immunogens except the orally administered wild-Hawaii control. 
Consequently, reactivity induced must be directed towards the S and PI regions 
of the target protein. However, although a higher reactivity was expected when 
serum from animals fed the wild-Hawaii VLP antigen was expected, no such 
difference was observed. Moreover, the 18-Hawaii construct showed a higher
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reactivity in one of the immunised mice which can be attributed to the individual 
variation of the immune system of different mice which can be better analysed 
in a larger scale experiment with production of sufficient amounts of the 
engineered proteins that permit immunisation of larger number of mice without 
lowering the antigen dose. Also, since the immunisation regime used here was 
short and used antigens at relatively low concentrations it may simply reflect a 
snapshot of the animals immune status when the experiment was terminated, 
rather than the hill potential of the immunity which was possible if the 
immunisations were to be continued.
In Xia et al. (2007) study they expressed VPl from VA 387-GII-4 in P. 
pastoris and purified VLPs which they used for both oral and intramuscular 
immunisation of mice. For oral iimnunisation, the protein was administered in a 
semi-purified fonn after exclusion of the lysed yeast cell debris in two different 
concentrations (0.1 and LOmg per dose) to two groups of mice (six each) by 
stomach gavage. The mice were fed the dose five times at two weeks intervals. 
Final blood and faecal samples were taken at 70 days after administration. For 
intramuscular immunisation, they administered 40pg of the purified protein for 
tliree times with two weeks interval, and blood was collected at the end. In the 
low dose (0.1 mg/ dose) orally-immunised group, only three mice responded 
with measurable IgG and only two of them also produced IgA after the 4^ '^ dose, 
while after the 5^ '^ dose all of the mice showed IgG and 5 of them showed also 
IgA against VA387. However, in the higher dose group the immune response 
was detected earlier and was stronger with production of IgG and IgA in five of 
the six mice after the 3*^  dosage followed by an increase in the antibody titers on 
subsequent administrations. In the lower dose group antibody was not detected 
until after the 5^^^ dose). This could support the dose effect discussed above.
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None of the fed mice showed side effects during our experiment and this 
was also true in the study of Xia and colleagues (2007). They concluded the 
possibility of inducing an effective immune response upon repeated 
administration of low dosage of the immunogenic protein and this is highly 
relevant to our data which we obtained by using a different immunisation 
schedule depending mainly on administration of frequent doses of the antigen to 
stimulate gradual induction of the immune system.
Xia also showed the induction of significant serum and faecal antibodies 
on both oral and intramuscular administration of the VA387 capsid protein to 
mice in agreement with the results of Ball et al. (1998). Faecal samples were 
collected from the immunised mice at the end of our experiment as well and it 
was our intention to seek faecal antibody as well. Indeed our ELISA was 
designed to use a detector antibody responsive to both IgG and IgA. However, 
we wanted first to prove the immunogenicity of our constructs through detection 
of IgG in mouse serum and time constraints have prevented the evaluation of 
faecal antibody. This is certainly an aspect of this work that could be followed 
up in a later study.
In Xia et al. (2007), they excluded yeast cell debris by centrifugation at 
12000 rpm for 20 minutes after cell lysis. The antigens were then used at 2 
different doses (0.1 and 1.0 mg). However, we used a completely unpurified 
antigen consisting of whole dried yeast. In order to be able to compare our 
results with others, we decided to immunise only two mice with each of the 
engineered proteins instead of lowering the dose with more mice used. 
According to our rough estimation of protein expression level of the engineered 
Hawaii protein in Pichia (2.7mg/ml), each oral yeast dose (0.2 gram dried yeast 
pellet) contained a similar amount of the antigen (0.1 mg) to the lower dose 
regime used in Xia et al. (2007) iimnunisation experiment although in their
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study antigens were introduced in competition. They detected specific IgG in 
sera from half of the immunised mice after the 4^ '^  dose and the remaining 
animals after the 5^*^ dose, our repeated administration of a similar dose for 
fourteen consecutive days shows reactivity in both of the immunised mice for 
three antigens.
Famos et al. (2005) used expressed VP60 contained in yeast cell debris 
for oral administration to rabbits. Rabbits developed a protective immunity 
against intramuscular challenge with homologous virus without showing any 
clinical signs of the disease. In contrast, the placebo group all died 48 hours after 
the challenge. They used initial and three booster doses (at weeks 2, 4, and 8) of 
160mg of biomass (wet weight) containing about lOOpg of VP60 per dose and 
resuspended in water, meaning a total of about 400pg protein. Final serum 
samples were taken at week 10 (i.e. two weeks after the final booster dose) and 
examined by Western blots with induction of specific antibodies. They also, 
evaluated rabbit response to subcutaneous injection of VP60 which proved 
successful. Unfortunately Farnos et al. (2005) used Western blots in preference 
to ELISA which makes dfrect comparison of our results difficult. The amount of 
antigen they used per oral dose was also similar to our estimated antigen 
amount, and all animals in their study were able to restrict the intramuscular 
viral challenge which we can not directly relate to our work. However, this does 
indicate a better induction of immunity than that observed by Xia et al. (2007) 
who used a similar dosage but excluding the yeast cell debris. It is therefore 
possible that the inclusion of yeast materials actually promotes immunity 
towards the carried antigens. In 2009, Farnos and his group compared the 
specific immune responses against the purified VP60 and that induced by the 
less purified cell-debris fraction (as insoluble protein) by subcutaneous 
immunisation of rabbits. They observed only a small difference and this study 
suggests that extensive purification is at least unrequired, whilst past work
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(above) may imply that at worst, it is actually deleterious to immunisation by 
this route. This supports the idea of our experiment in which we expect the 
intact yeast cells to favour the protection of the antigen while passing through 
the stomach.
Studies of edible NV rVLPs have passed many clinical trial steps in 
volunteers. In Ball et al. (1999) study volunteers ingested 250pg of the 
recombinant particles in Milli-Q water without adjuvant, and demonstrated a 
dose-dependent response in 83% of the test group with > four-fold increase in 
serum IgG. The antigen dosage used in this study was higher than that used in 
most of animal studies and although no adjuvant was used an immune response 
was obtained in most of the immunised volunteers with a high level of specific 
IgG which indicates promising applicability of the oral VLPs as a vaccine in 
humans.
When Mason et al. (1996b) tried using the raw transgenic potato as an 
oral delivery vehicle for NV recombinant capsid protein to mice, they detected 
both serum and mucosal antibody responses. Each oral dose contained 40-8Opg 
of NV capsid protein, however, when they used CT as an adjuvant it greatly 
affected the number of responding mice. Seven out of ten mice showed serum 
antibodies when they mixed lOpg of CT with each oral dose of potato tubers in 
contrast only four animals responded without the CT. Serum titers of orally-fed 
mice were lower than those detected in mice gavaged with the purified NV 
capsid protein expressed in tobacco leaves at similar doses. They attributed this 
difference in reactivity between orally-fed and gavaged mice to the more VLPs 
(although similar protein dose was used) which they detected in tobacco leaves 
than those deteceted in potato tubers (by sucrose gradient purification of NV 
capsid protein) and also the slow exposure of the less pure form of the protein 
from the potato tuber matrix. They estimated the recombinant protein expression
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level to represent about 0.23% of the total soluble protein in tobacco leaves and 
about 0.37% in potato tubers (34pg per gram of tuber weight).
Although plant expressed proteins are clearly antigenic, modest antigen level 
(usually less than 1% of total soluble protein) represents the main limitation of 
plant-derived edible vaccine (Santi et al 2008). Our rough estimation of the 
expression level of 8- and 18- Hawaii recombinant capsid proteins in our P. 
pastoris (2.7mg/liter) suggests a relatively higher concentration than that 
obtained from the plant expression system. We thus propose yeast as an easier 
recombinant protein expression system leading to increased yields (Ellis et al. 
1985) and more rapid antigen generation than recombinant plant systems.
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Preserving particle formation of engineered Hawaii capsid protein 
subunits expressed in insect cells was possible thi’ough bridging the gap 
which occurred as a result of the P2 subdomain deletion with a poly­
glycine amino acid chain.
Deletion of the P2 subdomain does not abolish the antigenicity of the 
engineered construct, and good IgG antibody responses were induced 
against S and PI regions, which require further investigation of the ability 
to restrict infection in animal challenge and also the neutralization 
efficacy. Mice faeces collected in our experiment need to be assessed for 
IgA responses by ELISA which we have already established; this will be 
considered in the future.
Capacity of the Hawaii VLPs to carry exogenous domain epitopes needs 
to be investigated further.
Yeast expression system fulfilled a better protein yield of the engineered 
Hawaii capsid protein constructs than that obtained from insect cells 
(Sf21).
Yeast has several advantages which make its use as heterologous protein 
expression system superior to other systems, and also as a candidate for 
oral immunisation using the whole yeast cells as deliveiy vehicles which 
could provide further antigen protection.
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Appendix I 
General Solutions
PCR
Ix PCR reaction buffer
1 OmM Tris-HCl (pH 9.0 at 25°C)
50mM KCl
0.1% Triton® X-100
Cloning
Annealing buffer
40niM TrisHCl (pH 7.5)
20mM MgC12 
50inM NaCl
Kinase buffer
40mM Tris (pH 7.5)
20inM MgAc
0.1% Bovine Serum Albumin
Agarose Gel Electrophoresis
lOx TBE Buffer;
890mM Tris base 
890mM Boric acid 
32mM EDTA
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2x TBE sample buffer; 20ml
4ml 1 Ox TBE buffer
4ml Glycerol
12ml Milli-Q water
0.1 g Bromophenol blue dye & xylene cyanol ff dye
Agarose gel running buffer: 250ml
2 5ml 1 Ox TBE buffer
225ml Milli-Q water
12.5pi Ethidium bromide ( 1 Omg/ml stock)
Ligation Reactions
lOx Ligase buffer
300mM Tris-HCl (pH 7.8)
lOOmM MgC12
lOOmM DTT
lOmM ATP
SDS-PAGE
AX2 buffer (Resolving gel buffer):
75 OmM 
- pH: 8.8
Tris
BX2 buffer (Stacker gel buffer): 500ml
2 5 OmM Tris
- pH: 6.8
187
Acrvlamide: Bis-acrvlamide;
563mM Acrylamide 
7mM Bis-acrylamide
SDS-PAGE Running buffer;
25mM Tris 
192mM Glycine 
3.5mM SDS
2x PAGE Sample buffer: 10ml
5 ml Bx2
2ml 20% SDS 
4g Glycerol 
0.5ml 2-Mercaptoethanol 
0.1 g Bromophenol blue dye 
- Made up to 10ml with Milli-Q water
Coomassie stain for protein gels
363ml Milli-Q water 
100ml Methanol 
37.5ml Acetic acid
1.25g Coomassie brilliant blue stain (BioRad)
Destaining of protein gels
363ml Milli-Q water 
100ml Methanol 
37.5ml Acetic acid
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Western Blot Solutions
Western Blot Transfer buffer:
25mM Tris
192mM Glycine
20% Methanol
lOx TBS - Tween-20:
200mM Tris base
1.4M NaCl
1% tween-20
- pH: 7.6
- Store at 4°C
Blocking solution
5% w/v Marvel in Ix TBS-tween
T ransformation
2x YT fluid medium: 1 liter
- Add the following to 800ml Milli-Q water
16g Bactotryptone 
lOg Yeast extract 
lOg NaCl
- Adjust volume up to 1 liter with Milli-Q water
- Sterilize by autoclaving
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2x YT agar plates; 100ml
- Dissolve 1.2 g Bactoagar in 100ml 2x YT fluid medium by boiling.
- Cool to 50C
Yeast growth Media 
lOx Yeast Nitrogen Base (YNB); 13.4%
- Dissolve 134 g of yeast nitrogen base with ammonium sulfate and
without amino acids in 1000 ml Milli-Q water
- Dissolve YNB by heating the solution
- Filter sterilize, and store at 4°C
- The shelf life is one year.
SOOx Biotin; 0.02%
- Dissolve 20 mg biotin in 100 ml Milli-Q water
- Filter sterilize, and store at 4°C
- The shelf life is one year
lOOx Histidine: 0,4%
- Dissolve 400 mg of L-histidine in 100 ml Milli-Q water by heating to no 
greater than 50°C in order to dissolve.
- Filter sterilize, and store at 4°C 
“ The shelf life is one year
lOx Dextrose: 20%
- Dissolve 200 g of D-glucose in 1000 ml Milli-Q water
- Filter sterilize, and store at 4°C
- The shelf life is one year
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lOx Methanol; 5%
- Mix 5 ml of methanol with 95 ml of Milli-Q water
- Filter sterilize, and store at 4°C
- The shelf life is two months.
lOx Glycerol: 10%
- Mix 100 ml of glycerol with 900 ml Milli-Q water
- Filter sterilize, and store at room temperature
- The shelf life is one year
Yeast Extract Peptone Dextrose Medium (YPD) with or without 
Zeocin: 1 liter
- Dissolve the following to 900ml Milli-Q water:
lOg yeast extract 
20g peptone
- Note: Add 20g agar if making YPD plates
- Autoclave for 20 minutes
- Add 100 ml of 1 OX Dextrose
- If desired, add 1ml of 100 mg/ml zeocin after cooling to ~ 60°C
- The liquid medium is stored at room temperature, while plates are stored 
at 4°C.
- The shelf life is several months
- Media containing zeocin should be stored at 4°C in the dark, and their 
shelf life is 1-2 weeks
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Buffered GIvcerol-complex Medium (BMGY)
Buffered Methanol-complex Medium (BMMY): 1 liter
- Dissolve the following in 700 ml Milli-Q water:
lOg yeast extract 
20g peptone
- Autoclave for 20 minutes
- Cool to room temperature, then add the following and mix well:
100ml IM potassium phosphate buffer, pH 6.0 
100 ml lOxYNB 
2 ml 500x Biotin 
100 ml 1 Ox Glycerol
- For BMMY, add 100 ml lOx Methanol instead of glycerol
- Store at 4°C
- The shelf life is two months
His-tagged protein purification
Lysis of yeast cell wall
- Each yeast colony was picked and resuspended in 10pi of sterile 
Milli-Q water.
- A 5pl of a 5U/pl lyticase solution was added and incubate at 
30°C for 10 minutes for lysis of yeast cell wall which was aided by 
freezing at -80°C for 10 minutes and then thawing.
Binding buffer
20mM Phosphate 
500mM NaCl 
20mM imidazole
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Elution buffer
20mM phosphate 
500mM NaCl 
500mM imidazole
ELISA
Ix PBS-Tween-20 (pH 7.4)
3.2mM Na2HP04 
0.5mM KH2P04 
L3mM KCl 
135mM NaCl 
0.05% tween-20
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Appendix II 
Vectors maps 
pGEM T-easv vector map (Promega):
Xmnl 2009 
Seal 1890 1 startNael 2707 ApatAatll
aNot!SacllEcoRI
11 on
pGEM®-T Easy lacZ 
Vector(3015bp)
EcoRIaPst!SailNdelSaolBstXINail
pGEM®-T Easy Vector sequence reference points;
T7 RNA polymerase transcription initiation site
multiple cloning region
SP6 RN/\ polymerase promoter (-17 to +3)
SP6 RNA polymerase transcription initiation site 
pUC/M13 Reverse Sequencing Primer binding site 
lacZ start codon 
liK operator
P-lactamase coding region
phage f l region
lac operon sequences
pUC/M13 Foi-ward Sequencing Primer binding site 
T7 RNA polymerase promoter (-17 to +3)
2836-:
1
10-128 
139-158 
141 
176-197 
180 
200-216 
1337-2197 
2380-2835 
2996,166-395 
2949-2972 
2999-3
194
pVL1393 vector map (Invitrogen):
Comments for pVL1393:9032 nucleotides
Recombination sequence (ORF603+); bases 1-3997Polyhedrin promoter: bases 3998-4092Polyhedrin gene: bases 4093-4738Multiple cloning site: bases 4128-4179Recombination sequence (ORF1629+): bases 4738-7002ColEI origin; bases 8029-7356Ampiclllin resistance gene: bases 8965-8177
Xho I
Apa I
Sac II
EcoR V
PVL13939.6 kb
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pVL1393 MCS
Polyhedrin promoter
Polylinker
Primer binding sites +] Trnnscriptional start
Polyhedrin forward sequencing priming site
3998 GATATCATGG AGATAATTAA AATGATAACC ATCTCGCAAA TAAATAAGTA TTTTACTGTT
Baculovinis fonvnrd PCR priming site w,t. ATG mutated to ATT
4058 TTCGTAACAG TTTTGTAATA AAAAAACCTA TAAATATTCC GGATTATTCA TACCGTCCCA
Pst IBaiiiHl Sm al X bal EcoRI N oll  » imI I  I t  I " P  “4118 CCATCGGGCG CGGATCCCGG GTACCTTCTA GAATTCCGGA GCGGCCGCTG CAGATCTGAT
4178 CCTTTCCTGG GACCCGGCAA GAACCAAAAA CTCACTCTCT TCAAGGAAAT CCGTAATGTT
Polyhedrin reverse sequencing priming site 
4238 AAACCCGACA CGATGAAGCT TGTC6TTGGA TGGAAAGGAA AAGAGTTCTA CAGGGAAACT
4298 TGGACCCGCT TCATGGAAGA CAGCTTCCCC ATTGTTAACG ACCAAGAAGT GATGGATGTT
4368 TTCCTTGTTG TCAACATGCG TCCCACTAGA CCCAACCGTT GTTACAAATT CCTGGCCCAA
4418 CACGCTCTGC GTTGCGACCC CGACTATGTA CCTCATGACG TGATTAGGAT CGTCGAGCCT
4478 TCATGGGTGG GCAGCAACAA CGAGTACCGC ATCAGCCTGG CTAAGAAGGG CGGCGGCTGC
4538 CCAATAATGA ACCTTCACTC TGAGTACACC AACTCGTTCG AACAGTTCAT CGATCGTGTC
4598 ATCTGGGAGA ACTTCTACAA GCCCATCGTT TACATCGGTA CCGACTCTGC TGAAGAGGAG
4658 GAAATTCTCC TTGAAGTTTC ÇCTGGTGTTC AAAGTÂAAGG ÀGTTTGCACC AGACGCACCT
I—4718 CTGTTCACTG GTCCGGCGTA TTAAAACACG ATAGATTGTT ATTAGTACAT TTATTAAGCG
Baculovirus reverse PCR priming site 1
4778 CTAGATTCTG TGCGTTGTTG a t t t a c a g a c  a a t t g t t g t a  c g t a t t t t a a  t a a t t c a t t a
4838 AATTTATAAT
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pPICZ vector maps (Invitrogen):
M ap o f pPICZ A, B, an d  C
.c-m yc epitope
B am H  I
Comments for pPICZ A:3329 nucleotides
5 'AOXf promoter region: bases 1-941 S' end of AOX1 mRNA: base 824 S' AOX1 priming site: bases 855-875 Multiple cloning site; bases 932-1011 c-myc epitope tag: bases 1012-1044 Polyhistidine tag: bases 1057-1077 3 ' AOX priming site: bases 1159-1179 3 ' end of mRNA: base 1250AOX1 transcription termination region: bases 1078-1418 Fragment containing TEF1 promoter: bases 1419-1830 EM7 promoter: bases 1831-1898 Sh ble ORF: bases 1899-2273
CYC1 transcription termination region: bases 2274-2591 pUC origin: bases 2602-3275 (complementary strand)
Ttie restriction site between Not I and the myc epitope is different In each version of pPlCZ;
Apa I In pPiCZA Xba I in pPICZ B SnaB I in pPiCZ C
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MCS of pPICZ-A vector
S' end iKAOXI mRNA g' AQX1 priming sits
811 AACCTTTTTT TTTATCATCA TTATTAGCTT ACTTTCATAA TTGCGACTGG TTCCAATTGA
871  CAAGCTTTTG ATTTTAAÇQA CTTTTAACGA CAACTTGA6A AGATCAAAAA ACAACTAATT 
Sf£/I amRI P m li SfH B sm B ÏA sp 7 W t K p tilX iw  l
931 a t t ’cgaaacg  ag g a a t tc a c ' gtggcccagc  cgg ccg tctc  ggatcg g tac ' ctcgagccgc
Sac 8 Not Ï Apa_I_____________________nyc epitope______________________ _
9 91 'g GÇGGCCGGÇ AGCTT IgGGCCCI'gAA GAA AAA CTC ATC TCA GAA GAG GAT CTg '
G ill G in  L sii l i e  S e r  G in  G in  A sp  Lmi
_________Polyhlstidlna tag________
1 0 4 2  AAT AGC GCC GTC GAG CAT CAT CAT CAT CAT CAT TGA GTTTTAGGCT TAGACATGAC
A sn  S e r  A la  V a l A sp H is  H is  H is  H i s  H is  H is  ***
10 9 8  TGTTCCTCAG TTCAAGTTGG GCACTTACGA GAAGACCGGT CTTGCTAGAT TCTAATCAAG 
______ 3' AOXf priming site
1 1 5 8  AGGATGTCAG AATGCCATTT GCCTGAGAGA TGCAGGCTTC A.TTTTTGATA CTTTTTTATT
3 'püîyadenyiat io n site 
11 2 1 8  TGTAACCTAT ATAGTATAGG ATTTTTTTTG TCATTTTGTT
- To use pPICZ-A vector for cloning we included an initiation codon ‘ATG’ 
as a part of yeast consensus sequence [(G/A)NNATGTCT] as recommended 
(Hamilton et aL 1987).
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Map of pPICZa A, 
B, and C
-S % .8  E % M S ' S.JC Œ c-myc ep itope  6xHis
5  ( X  U j  C  o 5  0 0 - s ç  : e s <  0 0  ^  5 <
Bamn I
pPICZa A,B,C
3.6 kb
Comments for pPICZa A 
3593 nucleotides
5" AOX1 promoter region; bases 1-941
5' AOX1 priming site: bases 855-875
«-factor signal sequence: bases 941-1207
«-factor priming site: bases 1144-1164
Multiple cloning site: bases 1208-1276
c-myc epitope: bases 1275-1304
Polytiistidine (6xHis) tag: bases 1320-1337
3" AOX1 priming site: bases 1423-1443
AOX1 transcription termination region: tiases 1341-1682
TEF1 promoter: bases 1683-2093
EM7 promoter: bases 2095-2162
Sh bfe ORF: bases 2163-2537
CYC1 transcription termination region: bases 2538-2855 
pUC origin: bases 2866-3539 (complementary strand)
Pst I Is In Version B only 
Cla I Is In Version C only
iTho two Xho I sites In tfie vector allow 
ttie user to done their gene in frame with 
the Kex2 deavsge site, resulting in 
expression of ttieir native gene witfiout 
additional amino acids at tfie IM-termlnus.
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MCS of pPICZa-A vector
5 end of A0X 1  mRNLA, S' A0X 1  priming site
8 1 1  AACCTTTTTT 'i'TTM'CATCA TTATTAGCTT ACTTTCATAA TTGCGACTGG TTCCAATTGA
8 7 1  CAAGCTTTTG ATTTTAACGA CTTTTAACGA CAACTTGAGA AGATCAAAAA ACAACTAATT
9 3 1  ATTCGAAACG ATG AGA TTT CCT TCA ATT TTT ACT GCT GTT TTA TTC GCA GCA 
Mat. A rg  Pha P ro  S e r  l i e  Pîje T hr A la  V a l Leu Phe A la  A la
983 TCC TCC GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCAS e r S e r A la L eu A la A la P ro V a l A sn T hr Thr Thr G lu A sp G lu T hr A la
a-factor signal siequence
10 3 4 CAA ATT CCG GCT GAA GCT GTC ATC GGT TAG TCA GAT TTA GAA GGG GAT TTCG in l i e P r o A la G lu A la V a l l i e  G ly  T y r  S e r  A sp Leu G lu G ly A sp P h e
1085 GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTTA sp  V a l A la  V a l  Leu P ro Phe S e r  A sn S e r T hr A sn A sn G ly  L eu L eu P he
1 a-factor priming site I Xhoi*
1 1 3 6 ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA TCT CTCl i e A sn Thr T hr l i e A la S e r l i e  A la A la L y s G lu Glu G ly V a l S e r L eu
Kex2 signal cleavage E coR l Pmi’f sni &fj7iB t A s p l i i
1 1 8 7  GAG AAA AGA^ GAG GCT GAA GCg GAATTCAC GTGGCCCAG CCGGCCGTC TCGGATCGGT 
G lu  L y s  A rg  G lo  AlaJj^Glu Alajjj^
Sl6l3 signal deavsge
Apral Xfiol Sap 11 Woff X6a ! ________________ i>myc epitope______________
1 2 4 4  ACCTCGAGCC GCGGCGGGC GCCAGCTTTC TA *GAA CAA AAA CTC ATC TCA GAA GAG
G lu  G in  L ys L eu  l i e  S e r  G lu  G lu  
________ polyhistidine tag__________
1 2 9 9  GAT CTG AAT AGC GCC GTC GAC CAT CAT CAT CAT CAT CAT TGA GTTTGÏAGCC
A sp  L eu A sn  S e r  A la  V a l A sp  H is  H is  H is  H is  H is  H is  * * *
1 3 5 1  TTAGACATGA CTGTTCCTCA GTTCAAGTTG GGCACTTACG AGAAGACCGG TCTTGCTAGA
3 ' priming site
1 4 1 1  TTCTAATCAA Ga 'gGATGTCA GAATGCCATT TGcbïGAGAG ATGCAGGCTT CATTTTTGAT
3' polyadenylation site
1 4 7 1  ACÏTTTTTAT TTGTAACCÏA TATAGTATAG GATTÏTTTTT GTcklTTTCT TÏCTTCTCGT
-T o  use the pPICZa-A vector for cloning we kept the ORF of the gene of 
interest in frame and downstream of the a-factor signal sequence and in frame 
with the C-terminal His-tag.
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Appendix III 
Primer design
General rules were followed:
- Tni was calculated according to the formula:
Tm = [4*(G +0 + 2^(A+T)1 for only the specific sequence of the primer 
(excluding the added restriction sites and additional nucleotides).
- Different restriction sites were selected to flank different PCR products to 
force orientation of cloning according to the designed strategy.
- The sequence to be amplified was checked to exclude the existence of the 
restriction sites destined for use (to flank its ends).
- Additional 2-4 nucleotides were added to the 5’ end of each designed 
primer (upstream of the added restriction site) to allow proper digestion 
with the relevant enzyme.
- Extra nucleotides were added (as required) downstream of the added 
restriction site to different primers to keep the ORF of the amplified 
sequence after its cloning into the expression vector.
Hawaii LH segment:
Hawaii LH segment consists of 827bp
Forward primer of Hawaii LH segment : Tm: 58
5’-AGAGGATCCATGAAGATGGCGTCGAATGA-3’
Reverse primer of Hawaii LH segment: Tm: 56
5 ’-GACTÇGAGCCCGTGGTGCCCAACAATTC-3 ’
The forward primer starts at position 5085 of the selected Hawaii virus genome 
and consists of 20 nucleotides, preceded by a BamHI restriction site
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(underlined). The start codon is boxed. The reverse primer starts at position 
5912 of the Hawaii virus genome and consists of 18 nucleotides with an Xhol 
restriction site (underlined) added to its 5’ end and 2 extra nucleotides (bold) to 
keep the ORF.
Hawaii RH segment:
Hawaii RH segment consists of 443bp 
^Forward primer for Hawaii RH segment: Tm: 58
5 ^ -GCAAGCTTGGGTCTGTTTAACACTGACCA-3 ’
^Reverse primer of Hawaii RH segment: Tm: 66
5 ’-GCCTGCAGTTACTGCACTCTTCTGCGCCC-3 ’
The forward primer starts at position 6246 of the selected Hawaii virus genome 
and consists of 20 nucleotides, preceded by 1 extra nucleotide (bold) to keep the 
ORF and a Hindlll restriction site (underlined). The reverse primer starts at 
position 6672 of the Hawaii virus genome and consists of 21 nucleotides with a 
Pstl restriction site (underlined) added to its 5’ end. The stop codon is boxed.
Lambda staffer segment:
The Lambda stuffer segment consists of 549bp 
F^orward primer for Lambda staffer; Tm: 54
5 ’-GCAAGCTTAGTCTGGATAGCCATAAGT-3 ’
^Reverse primer for Lambda stuffer; Tm: 56
5 ’-GCAAGCTTATTGAAATCGACCATGACGT-3 ’
Both the forward and reverse primers of the Lambda stuffer were preceded by a 
Hindlll restriction site (underlined).
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Influenza ‘A’ HA segment:
The selected segment of the Influenza Hemagglutinin domain consists of 728bp 
F^orward primer for HA segment; Tm: 56 
5 ’-AAAACTCGAGGCGGACAAACATCCCCAA-3 ’
^Reverse primer for HA segment: Tm: 56
5 ’-TTTAAGCTICCTCCACTGTGGTAGCATTC-3 ’
The forward primer starts at position 177 of the selected Influenza (A/fowl/ 
Dobson/ 1927(H7N7)) virus HA gene and consists of 18 nucleotides, preceded 
by an Xhol restriction site (underlined). The reverse primer starts at position 886 
of the HA gene and consists of 20 nucleotides with a Hindlll restriction site 
(underlined) added to its 5’ end.
Yeast cloning primers used for intracellular expression of the engineered 
Hawaii constructs:
These primers were designed to amplify the finally engineered Hawaii 
constructs (cloned in pVL1393 vector, used in Baculovirus expression system) 
with the addition of certain restriction enzyme sites at both ends of different 
Hawaii constructs so as to allow their cloning into the yeast shuttle vector 
pPlCZ-A for intracellular expression in yeast.
*The forward primer (Left hand-intracellular): Tm: 58 
5 '-ATCCGCGGAAAAATGTCTAAGATGGCGTCGAATGACG-3 ’
*The reverse primer (Right hand-intracellular); Tm: 60
5’-ATGGGCCCTTACTGCACTCTTCTGCGCCC-3'
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The forward primer starts at position 5088 of the Hawaii virus genome„and 
consists of 19 nucleotides, preceded by yeast consensus sequence (which 
contains the start codon ‘ATG’) (bold) and a SacII restriction site (underlined). 
The reverse primer starts at position 6672 of the Hawaii virus genome and 
consists of 21 nucleotides with Anal restriction site (underlined) added to its 5’ 
end. The stop codon is boxed.
Yeast cloning primers used for secreted expression of the engineered 
Hawaii constructs:
These primers were designed to amplify the finally engineered Hawaii 
constructs (cloned in pVL1393 vector, used in Baculovirus expression system) 
with the addition of certain restriction enzyme sites at both ends of different 
Hawaii constructs so as to allow their cloning into the yeast shuttle vector 
pPlCZa-A for secreted expression in yeast.
*The forward primer (Left hand-secreted); Tm: 46
5’-AAAGGCCCAGCCGGCCAATGAAGATGGCGTCG-3 ’
*The reverse primer (Right hand-secreted); Tm: 64
5'-CGCCGCGGGATACTGCACTCTTCTGCGCCC-3*
The forward primer starts at position 5085 of the Hawaii virus genome_and 
consists of 15 nucleotides, preceded by 1 extra nucleotide (bold) to keep the 
ORF with the N-terminal secretion signal in pPlCZa-A vector and a Sfil 
restriction site (underlined). The reverse primer starts at position 6668 of the 
Hawaii virus genome and consists of 20 nucleotides with 2 extra nucleotides 
(bold) to keep the ORF with the C-terminal His-tag sequence in pPlCZa-A 
vector and a Sacll restriction site (underlined) added to its 5’ end.
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Appendix IV 
Sequencing data
Key for Samples Names:
Number Sequence flie name Sample Sequencing primer
1 First M13F F05 8-Hawaii M l3 forward
2 First M13R G05 8-Hawaii M l3 reverse
3 8-Hawaii Hawaiijunctseq G06 8-Hawaii Hawaii-junct-seq.
4 18-Hawaii leflHawaiiseq C07 18-Hawaii Lefl-Hawaii-seq.
5 HA Hawaiijunc F04 HA-Hawaii Hawaii-junct-seq.
6 8 M13F F05 8-Hawaii M l3 forward
7 8_M13R_G05 8-Hawaii M l 3 reverse
8 W M13F H05 Wild-Hawaii M l 3 forward
9 W M13R A06 Wild-Hawaii M l3 reverse
10 LG M13F E07 18-Hawaii M l3 forward
11 LG M13R F07 18-Hawaii M l3 reverse
12 HA M13F C08 HA-Hawaii M l 3 forward
13 HA M13R D08 HA-Hawaii M l3 reverse
14 W M13F J23 Wild-Hawaii M l3 forward
15 W M13R L23 Wild-Hawaii M l3 reverse
16 8 AOXforw N il 8-Hawaii AOXl forward
17 8 AOXrev P ll 8-Hawaii AOXl reverse
18 18 AOXforw B13 18-Hawaii AOXl forward
19 18 AOXrev D13 18-Hawaii AOXl reverse
20 HA AOXforw F13 HA-Hawaii AOXl forward
21 HA AOXrev H I3 HA-Hawaii AOXl reverse
22 8G YeastR D07 8-Hawaii Right Hand-secreted
23 LG YeastR G07 18-Hawaii Right Hand-secreted
24 W YeastR B08 Wild-Hawaii Right Hand-secreted
25 HA YeastR E08 HA-Hawaii Right Hand-secreted
Important landmarks are shown on each sequence.
Sequences number 3 and 4 show the poly-glycine amino acid chain (8 & 18 
respectively).
Sequence number 5 shows the HA segment of Influenza virus.
Constructs in sequences (16 to 19) were derived by PCR of tlie same constructs (8- 
and 18-Hawaii in pVL1393 vector used in the Baculovirus expression system) with 
addition of the required restriction enzyme sites for cloning into yeast shuttle vector 
pFlCZa-A.
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Appendix V 
Antibodies
Primary antibodies;
Antibody Source
Rabbit anti-Hawaii capsid protein antibodies Kim Green, USA
Guinea pig anti-Hawaii capsid protein antibodies Kim Green, USA
Mouse anti-His-tag monoclonal antibody Millipore, USA
Secondary antibodies:
Antibody Source
Rabbit anti-mouse Horse radish peroxidise 
conjugate
Dako, Denmark
Donlcey anti-guinea pig Horse radish peroxidise 
conjugate
Millipore, USA
Norovirus-specific ‘GIF polyclonal detector 
antibody conjugated to horseradish peroxidase
Norovirus Dakocytomation 
detection Kit., Dako, Denmark
Goat anti-mouse IgG, IgM, IgA horseradish 
peroxidise conjugate
Millipore, USA
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